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1.1  AIM OF THE WORK 
 
MicroRNAs (miRNAs) are a new class of small non-coding RNAs involved in the 
negative regulation of gene expression. In humans, it has been shown that 
miRNAs play a key role in the modulation of the innate immune response and in 
the regulation of normal and neoplastic hematopoiesis. The expression profile of 
these molecules varies in the different stages of differentiation of the 
hematopoietic system cellular components and any alteration of these processes 
is directly associated with dysregulation of one or more miRNAs. At this regard, 
in human medicine, the miRNA expression profiles are used for the classification 
of hematopoietic tumors, and other types of cancer, for diagnostic and 
prognostic purposes. The frequency and nature of some of these tumors are 
similar in dogs and humans. In dog, the studies of hemato-oncology performed 
to date have shown that the currently used methodologies are not always able to 
obtain comprehensive information about the staging, grading, 
immunophenotyping and prognosis. This makes miRNAs very attractive as new 
potential diagnostic and prognostic markers allowing better subclassification of 
these tumors in dogs. It should be considered that dogs are affected by 
spontaneous hematopoietic and immunological disorders resembling those 
affecting humans. This opens the possibility that some evolutionarily conserved 
miRNAs may play a role in the pathogenesis of, for example, canine lymphomas 
and leukemias, as reported in humans. 
The purpose of the study undertaken in this project was to examine, using real 
time RT-PCR, the expression profile of a panel of miRNAs in some hematological 
malignancies of the dog, such as chronic lymphocytic leukemia (CLL), lymph node 
lymphoma and splenic lymphoma, in relation to their non cancer tissues. Panels 
of miRNAs, already known in humans because of their importance in 
hematopoietic malignancies, have been selected for investigation, according to 
the information available in the literature and databases, and to their level of 
conservation in the canine genome. As a preliminary step, for each studied 
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canine neoplasia, an accurate validation of suitable candidate endogenous 
control genes for normalization of miRNA expression levels in normal and 
neoplastic lymphoid tissues was made. This was performed by means of real 
time RT-PCR followed by statistical analysis using the algorithms NormFinder and 
geNorm. The results of this study confirm that in dogs, as already shown in 
humans, there is differential expression of some miRNAs in various hematologic 
malignancies, suggesting the potential utility of miRNA monitoring as a new 
diagnostic strategy in canine hematopoietic malignancies. At this regard, it 
should be underlined that in dogs is often difficult to obtain a sufficient number 
of fresh clinical samples to perform large diagnostic studies. From here the need 
arises to carry out studies of retrospective nature based on appropriately 
validated methods of analysis that make possible to analyze archival samples, 
such as paraffin-embedded tissues or cytological smears on glass slides. With 
regard to miRNAs, analysis procedures of cytological smears are not currently 
available in the literature, and only a little number of studies using tissue 
samples fixed in formalin and embedded in paraffine have been published, with 
no reference to canine tumours. Therefore, one of the goals of this study was to 
develop a methodology for extraction and analysis of miRNAs from smears of 
aspirated lymph node (for the study of lymph node lymphoma) and peripheral 
blood (for the study of CLL) and from tissue sections fixed in formalin and 
included in paraffin (for the study of splenic lymphoma). The results obtained 
during this study confirm the possibility to analyze miRNAs for retrospective 
studies starting from such archival samples, as the data obtained from these 
samples are comparable to those obtained from fresh samples. This reinforces 
the potential utility of miRNA monitoring in the diagnosis of canine 
hematopoietic malignancies.  
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1.2  INTRODUCTION 
 
1.2.1 microRNAs  
 
MicroRNAs (miRNAs) are a class of short (approximately 21-22 nucleotides) 
noncoding RNAs that are involved in gene expression negative regulation 
through sequence-specific base pairing to target mRNAs, usually in their 3’-UTR 
part, resulting in translational repression or mRNA degradation and gene 
silencing (Bartel D.P. 2004). Each miRNA can control hundreds of gene targets, 
and different miRNAs can regulate the same target mRNA. Most miRNAs are 
widely expressed in several tissues and organs, whereas a limited number are 
restricted to certain cell types reflecting the diversity in cellular phenotypes and 
as such suggest a role in tissue differentiation and maintenance. Due to their 
abundant presence and far-reaching potential, miRNAs have been reported to be 
involved in a variety of functions, including developmental transitions, neuronal 
patterning, apoptosis, adipogenesis metabolism and hematopoiesis in different 
organisms (Singh S.K. et al 2008). 
 
1.2.2 miRNAs: history 
 
MiRNAs were first discovered in 1993 by Victor Ambros, Rosalind Lee and 
Rhonda Feinbaum during a study regarding the nematode Caenorhabditis 
elegans (C. elegans) development (Lee R.C. and Ambros V., 1993). This study 
discovered that the lin-14 gene was able to be regulated by a short RNA product 
from lin-4 gene. Indeed, lin-4 gene encoded for a 61 nucleotide precursor RNA 
that accrued to a 22 nucleotide mature RNA, containing sequences partially 
complementary to multiple sequences in the 3’ UTR of the lin-14 mRNA. This 
complementarity was sufficient and necessary to inhibit the translation of lin-14 
mRNA. Retrospectively, this was the first miRNA identified, even though Ambros 
et al. speculated that it was a nematode idiosyncrasy. Later, in XXI Century, when 
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let-7 (phylogenetically conserved beyond nematodes) was discovered to be able 
to repress lin-41, lin-14, lin28, lin42 and daf12 mRNA during the developmental 
stages of C. elegans, became apparent that the short non-coding RNA identified 
in 1993 was part of a wider phenomenon (Singh S.K. et al, 2008; Reinhart B.J. et 
al 2000; Pasquinelli A.E. et al 2000). Since then, over 4000 miRNAs have been 
discovered in all studied eukaryotes including mammals, fungi and plants.  
 
1.2.3 miRNAs: biogenesis and mechanism of action 
 
 
Figure 1. miRNA biogenesys (Chen C.Z. 2005) 
 
14 
 
miRNA biogenesis includes miRNA transcription in the nucleus, the export of 
miRNAs from the nucleus to the cytoplasm, and subsequent processing and 
maturation in the cytoplasm (Figure 1) (Singh S.K. et al, 2008). In many cases, the 
transcription of miRNA genes is mediated by RNA polymerase II (Pol II), resulting 
in long primary miRNA (pri-miRNA) transcripts, although a cluster of human 
miRNAs interspersed within Alu elements in Chromosome 19 have recently been 
shown to utilize RNA Polymerase III for their transcription (Cai X et al, 2004; 
Erson A. E. et al, 2008; Liu X et al, 2008). Moreover, viral miRNAs transcribed by 
pol III were identified, raising the possibility that some endogenously encoded 
miRNAs may utilitize this polymerase (Pfeffer S. et al, 2005). 
Many miRNA genes tend to be in close proximity to other miRNAs, and are 
transcribed as polycistronic transcripts (Lee Y et al, 2002). According to the 
genomic region that a miRNA resides in, miRNAs can be grouped into several 
categories: intronic miRNAs in protein-coding genes, exonic miRNAs in non-
coding genes and intronic miRNAs in non-coding genes (Rodriguez A et al, 2004; 
Lee Y et al, 2004; Liu X et al, 2008). As illustrated in Figure 2, pri-miRNAs exist in 
several configurations. One or more miRNAs may be found within a single pri-
miRNA. Many pri-miRNAs are long, unspliced transcripts. Alternatively, pri-
miRNAs may be spliced with the miRNA hairpin located in an intron, exon, or the 
3' UTR. These spliced host transcripts often encode proteins, although many lack 
of identifiable coding potential (Rodriguez A et al, 2004). 
 
 
Figure 2. Structures of primary miRNA transcripts (pri-miRNAs)  
(Mendell J.T. 2005) 
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A typical monocistronic pri-miRNA is composed of a doublestranded stem of ~33 
base pairs, a terminal loop and two flanking unstructured single-stranded 
segments (Figure 2) (Lee Y et al, 2002; Liu X et al, 2008). The generation of 
precursor miRNA (pre-miRNA) from the pri-miRNA transcript takes place in the 
nucleus through the action of the microprocessor complex, composed of the 
RNase III enzyme Drosha and the double-stranded RNA-binding domain (dsRBD) 
protein DiGeorge syndrome critical region gene 8 (DGCR8), into 70– 80 
nucleotide pre-miRNAs (Figure 1)(Lee Y et al, 2003; Denli A.M et al, 2004; 
Gregory R.I. et al, 2004; Singh S.K. et al, 2008). This process is known as cropping: 
during this step Drosha liberates the double-stranded stem from the remainder 
of the pri-miRNA by cleaving proximal and distal of the stem, and thus generates 
a pre-miRNA that has a 5′ monophosphate and a 3′2-nt hydroxyl overhang (Lee Y 
et al, 2003; Liu X et al, 2008). Cleavage of a pri-miRNA by microprocessor begins 
with DGCR8 recognizing the ssRNAdsRNA junction typical of a pri-miRNA (Han J. 
et al, 2004). Drosha is brought close to its substrate through interaction with 
DGCR8 and cleaves the stem of a pri-miRNA ~11 nt away from the two 
singlestranded segments (Han J. et al, 2006). The precision of Drosha–DGCR8 
cleavage is very important for miRNA maturation. Any shift in the position of the 
Drosha cut, even by a single nucleotide on the primiRNA, will affect the position 
of Dicer cleavage. A shift in the Dicer cleavage site could result in different 5’-
ends and 3’-ends in the mature miRNA, resulting in different affinity for the 
mRNA target (Singh S.k. et al, 2008). Although microprocessor is already 
sufficient for conversion of a pri-miRNA into a pre-miRNAs in vitro, cleavage of 
pri-miRNA in vivo does not depend on Drosha and DGCR8 only, but also on other 
accessory proteins, such as the RNA binding protein hnRNP A1 and the p68 and 
p72 RNA helicases (Liu X et al, 2008). There is evidence that pre-miRNAs can be 
produced without having to undergo the microprocessor machinery if they are 
directly spliced from the introns in which they reside (Figure 3) (Okamura et al., 
2007; Ruby et al., 2007). These miRNAs are called mirtrons and have traditionally 
been thought to only exist in Drosphila and C. elegans. However, mammalian 
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mirtons that even show conservation between species have recently been 
discovered (Berezikov et al., 2007).  
 
 
Figure 3. splicing mirtrons (Lages E. et al, 2012) 
 
Pre-miRNAs are exported to the cytoplasm from the nucleus by exportin-5 (Exp-
5) in the presence of Ran-GTP as a cofactor (Fig. 1) (Lund E et al, 2004; Bohnsack 
M.T. et al, 2004; Singh S.K. et al, 2008). The nuclear membrane protein exportin 
5 recognises the 2 nucleotide overhang on the 3’ end of the pre-miRNA (Zeng 
and Cullen, 2004) and then transports it into the cytoplasm using ran-guanine 
triphosphatase (Ran-GTP) which is hydrolyzed in Ran-GDP. The role of Exp-5 in 
nucleocytoplasmic transport was verified by using RNA interference (RNAi). In 
the event of Exp-5 depletion by RNAi, the level of mature miRNAs goes down but 
pre-miRNA does not accumulate in the nucleus. The lack of accumulation could 
be due to instability of pre-miRNA. This suggests the possibility that interaction 
of pre-miRNA with Exp-5 is required for the stability of pre-miRNA (S.K. et al, 
2008). 
In the cytoplasm the pre-miRNAs are processed into a short RNA duplex, termed 
miRNA duplex, by RNase III enzyme Dicer (Figures 1 and 4) (Liu X et al, 2008; 
Singh et al, 2008). Dicer cleavage ends with the release of an imperfect 
miRNA:miRNA duplex around 20-25 nucleotides in size containing the mature 
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miRNA strand and its opposite complementary miRNA strand. Both arms of the 
pre-miRNA stem loop structures are imperfectly paired, containing G:U wobble 
pairs and single nucleotide insertions. These imperfections cause one strand of 
the duplex to be less stably paired at its 5’-end (Seitz H and Zamore PD 2006). 
 
 
Figure 4. Precursor miRNA (Pre-miRNA) processing (Liu X. et al, 2008) 
 
After processing with Dicer, miRNA duplex interacts with the RNA Induced 
Silencing (RISC) loading apparatus. RISC is an RNA–protein complex that 
mediates the effect of inhibition of target mRNA by the action of miRNAs. The 
miRNA duplex loaded into RISC is first carried out to give the mature miRNA 
single-stranded, which represents the biologically active form; the unwinding of 
the duplex strands starts at the ends with the lowest thermodynamic stability. 
The relative stabilities of the base pairs at the 5’-ends of two strands determine 
the fate of the strand (Schwarz D.S. et al, 2003). In general, the miRNA strand 
which has its 5’-terminus at the lowest thermodynamic stability, acts as the 
mature miRNA, guide strand, and the other strand, passenger strand, is 
degraded. However, a report has shown that both strands could be 
coaccumulated as miRNA pairs in some tissues, and subjected to strand selection 
in other tissues (Ro S. et al 2007). Mature miRNAs are incorporated into the 
effector complexes, known as miRNP (microRNA ribonucleoprotein), mirgonaute, 
or miRISC, which is composed of Dicer, transactivating response RNA binding 
protein (TRBP) and protein Argonaute 2 (Ago 2) (Figure 1 and 5)(Singh et al, 
2008). 
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Figure 5. miRNA processing (Liu X. et al, 2008). 
 
The Argonaute family includes different proteins, each containing characteristic 
domains termed PAZ and PIWI. The Argonaute family can be phylogenetically 
divided into two protein families: Ago and Piwi, depending on similarities to 
Arabidopsis AGO1 and Drosophila Piwi proteins, respectively (Carmell M.A. et al, 
2002). miRNAs bind Ago proteins whereas Piwi proteins bind a newly discovered 
class of small RNAs known as piwi-interacting RNAs (piRNAs), which are almost 
exclusively expressed in the germline (Aravin A.A. et al, 2007; Kim V.N. 2006). 
The miRNA/Ago ribonucleoprotein that is formed represents the core 
component of the effector complexes that mediate miRNA function and is known 
as miRNP (Mourelatos Z. et al, 2002). It is important to note that, in 4 
mammalian argonaute proteins, only Ago2 has endonucleolytic (also known as 
slicer) ability and is the only argonaute necessary for RNA silencing, whereas the 
others are involved in translational repression (Meister et al., 2004).  
19 
 
miRNAs base-pair with miRNA recognition elements (MREs) located in their 
mRNA targets (typically in the 3′ untranslated region—3′UTR) and deposit their 
bound Ago proteins onto mRNA targets. The result is translational repression of 
the targeted mRNA, often followed by mRNA destibilization or endonucleolytic 
cleavage of the targeted mRNA. The exact molecular function is dependent upon 
how extensive the complementarity of the miRNA is with its mRNA target and 
which Ago protein is deposited on the mRNA target. If a miRNA, bound to Ago2, 
pairs with extensive complementarity with a cognate mRNA target, then the 
mRNA is cleaved at a position across from nucleotides 10 and 11 of the miRNA, 
while the miRNA remains intact (Figure 6) (Elbashir S.M. et al, 2001; Hutvagner 
G. and Zamore P.D. 2002; Liu J et al, 2004; Liu X et al, 2008). This cleavage event 
produces 5′-phosphate and 3′-hydroxyl terminal products, characteristic of other 
RNase H-like enzymes (Martinez J. and Tuschl T. 2004, Schwarz et al, 2004). The 
target mRNA is subsequently degraded via routine cellular pathways (Figure 6).  
 
Figure 6. Target RNA cleavage by Ago2-containing miRNP (Liu X et al, 2008). 
 
mRNA target cleavage by miRNAs is the major mechanism of regulation by plant 
miRNAs (Dugas D.V. and Bartel B. 2004, Llave C et al, 2002). In animals, however, 
there are very few examples of miRNAs that regulate their mRNA targets by 
cleavage (Yekta S. et al, 2004); rather, the predominant silencing mode of animal 
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miRNAs is to repress the translation of their mRNA targets and/or to destabilize 
them without endonucleolytic cleavage (Figure 7B) (Ambros V. 2004; Filipowicz 
W. 2005). The vast majority of animal miRNAs base-pair with imperfect 
complementarity with their mRNA targets. Experimental and bioinformatics 
approaches have shown that the most important determinant of target RNA 
recognition by a miRNA is perfect or near-perfect complementarity between the 
proximal (5′) region of the miRNA (nucleotides 2–8) and the mRNA, also known 
as the “seed” region or the “nucleus” (Figure 6A) (Doench J.G. and Sharp P.A. 
2004; Kiriakidou M. et al, 2004; Lai E.C. 2002; Rajewsky N. and Socci N.D. 2004; 
Liu X et al, 2008). The miRNAs sharing common seed sequences are grouped into 
miRNA families. These miRNAs possibly have overlapping targets and are 
considered to be redundant (Hwang H.W. et al, 2007). 
 
 
Figure 7. Principles of miRNA binding to target RNA (Liu X et al, 2008). 
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Recent reports have demonstrated that mRNA subjected to miRNA repression 
accumulates in P-bodies (Teixeira D. et al, 2005). P-bodies have been reported as 
the sites for decapping and degradation of mRNAs. P-bodies include the Dcp1p ⁄ 
Dcp2p, activators of decapping, Dhh1p (referred to as RCK in mammals), Pat1p, 
Lsm1-7p, Edc3p and the 5’–3’-exonuclease Xrn1p. The decapping process 
exposes the transcript to degradation by the 5’ 3’-exonuclease Xrn1p. 
Alternatively, transcripts can be degraded in the 3’ 5’ direction following 
deadenylation in exosomes, by a conserved complex of 3’-to-5’- exonucleases 
(Singh S.K. et al, 2008). P-bodies contain untranslated mRNAs and can serve as 
sites of mRNA degradation. This suggests that RISC proteins direct the mRNA to 
P-bodies, possibly for storage. So, the P-bodies do not just degrade mRNA, but 
also temporarily sequester them away from the translation machinery (Singh S.K. 
et al, 2008). 
 
1.2.4 miRNAs: target prediction and validation 
 
To delineate the function of any specific miRNA is necessary the target 
identification (Mendell J.T. 2005). In plants, target identification is greatly 
simplified because of the perfect complementarity between miRNAs and their 
mRNAs target. Instead, in C. elegans, Drosophila and mammals the target 
identification is more difficult because miRNAs and their mRNAs target are not 
perfectly complementary (Ambros V. 2004). Based on the interaction between 
lin-4 and its mRNA target lin-14 in C. elegans (Figure 8), it is generally believed 
that miRNAs bind one or several partially complementary sites in mRNA target 3' 
UTR (LeeR.C. et al, 1993), and the region of base-pairing in miRNA 5' end is 
considered the most critical. Specifically, miRNA nucleotides 2-8 form the “seed” 
region and many current target prediction algorithms operate a searching for 
complementarity with this sequence (John B. et al, 2004; Lewis B.P. et al, 2003). 
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Figure 8. miRNA recognition of target mRNAs (Mendell J.T. 2005) 
 
A recent study identified many putative miRNA targets by searching for seed 
sequence complementarity that was conserved in several vertebrate genomes. 
That study predicted that up to 30% of human transcripts are regulated by 
miRNAs (Lewis B.P. et al, 2005). Additional studies have now demonstrated that 
base-pairing between the 3' end of a miRNA and a target without a strong seed 
match can also induce silencing (Brennecke J. et al, 2005). Therefore, the 
computational prediction of miRNA targets depends on rules that have been 
built on a small number of known interactions between some miRNAs and their 
targets, which were then generalized in search of the entire genome. 
Starting from three animal miRNAs, lin-4, let-7 and Bantam, with experimentally 
validated target known, the group of Stark A. et al. screened the entire 
Drosophila genome on the basis of three criteria: 
 perfectly complementary, or G-U pairing, between the target 3'-UTR and 
the first 8 nucleotides of the miRNA 
 formation of structurally and thermodynamically favored heteroduplex 
between miRNA and its putative target,  
 evolutionarily conserved miRNA target sites, between Drosophila 
melanogaster and D. pseudoobscura 
 
To experimentally validate the potential target, GFP reporter gene was fused 
upstream the 3'UTR of the predicted target and the expression of GFP in "WING 
DISC" with and without overexpression of the corresponding miRNA was 
examined. (Stark A. et al. 2003). 
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The research group of Burge et al., instead, developed the TargetScan algorithm 
to predict miRNA targets in vertebrates, on the basis of complementarity with 
the miRNA-target (particularly in 5'-miRNA region) and the evolutionary 
conservation among vertebrates. 29% of their predicted targets have unknown 
functions, while 71% have different functions, such as DNA binding, 
transcriptional regulation, signal transduction and kinase activity. Subsequently, 
they experimentally validated 11 predicted target, using a HeLa cells line, with 
luciferase fused to the 3'-UTR of the target predicted, as a reporter system.  
Although the prediction success rate in the entire genome is difficult to 
determine, these studies constitute an important step toward understanding the 
animals miRNAs function (Lewis B.P. et al, 2005). 
 
While computational prediction of miRNA targets has advanced rapidly, still few 
mammalian targets have been verified through direct experimentation (Mendell 
J.T. 2005). These studies are critical not only for understanding miRNA function, 
but also for refining and improving target prediction algorithms. Two main 
approaches are utilized to targets validation. The most common method involves 
the generation of plasmids containing the target mRNA 3' UTR fused to a 
reporter gene, such as luciferase (Lewis B.P. et al, 2003). Paired constructs are 
generated with mutations in the miRNA binding sites. When these reporters are 
expressed in cell lines expressing the miRNA of interest, the mutant construct 
exhibits enhanced expression since the miRNAs can no longer bind. This method 
is experimentally tractable and allows direct definition of the miRNA binding 
sites. However, like all reporter assays, these experiments do not recapitulate 
the precise context of the miRNA recognition sites nor do they reproduce 
endogenous expression levels. Thus, these experiments must be interpreted with 
caution (Mendell J.T. 2005). Another strategy utilizes a recently described 
method to inhibit the function of miRNAs in cell lines. 2'-O-methyl 
oligoribonucleotides that are complementary to miRNAs act as sequence-specific 
competitive inhibitors of miRNA function (Meistell G. et al, 2004; Hutvagner G et 
al, 2004). Thus, transfection of cells with these antisense reagents allows direct 
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examination of endogenous target mRNA and protein levels in the presence and 
absence of functional miRNAs. These studies more reliably demonstrate in vivo 
regulation of a target by a miRNA, but they do not provide proof that the 
regulation is direct. Ideally, both reporter assays and analysis of endogenous 
miRNA function with antisense oligos should be performed to establish a miRNA-
target interaction (Mendell J.T. 2005). The development of methodologies that 
would allow direct demonstration of a miRNA-target mRNA interaction in vivo, 
perhaps utilizing crosslinking and immunoprecipitation in a manner analogous to 
chromatin immunoprecipitation, would significantly advance these efforts 
(Mendell J.T. 2005). 
 
1.2.5 miRNAs database 
 
The microRNA Registry was created in 2003 with the purpose of to provide an 
archive, in an organized and understandable way, of all published miRNA 
sequences, in order to facilitate the development of the computational approach 
to predict miRNA genes and targets and to avoid, given the high rate of miRNAs 
gene discovery, unexpected overlap of identical miRNA denominated in a 
different way (Griffiths-Jones S. 2004).  
The miRBase database, dated 2007, comes from an expansion of the miRNA 
Registry, and encompasses both the nomenclature of genes and sequence data. 
It has three main functions:  
1. miRBase Registry. It provides an independent service of names assignment for 
new miRNA genes, prior to publication  
2. miRBase Sequences. It provides sequence data, annotations, bibliographic 
references and links to other resources, for all published miRNAs. The database 
(Version 10.0) contains more than 5000 sequences for 58 species. A number of 
access for both strands of the precursor and the mature sequence is assigned, in 
order to be able to trace the origin of the sequence (Griffiths-Jones, S. 2008). 
Figure 9 shows an example of miRBase Target screen. 
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Figure 9. Example of miRBase Target screen (from Griffiths-Jones S., 2006). 
 
3. miRBase Targets. It provides an automated system for predicting the targets of 
all miRNAs from animals. The current version of the database v5 includes more 
than 500000 target transcripts for all miRNAs in 24 species using the Miranda 
algorithm (John B. et al. 2005) 
 
The main objective of the miRBase Registry is to assign unique names to the 
different miRNAs. For every miRNAs is assigned a numerical identifier based on 
sequence similarity. Homologues miRNAs in different organisms receive the 
same name. The name depends on the sequence of the mature miRNA and not 
on the precursor sequence.  
The scheme of the nomenclature is as follows:  
1.  the name of the miRNA contains three or four letters of the species, as prefix 
and suffix number. For example, hsa-miR-212  
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2.  mature sequences identical, but originating from different loci in an organism, 
have the same name with a numerical suffix (mir-6-1 and mir-6-2)  
3.  to sequences that vary by one or two nucleotides, is given a letter suffix (miR-
181a and miR-181b)  
4.  to genes of miRNAs in plants are given a structured name such as ath-
MIR166a. the letter as a suffix describes mature miRNA derived from related but 
different loci  
5.  the names of the viral miRNAs are conventionally related to the locus from 
which are derived, such as EBV-mir-BART1 derived from the Epstein Barr virus 
BART to the locus (Griffiths-Jones, S. 2008).  
Figure 10 shows an example of screen miRBase. 
 
 
Figure 10. Example of miRBase screen (from Griffiths-Jones S., 2006). 
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All miRNAs present in the database have been mapped for their coordinates 
within the genome. The groups of miRNA sequences are highlighted within the 
genome and can be defined and retrieved in block (Griffiths-Jones, S. 2008). 
Furthermore, the overlap between miRNAs sequences, transcripts, proteins and 
noncoding sequences are noted (http://microrna.sanger.ac.uk/). 
 
1.2.6 miRNAs expression studies 
 
miRNAs expression was initially determined using a cloning strategy (Chen C.Z. et 
al, 2004), while the techniques most commonly applied nowadays are: Northern 
blotting, quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) 
or microarray technology. However, these high throughput methods should be 
used with caution, especially miRNA microarrays, because irreproducible results 
may be obtained, for instance due to large differences in individual optimal 
hybridization temperatures of the probes. Quantitative RT-PCR specific for 
mature miRNAs seems to provide more accurate results and is currently 
considered the golden standard method (Chen C. et al, 2005; Kluiver J. et al, 
2006). 
Northern blot analysis is a well-established technique for studying messenger 
RNA expression and was soon adapted to detect miRNAs in cells or tissues (Lee 
R.C. et al. 1993; Valoczi A. et al, 2004). Subsequently, conventional DNA 
microarray technology was modified to form miRNA microarrays, allowing the 
simultaneously detection of multiple miRNAs across various samples (Miska E.A. 
et al, 2004; Nelson P.T. et al, 2004; Thomson J.M. et al, 2004; Castoldi M. et al, 
2006). Lu et al. developed a novel microarray strategy to improve probe 
specificity, which is critical due to the short nature of mature miRNAs. They 
performed hybridization in solution using polystyrene capture beads that are 
coupled to oligonucleotide probes complementary to the miRNAs of interest. 
The hybrid solutions are then analyzed using a multicolor flow cytometer that 
measure bead color, denoting miRNA identity, and label intensity, denoting 
miRNA abundance (Lu J. et al, 2005). In parallel to microarray platforms, 
28 
 
commercial assays for quantitative reverse transcriptase polymerase chain 
reaction (RT-PCR) have become available. These allow the analysis of miRNAs in 
small tissue samples or even single cells (Tang F. et al, 2006). RT-PCR is currently 
the choosen technique to quantify the expression profiles of individual miRNAs 
in a wide variety of cell types and pathological situations. In 2005, the group of 
Chen et al. has developed a new TaqMan-based real-time quantification of 
miRNAs that includes two steps: stem–loop RT and realtime PCR. Stem–loop RT 
primers bind to at the 3’ portion of miRNA molecules and are reverse transcribed 
with the reverse transcriptase enzyme. Then, RT product is quantified using 
conventional TaqMan PCR that includes miRNA-specific forward primer, reverse 
primer and a dye-labeled TaqMan probes. The purpose of tailed forward primer 
at 5’ is to increase its melting temperature (Tm) depending on the sequence 
composition of miRNA molecules (Figure 11) (Chen C. et al. 2005). 
 
 
Figure 11. TaqMan-based real-time quantification (Chen C. et al. 2005). 
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Housekeeping selection for qRT-PCR 
The quantitative Real-Time PCR (qRT-PCR) is used to evaluate gene expression, 
and requires the same type of normalization of traditional methods of mRNA 
quantifying (Vandesompele J. et al. 2002). In gene expression analysis, there are 
several variables that must be kept controlled, as the amount of starting 
material, enzymatic efficiencies and differences between tissues or cells in the 
activity transcriptional overall. In order to normalize these variables different 
strategies are used, including controlled conditions for reproducible RNA 
extraction and standardization of the number of transcribed genes compared to 
the number of cells contained in the sample, even though an accurate count of 
the cells is often compromised, for example starting from tissues. Another 
method of normalization is to use the amount of total RNA. The major problem 
of this method depends on the fact that most of the RNA is rRNA and therefore it 
is not always is representative of the mRNA fraction (Vandesompele J. et al. 
2002). Until now, the standardization system most commonly used to normalize 
the mRNA fraction is utilize an internal control gene. This internal control, also 
called housekeeping gene, must shoes a stable level expression, i.e. not to vary in 
tissues or cells under investigation or in response to experimental treatments. 
This ideal condition is actually not achievable in practice, since the literature 
shows that there are no universal control genes, and the expression of the 
housekeeping genes can considerably vary in different conditions. The choice of 
the gene and the number of housekeeping depends on the tissue or on the cell 
type examined (Warrington JA et al. 2000). Vandesompele, in 2002, has done an 
extensive evaluation of 10 housekeeping genes commonly used in 13 different 
human tissues and described a procedure to calculate the factor of normalization 
based on more control genes to obtain a normalization of gene expression data 
more accurate and realistic. Among the candidate genes, are selected genes 
belonging to different functional classes, which allows to significantly reduce the 
possibility that they can be co-regulated. The level of expression of these internal 
control genes must be determined in a sufficient number of representative 
samples of the study that you want to lead (Vandesompele J. et al. 2002). It is 
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generally accepted that the levels of gene expression can be normalized through 
an internal control gene stable and accurately selected. However, in order to 
validate the presumed stable expression of the control gene any nonspecific 
variation must be eliminated. Therefore the study in question has developed a 
measurement of the gene stability to determine the stability of expression of the 
control genes based on not normalized expression levels. This measurement is 
based on the principle that the expression ratio between two ideal internal 
control genes is identical in all samples, regardless of the experimental 
conditions and the cell type. Consequently, the variation of the relationship of 
expression between two authentic housekeeping reflects the fact that one or 
both the genes are not expressed constantly; the increase of the variation of the 
ratio corresponds to a decrease in the stability of expression. For each control 
gene candidate is determined the variation "pairwise" (two by two) with all other 
control genes in the form of standard deviation of the ratios of expression 
transformed into logarithmic scale; the result is defined as the measure M of the 
genetic stability of internal control as the average pairwise variation of a 
particular gene compared to all other control genes candidates. M genes with 
lowest expression values are more stable. Assuming that the control genes are 
not co-regulated, the gradual exclusion of the gene with the highest value of M 
gives rise to a combination of the 2 constitutively expressed housekeeping genes 
that have the most stable expression in the samples tested. For this purpose has 
been created a Visual Basic Application (VBA) for Excel, called geNorm, freely 
available for use, which automatically calculates the M value of gene expression 
stability for all control genes in a given set of samples. The program allows the 
elimination of housekeeping genes with worst performance (highest M value) 
and recalculates the new M value for the remaining genes. Furthermore the 
systematic variation is calculated in the form of pairwise variation, V, for 
repeated experiments of RT-PCR on the same gene that reflects the variations of 
pipetting, enzymatic and inherent to the machine. The work of Vandesompele et 
al. has shown that, to accurately measure the levels of expression is required 
normalization with more housekeeping genes rather than just one. Consequently 
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is necessary to calculate a normalization factor based on the expression levels of 
housekeeping genes with the best performance. For an accurate calculation of 
the average of the control genes, Vandesompele et al. proposed to use the 
geometric mean instead of the arithmetic mean that allows a better control of 
the extreme values and the differences between quantities of different genes. 
The number of genes used to calculate the geometric mean is a compromise 
between precision and practical considerations; fact becomes impractical to use, 
for example, eight genes control when you must study few target genes or when 
it has a reduced amount of RNA available. In general, then, using a minimum of 3 
most stable control genes with a gradual increase in the number of genes based 
on the improvement generated (Vandesompele J. et al. 2002). 
Another approach for the selection of housekeeping genes is based on the work 
of Andersen et al. in 2004. This approach involves the application of a 
mathematical model to describe the expression values measured by qRT-PCR, 
divide the analysis of the various sub-groups of samples, estimate the variations 
of expression between the different groups and within the same group and 
calculate the "stability value" M candidate gene (Andersen C.L. et al., 2004). The 
group of Andersen created a VBA for Microsoft Excel, called NormFinder, freely 
available for use, which automatically calculates the stability of M for all genes 
standardization candidates and tested in a set of pilot samples. The authors 
suggest that the approach based on NormFinder, which takes account of the 
groups of samples and the direct estimation of the variation of expression, 
provides a more accurate measurement and solid stability of gene expression 
than the approach comparative two by two (geNorm). geNorm, basically, sort 
the genes according to the similarity of their expression profiles. Assuming a 
situation in which the set of samples is composed by two sub-groups in which all 
but one of the candidates have differences between the groups, in this case the 
optimal candidate with no differences between the groups in the approach 
geNorm could be excluded prematurely, while in NormFinder approach would be 
presented with the value of M less than the other candidates. Furthermore, the 
ranking of genes assigned on the basis of the similarity of their expression 
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profiles is problematic if there are co-regulated genes between the candidates 
that will tend to show expression profiles similar and therefore, regardless from 
their actual stability of expression, will be selected as the pair more stable 
(Andersen C.L. et al., 2004). These considerations suggest that the optimal 
strategy for the choice of the housekeeping genes consists in analyze the 
expression data with both methods (geNorm and NormFinder) that can mutually 
cross the results obtained. 
 
1.2.7 miRNAs and cancer 
 
 To date, over 1000 miRNAs have been identified in animal genomes through 
cloning and bioinformatics approaches. Although the biological roles of only a 
small fraction of identified miRNAs have been elucidated, in mammals these 
miRNAs regulate processes essential to cell growth, embryogenesis, stem cell 
maintenance, hematopoietic cell differentiation, and brain development (Lagos-
Quintana M. et al, 2003; Alvarez-Garcia I. and Miska E.A. 2005; Kloosterman W.P. 
and Plasterk R.H. 2006;  Bartel D.P. 2009; Liu J. et al, 2011). Since Croce‘s 
research group first reported the link between the abnormal expression of 
miRNAs and cancer in 2002 (Calin G.A. et al, 2002), more and more studies have 
shown that many miRNAs take part in the progressions of various cancers, 
including tumor growth, differentiation, adhesion, apoptosis, invasion, and 
metastasis (Calin G.A. et al, 2004; Calin G.A. et al, 2006; Gaur A. et al, 2007). 
Moreover, several miRNAs were shown to be located at fragile sites or at 
genomic sites that are altered in cancer (Calin G.A. et al, 2004). Specific miRNAs 
were shown to be underexpressed and map to regions that are frequently 
deleted, whereas others were reported to be overexpressed and map at regions 
that are frequently amplified in cancer (Calin G.A. et al, 2002; Johnson S.M. et al, 
2005; He L. et al, 2005; Tagawa H. et al, 2005). miRNA profiling experiments have 
revealed that many miRNAs are abnormally expressed in clinical cancer samples. 
In addition, in in vitro and in vivo models, these abnormal expressions have been 
pointed out to be closely related to various biological behaviors of cancers (Lu J. 
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et al, 2005; Sassen S. et al, 2008; Liu J. et al, 2011). Thus, alterations of miRNAs 
expression may promote tumor formation by modulating the functional 
expression of critical genes involved in tumor development and progression 
(Wiemer E.A. 2007). 
 
1.2.8 miRNAs in hematopoiesis  
 
Hematopoiesis is regulated by miRNAs. Various miRNAs are up-regulated at 
specific stages during hematopoietic development and the functional relevance 
of miRNAs has been proven at many different stages of lineage specification. 
Knockout of specific miRNAs can produce dramatic phenotypes leading to severe 
hematopoietic defects. Furthermore, several studies demonstrated that specific 
miRNAs are differentially expressed in hematopoietic stem cells. However, the 
emerging picture is extremely complex due to differences between species, cell 
type dependent variation in miRNA expression and differential expression of 
diverse target genes that are involved in various regulatory networks. There is 
also evidence that miRNAs play a role in cellular aging or in the inter-cellular 
crosstalk between hematopoietic cells and their microenvironment. The field is 
rapidly evolving due to new profiling tools and deep sequencing technology. In 
human, the miRNAs expression profiles are of diagnostic relevance for 
classification of different diseases. Recent reports on the generation of induced 
pluripotent stem cells with miRNAs have fuelled the hope that specific miRNAs 
and culture conditions facilitate directed differentiation or culture expansion of 
the hematopoietic stem cell pool (Bissels U. et al, 2012). 
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Figure 12. Role of miRNAs in hematopoietic development (Bissels U. et al, 2012). 
These miRNAs were mainly identified using in vitro assays with human cells - only 
those miRNAs labeled with ‡ were identified in the murine system.  
Some transcription factors are demonstrated in green according to Orkin and 
Zon 2008. 
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MiRNA expression in normal hematopoiesis has been studied in murine and 
human hematopoietic tissue by several groups. It has been shown that these 
non-coding RNAs play critical roles in almost every stage of hematopoiesis (Table 
1, Figure 12).  
 
miRNA Function 
miR-150 Controls B- and T- cell differentiation 
Expressed in mature B cells and T cells 
Blocks transition from pro-B to pre-B cells 
Down-regulates C-MYB 
miR-155 Controls B- and T- cell differentiation 
Controls germinal center reaction 
↑ in activated T cells 
Reduces erythroid, myeloid and megakaryocytic 
differentiation 
miR-221 and miR-222 Block erythroid differentiation by targeting c-KIT 
miR-181a B- and T-cell differentiation 
↑ in murine B-cell lineage 
Blocks differentiation of human progenitor cells 
miR-223 ↑ in myeloid lineage 
Up-regulates granulopoiesus 
Down-regulates erytropoiesis 
miR-142 ↑ B and myeloid lineage 
miR-146 Blocks lymphoid differentiation 
↑ in murine Th1 cells 
miR-10a, miR-126, miR-106, 
miR-10b, miR-17, miR20 
↓ in megakaryocyte lineage 
 
Table 1. MiRNA expression in normal hematopoiesis  
(from Kluiver J. et al, 2006; Vasilatou D. et al, 2009) 
 
 
miRNAs in lymphoid differentiation 
The first study demonstrating the relation between miRNAs and hematopoiesis 
was published in 2004. In this study, Chen et al. cloned 150 miRNAs from murine 
bone marrow and found that three miRNAs (mir-181, mir-223 and mir-142) were 
preferentially expressed in hematopoietic cells. mir-181 was highly expressed in 
B-lymphoid cells of murine bone marrow. Its ectopic expression in hematopoietic 
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stem cells resulted in an increase in the proportion of B-lineage cells in vivo and 
in vitro. In addition, mir-223 and mir-142 were highly expressed in myeloid 
lineage (mir-142 in B-lymphoid cells too). However, ectopic expression of these 
two miRNAs resulted in an increase in the proportion of T cells, but not of B or 
myeloid cells as it might be expected (Chen C.Z. et al, 2004; Vasilatou D. et al, 
2009). On the other hand, Ramkinssoon et al. who studied expression profiles of 
mir-142, mir-181, mir-223 and mir-155 found differences in expression patterns 
between human and mouse hematopoietic cells (Ramkinssoon S.H. et al, 2005; 
Vasilatou D. et al, 2009). A very important miRNA in hematopoiesis is mir-150. It 
is preferentially expressed in mature, resting T and B cells but not in their 
progenitors. It is up-regulated during B-cell and T-cell maturation but down-
regulated again during further differentiation of naive T cells into Th1 and Th2 
cells of murine hematopoietic tissue (Monticelli S. et al, 2005). Ectopic 
expression of mir-150 in hematopoietic stem cell progenitors reduces mature B-
cell levels in the circulation, spleen and lymph nodes with little effect on T-cell or 
myeloid cell levels. Further experiments provide evidence that mir-150 blocks 
the transition from pro-B to pre-B cell during B-cell maturation (Zhou B. et al, 
2007) probably explaining the way that ectopic expression of this miRNA reduces 
mature B cells. In addition, TG and knockout (KO) mice models have shown that 
mir-150 induces the apoptosis of pro-B cells. Moreover, miR-150 was found to 
target C-MYB, a transcription factor that controls lymphocyte development. As 
previously mentioned, mir-150 is preferentially expressed in mature B 
lymphocytes but not in their progenitors. C-MYB, on the other hand, is highly 
expressed in lymphocyte progenitors and down-regulated in mature cells. Xiao et 
al. demonstrated, in vivo, an interesting relationship between these expression 
patterns (Xiao C. et al, 2007). Indeed, miR-150 directly down-regulates C-MYB, by 
binding to its mRNA and consequently controls its protein expression in a dose-
dependent manner. Another important miRNA in lymphoid differentiation is mir-
155. It is a product of B-cell integration cluster (BIC) transcript that was first 
described as a frequent site of integration for the avian leucosis virus (Tam W. et 
al, 1997). High levels of mir-155 are present in activated B cells and T cells and in 
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activated monocytes (Fabbri M. et al, 2009). The function of mir-155 has been 
studied in both TG and KO mice. The first TG mice that specifically over-
expressed mir-155 in B cells developed a pre-leukemic pre-B-cell proliferation 
evident in spleen and bone marrow, followed by a B-cell malignancy (Costinean 
S. et al, 2006). Two independent groups developed mir-155 KO mice to study the 
role of mir-155 in B-cell and T-cell differentiation. Thai et al. showed that mir-155 
regulates germinal center reaction and T-helper cell differentiation by affecting 
cytokine production while Rodriguez et al. showed that bic⁄miR-155 regulates 
the function of both lymphocytes and dendritic cells leading to defective immune 
response (Rodriguez A. et al, 2007; Thai T.H. et al, 2007). Finally, Georgantas et 
al. found 33 miRNAs that were expressed in human stem-progenitor cells (HSPC) 
from bone marrow and peripheral blood. The authors used bioinformatic 
techniques to combine these results with HSPC mRNA expression data and with 
miRNA–mRNA target prediction so as to create a miRNA–mRNA interaction 
database, the Transcriptome Interaction Database. Then, they formed a model 
for miRNA control of hematopoiesis. According to this model, mir-181 and mir-
128 inhibit differentiation of all hematopoietic lineages while mir-146 inhibits 
differentiation of multipotent progenitor cell (MPP) into common lymphoid 
progenitors (CLP) (Georgantas R.W. et al, 2007). 
 
miRNAs in granulocyte and monocyte differentiation 
A miRNA that plays an important role in myeloid differentiation is mir-223. Fazi 
et al. studied myeloid differentiation in acute promyelocytic leukemia (APL) cells 
and demonstrated that mir-223 up-regulates mouse granulopoiesis in association 
with the transcription factors negative nuclear factor IA (NFIA) and 
CCAAT⁄enhancer binding protein a (CEBPA). Both transcription factors are able 
to bind to mir-223 promoter. NFIA down-regulates while CEBPA up-regulates 
mir-223 expression. Treatment of APL cells with retinoic acid (RA) resulted in 
CEBPA replacement of NFIA, up-regulation of mir-223 and enhanced granulocytic 
differentiation. Interestingly, mir-223 was found to inhibit translation of NFIA, 
resulting in a negative-feedback loop that favors granulocytic differentiation (Fazi 
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F. et al, 2005). However, two recent studies do not confirm the previous results. 
In the first study, Fukao et al. found that myeloid expression of mir-223 might be 
specified by the conserved 5’ proximal cis-regulatory element where 
transcription factors PU.1 and C⁄EBP cooperatively act on. In addition, by 
studying the APL cell model that was used by Fazi et al., they found that RA 
induced differentiation of APL cells, repressed PU.1 and resulted in down 
regulation of mir-223 (Fukao T. et al, 2007). In the second study, Johnnidis et al. 
found that mir-223 negatively regulates progenitor proliferation and granulocyte 
differentiation and activation in KO mice. In addition, they showed that miR-223 
targets Mef2c, a transcription factor that promotes myeloid progenitor 
proliferation and that genetic ablation of Mef2c suppresses progenitor expansion 
and corrects the neutrophilic phenotype in mir-223 null mice (Johnnidis J.B. et al, 
2008). Further investigations are required to shed light on the real mechanisms 
that regulate mir-223 expression. Fontana et al. investigated the role of mir-17-
5p, mir-20a and mir-106a in monocytic differentiation and maturation. In 
unilineage monocytic cultured cells these miRNAs are down-regulated while 
acute myeloid leukemia 1 (AML1) transcription factor, which promotes M-CSFR 
transcription (M-CSF receptor), is up-regulated at the protein but not at the 
mRNA level. Transfection with miR-17-5p, miR-20a and miR-106a caused the 
opposite results in AML-1 protein expression followed by enhanced blast 
proliferation and inhibition of monocytic differentiation and maturation. Further 
experiments confirmed that these miRNAs target AML-1. In addition, AML1 binds 
the miRNA 17-5p-92 cluster and 106a-92 cluster promoters and inhibits the 
expression of mir-17-5p-20a-106a as a negative feedback, indicating that 
monocytopoiesis is controlled by a circuitry involving miR-17-5p, miR-20a, miR-
106a, AML-1 and M-CSF (Fontana L. et al, 2007). Finally, according to the earlier 
mentioned model of Georgantas et al., mir-155, mir-24a and mir-17 may inhibit 
the differentiation of MPP into common myeloid progenitor (CMP), while mir-16, 
mir-103 and mir-107 may inhibit the differentiation of CMP into 
granulocyticmacrophage progenitor (GMP) (Georgantas R.W. et al, 2007). In 
addition mir-125b supports myelopoiesis but not G-CSF-induced granulocytic 
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differentiation and it has been suggested that this involves targeting of the c-Jun 
and Jund pathways (Surdziel E. et al, 20011). 
 
miRNAs in erythroid and megakaryocytic differentiation 
There is an increasing interest in the role of miRNAs in erythroid and 
megakaryocytic differentiation too. mir-221 and mir-222 are down-regulated 
during erythroid differentiation and maturation. The first eight nucleotides of the 
5’ sites of these miRNAs (seed region) are identical. This fact indicates that miR-
221 and miR-222 can bind to the same target, which is KIT receptor, a key factor 
for the proliferation control of hematopoietic cells. Down-regulation of mir-221 
and mir-222 probably unblocks KIT expression causing the expansion of 
erythroblasts (Felli N. et al, 2005). In addition, both erythroid and myeloid colony 
formation are reduced by mir-155 (Georgantas R.W. et al, 2007). Furthermore, it 
was demonstrated that mir-150 drives megakaryocyte-erythrocyte progenitor 
(MEP) differentiation towards megakaryocytes at the expense of erythroid cells 
(Lu J. et al, 2008). Additionally, Bruchova et al. studied miRNA expression in 
normal and polycythemia vera erythropoiesis. They evaluated 12 miRNAs by 
quantitative real time PCR (qRT-PCR) in a large number of samples from 
peripheral blood mononuclear cells, cultured in a three phase liquid system. 
During normal erythropoiesis, mir-150, mir-155, mir-221 and mir-222 were 
progressively down-regulated (in agreement with the studies mentioned earlier), 
mir-451 (which was found to be erythroid specific) and mir-16 (in reticulocytes) 
were up-regulated while mir-339 and mir-378 showed a biphasic expression 
pattern (Bruchova H. et al, 2007). Georgantas et al. had also showed that mir-155 
blocks both myeloid and erythroid differentiation (Georgantas R.W. et al, 2007), 
while the study by O’Connel et al. demonstrates the role of mir-155 in 
erythropoiesis too. In this study, mouse transplanted with MPP cells that over-
express mir-155 developed a myeloproliferative disorder with decreased 
erythroid⁄megakaryocytic lineage in bone marrow (O’Connell R.M. et al, 2008). 
Moreover, Dore et al. showed that the transcription factor GATA-1 activates in 
vivo the transcription of a single pri-miRNA, encoding miR-144 and miR-451. 
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Zebrafish embryos depleted of mir-451 form erythroid precursors, but their 
development into mature circulating red blood cells is strongly and specifically 
impaired. That was not true when mir-144 was silenced, suggesting that mir-451 
has a specific role in erythropoiesis (Dore L.C. et al, 2008). Recently, mir-223 was 
also found to control erythroid differentiation too. Its down-regulation in 
progenitor and precursor cells of erythroid lineage seems to be necessary for 
erythroid maturation while the expression levels of mir-223 are inversely related 
to the levels of LIM—only protein 2 (LMO2, RBNT2), a highly conserved protein 
that plays in critical role in hematopoietic differentiation. Further experiments 
demonstrated that mir-233 downregulates LMO2 protein, by binding to its 3’-
UTR, and inhibits differentiation and maturation of erythroid cells (Felli N. et al, 
2009). MiRNAs seem to be important in megakaryocytic maturation. Garzon et 
al. performed miRNA expression profiling of in vitro differentiated 
megakaryocytes derived from CD34+ hematopoietic progenitors. Twenty miRNAs 
(including mir-10a, mir-126, mir-106, mir-10b, mir-17 and mir-20) were found to 
be down-regulated. It was also confirmed that miR-130a targets the transcription 
factor MAFB, which is involved in the activation of the GPIIB promoter (a key 
protein for platelet physiology) and that miR-10a directly targets HOXA1 in 
megakaryopoiesis. These two genes are over-expressed during megakaryopoiesis 
suggesting that down-regulation of miRNAs unblocks their expression (Garzon R. 
et al, 2006). Moreover, Labbaye et al. studied leukemic cells lines and showed 
that megakaryopoiesis is controlled by a pathway, in which PZLF transcription 
factor suppresses mir-146 transcription and thereby activates the SDF-1 receptor 
CXCR4 (44). Finally, the transcription factor RUNX1 (also known as AML1 protein) 
is up-regulated during early hematopoiesis and up-regulates mir-27a. During 
differentiation of megakaryocytic lineage, mir-27a negatively regulates RUNX1 
expression forming a feedback loop (Labbaye C. et al, 2008). 
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1.2.9 miRNA profiling in haematological malignancies in human 
 
MiRNAs expression in hematological malignancies has been extensively studied. 
There is an increasing number of reports demonstrating a key role of these non-
coding RNAs in the pathogenesis and prognosis of hematological malignancies, 
the most important of which are summarized in Table 2. 
 
 miRNA Status Function Target 
Lymphomas     
HL miR-155 UR OG PU.1 
 Let-7a UR OG PRDM1/BLIMP-1 
 miR-9 UR OG PRDM1/BLIMP-1 
DLBCL miR-155 UR in ABC OG PU.1, SHIP1 
 miR-15a DR TSG BCL-2 
 miR-21 UR in ABC OG BCL-2 
 miR-221 UR in ABC OG E2F1 
 miR-17-92 UR OG  
MCL miR-17-92 UR OG E2F1 
 miR-16-1 Binding site 
deleted 
TSG CCND1 
Leukemias     
AML miR-181a UR in M1, M2 
DR in M4, M5 
OG/TSG TCL-1 
APL miR-15a, 16-1 UR* TSG BCL-2 
 miR-181b DR   
ALL miR-17-92 UR OG BIM 
 miR-128b UR   
 miR-204 UR   
CLL miR-15a DR TSG BCL-2 
 miR-16-1 DR TSG BCL-2 
 miR-29b DR in poor 
prognosis CLL 
TSG TCL-1 
 miR-181b DR in poor 
prognosis CLL 
TSG TCL-1 
 miR-155 UR OG  
CML miR-203 DR TSG ABL-1 
 miR-17-92 DR OG  
MM miR-15a, 16 DR TSG  
 
Table 2. miRNAs in hematological malignancies (Vasilatou D. et al, 2009). UR: up-
regulated; DR: down-regulated; OG: oncogenes; TSG: tumor suppressor gene 
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miRNA expression in CLL (chronic lymphocytic leukaemia) 
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the 
Western world, accounting for 30% of all leukemia cases in the US (Byrd J.C. et al, 
2004). The del13(q14) is the most common cytogenetic abnormality in CLL and is 
usually associated with good prognosis (Dohner H. et al, 2000). Hemizygous 
and⁄or homozygous loss at 13(q14) occur in more than half CLL cases. Deletions 
of 13(q14) loci are frequently found in other types of cancers, such as mantle cell 
lymphoma, multiple myeloma (MM), prostate cancers and pituitary tumors, 
suggesting that one or more tumor suppressor genes are located in this region 
(Nicoloso M.S. et al, 2007). However, until recently, several studies had failed to 
identify the involved gene located in the deleted region. Calin et al. showed that 
a cluster of two miRNA genes, mir-15a and mir-16-1 (with < 200 bp distance 
between them), is located exactly in 13(q14) region. These genes are highly 
expressed in normal CD5+ B-lymphocytes with mir-16-1 being expressed at 
higher levels than mir-15a. It was also found that both genes are down-regulated 
or deleted in the majority (68%) of the CLL samples and that down-regulation of 
mir-15a and mir-16-1 expression correlates with allelic loss at 13q14, suggesting 
that these two miRNAs may act as tumor suppressors and that their loss 
contributes to the pathogenesis of CLL (Calin G.A. et al, 2002). However, in a 
more recent report, down-regulation of mir-15a and mir-16-1 was found only in 
a small subset of patients. Fulci et al. evaluated 56 patients with the diagnosis of 
CLL for miRNA profiling using miRNA cloning and qRT-PCR. Low expression of 
these miRNAs was found in 11.7% of patients by qRT-PCR and in 11.1% by 
cloning (Fulci V. et al, 2007). These discrepancies may be attributed to the 
methodological differences between the two studies, namely the northern blot 
procedure in the first and the miRNA cloning and qRT-PCR in the recent study, 
the different controls used (CD5+ cells from tonsils in the first and CD5+ cells 
from cord blood in the latter study), as well as in the different population of 
patients. More specifically 68% of informative samples displayed loss of 
heterozygosity (LOH) at the 13q locus in the study by Calin et al., while 26⁄67 
(38.8%) analyzed patients revealed del(13q) by FISH, in the study by Fulci et al. 
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Thus a significantly lower percentage of patients in the latter study had deletions 
at the 13q locus accounting perhaps for the lower frequency of mir-15a⁄mir-16-1 
deletions. Moreover, an alternative mechanism of mir-15a and mir-16-1 
reduction is germ line mutations. A germ-line mutation in the mir-16-1-mir-15a 
primary precursor, in association with deletion of the normal allele was detected 
in two CLL patients. Interestingly, one patient had a family history of CLL and 
breast cancer (Calin G.A. et al, 2005). In addition, miR-15a and miR-16-1 have 
been associated with protein expression in CLL. Mostly non-dividing B-CLL cells 
over-express BCL-2. No mechanism for this aberrant expression has been 
identified, although the overexpression of bcl-2 may be attributed in the 
juxtaposition of BCL-2 to immunoglobulin loci, this mechanism refers to < 5% of 
the CLL cases. Mir-15a and mir-16-1 expression is inversely correlated with BCL-2 
protein levels. Although in normal CD5+ lymphoid cells the levels of both miRNAs 
were high and the BCL-2 protein was expressed at low levels, in the majority of 
leukemic cells both mir-15 and mir-16 were expressed at low levels and BCL-2 
was over-expressed. Further research showed that miR-15a as well as miR-16-1 
downregulate BCL-2 at the post-transcriptional stage of expression. The MEG-01 
cell line (a leukemia-derived cell line with deletion of one allele and alteration of 
the other mir-15a and mir-16-1 loci and no expression of miR-15a and miR-16-1) 
was selected to be transfected by a vector that contains the full mir-15a⁄16-1 
cluster. BCL-2 levels were highly reduced in comparison to WT MEG-01 cells (not 
transfected) or cells transfected with an empty vector. It was also shown that 
both miRNAs can affect BCL-2 protein expression separately and that miR-15 and 
miR-16 regulate BCL-2 expression at the post-transcriptional level (Cimmino A. et 
al, 2005). These data first and foremost indicate a possible mechanism for BCL-2 
aberrant expression and secondly explain how miR-15a and miR-16-1 exert their 
tumor-suppressing function in CLL. However, in contrast to the previous results, 
Fulci et al. reported that down-regulation of mir-15 and mir-16 was not followed 
by significant increase in BCL-2 expression levels. These data do not support the 
hypothesis that in CLL, the high levels of BCL-2 expression are secondary to a 
down-regulation of mir-15 and mir-16 (Fulci V. et al, 2007). Two other miRNAs, 
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miR-29b and miR-181b, act as tumor-suppressors in aggressive CLL by targeting 
the S-cell leukemia⁄lymphoma 1 (TCL-1) oncogene. The levels of both miRNAs 
inversely correlated with levels of TCL-1 in CLL patients (Pekarsky Y. et al, 2006). 
TCL-1 is a coactivator of AKT, an oncogene that inhibits apoptotic processes and 
has a critical role in the regulation of many pathways involved in cell survival, 
proliferation and death. Its high expression is associated with expression of 
unmutated IgVH and ZAP-70, factors that indicate aggressive CLL (Nicoloso M.S. 
et al, 2007). Several groups have investigated miRNA expression profiling of CLL. 
Calin et al., compared miRNA expression in CLL cells vs. normal CD5+ B cells with 
a microarray chip and confirmed their results with Northern blot and qRT-PCR. 
Two groups of miRNAs, the first composed of 55 genes and the second of 29 
genes, were found to have statistically significant differences in expression levels 
between normal and malignant cells. Some of them are located in fragile sites, 
such as mir-183 at FRA7H, mir-190 at FRA12A, mir-24-1 at FRA9D and mir-213 
(Calin G.A. et al, 2004). To investigate whether the expression of miRNAs genes is 
associated with factors that predict the clinical course of CLL (ZAP-70 expression 
and mutated⁄unmutated status of IgVH), Calin et al., performed a genome wide 
miRNA microchip in a large number of CLL patients. By studying 94 samples of 
CLL, the group demonstrated that there is a signature of 13 miRNA genes (mir-
15a, mir-195, mir-221, mir-23b, mir-155, mir-223, mir-29a-2, mir-24-1, mir-29b-
2, mir-146, mir-16-1, mir-16-2, mir-29c) that has prognostic value, because the 
expression levels of the members of the signature correlate with CLL prognostic 
factors such as ZAP-70 expression and IgVH mutation status (Calin G.A. et al, 
2005). Finally, mir-150, mir-223, mir-29b and mir-29c were over-expressed in 
patients with IgVH mutated cells supporting previous results (Fulci V. et al, 2007). 
 
miRNA expression in Hodgkin’s lymphoma 
Hodgkin’s lymphoma is a paradigm for a curable cancer. This is especially true in 
early stages and for younger patients. Nevertheless, some patients relapse, and 
some ultimately die of refractory disease. The malignant cells (Hodgkin–Reed–
Sternberg cells) are a minority in the involved lymph node and usually are 
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surrounded by reactive cells. Most of the malignant cells are derived from B-
cells, but have lost the expression of typical B-cell genes and acquired multiple 
other markers. Multiple signalling pathways are deregulated in Hodgkin–Reed–
Sternberg cells, including NF (nuclear factor)-κB, JAK (Janus kinase)/STAT (signal 
transducer and activator of transcription), Pl3K (phosphoinositide 3-kinase)/Akt, 
ERK (extracellular-signal-regulated kinase), AP1 (activator protein 1), Notch1 and 
receptor tyrosine kinases (Kuppers R. 2009; Munker R. and Calin G.A 2011).  
There are a few studies referring to miRNAs alterations in Hodgkin’s Lymphoma 
(HL). Kluiver et al., analyzed HL cell lines and tissue samples and detected high 
levels of BIC and miR-155 in HL (Kluiver J. et al, 2005). Three years later, Navarro 
et al., analyzed the expression of 157 miRNAs in 49 lymph nodes from classical 
HL and ten reactive lymph nodes (RLN) by qRT-PCR and revealed three 
welldefined groups: nodular sclerosis cHL, mixed cellularity cHL and RLNs. They 
also found a distinctive signature of 25 miRNAs which differentiated cHL from 
RLNs, and 36 miRNAs that were differentially expressed between nodular 
sclerosis and mixed cellularity subtypes. Finally, mir-96, mir-128a and mir-128b 
were found to be selectively down-regulated in cHL with Ebstein Barr virus (EBV) 
infection, while mir-138 was related with Ann Arbor stage I-II cHL (Navarro A. et 
al, 2008). These findings indicate different miRNAs expression patterns in 
different histological subtypes as well as in early stage disease. Recently, Nie et 
al. showed that PRDM1⁄Blimp-1, an important regulator in terminal B-cell 
differentiation, is targeted by miR-9 and let-7a in cultured Hodgkin⁄Reed-
Sternberg (HRS) cells. MiRNA expression profile demonstrated that both miRNAs 
are highly expressed in Hodgkin⁄Reed-Sternberg cells, suggesting that mir-9 and 
let-7a act as oncogenes in HL cells (Nie K. et al, 2008). Navarro et al. described a 
25-miRNA signature based on RNA extracted from entire lymph nodes and found 
that the expression of mir-135a has prognostic relevance (Navarro A. et al, 2009). 
Patients with low mir-135a expression relapse earlier and have a shorter disease-
free survival duration compared with patients with high expression. When the 
precursor miR-135a was transfected into cell lines derived from Hodgkin’s 
lymphoma, cell growth slowed, and the cells became apoptotic. The authors also 
46 
 
showed that miR-135a targets the JAK2 pathway and that its re-expression leads 
to a decrease in the anti-apoptotic gene Bcl-XL (Van Vlierberghe P. et al, 2009).  
 
miRNA expression in NHLs (non-Hodgkin’s lymphomas) 
NHLs are common, especially in elderly patients, and have widely divergent 
clinical, immunological and molecular presentations. On the basis of these 
characteristics (aggressive compared with indolent, T-lineage compared with B-
lineage), the prognosis and treatment are very different. Because of the 
divergent immunological, genetic and clinical phenotypes, no universal GEP for 
all NHLs is feasible (Munker R. and Calin G.A 2011). Diffuse large B-cell 
lymphoma (DLBCL) is the most common type of lymphoma representing nearly 
40% of lymphoid malignancies. There are at least two types of DLBCL that have 
different prognostic value, the germinal center type (GC) with a better outcome 
and activated B-cell type (ABC) with worse prognosis (Lawrie C.H. 2007). MiRNA 
expression in B-cell lymphomas has been studied by several groups. Eis et al. 
analyzed lymphoma samples and cell lines and found increased levels of miR-
155, in DLBCL. Both BIC RNA and miR-155 were quantified in 23 DLBCL samples. 
BIC RNA levels were elevated from two to tenfold in DLBCL in comparison with 
normal CD19+ B cells, which were used as normal control. miR-155 levels were 
increased to even greater extents. Significantly higher levels of miR-155 were 
detected in the ABC type compared to the GC phenotype. It was also found that 
the levels of miR-15a were reduced in DLBCL, which shows that the reduction of 
this miRNA is not specific to CLL. On the other hand, the levels of miR-16 showed 
no specific pattern of increase or decrease relative to the control B cells (Eis P.S. 
et al, 2005 ). In addition, Kluiver et al. also demonstrated that BIC and mir-155 
are highly expressed in DLBCL and primary mediastinal lymphomas, but not in 
other non-HLs (Kluiver J. et al, 2005). Roehle et al., who analyzed the expression 
of micro-RNAs in DLBCL, follicular lymphoma (FL) and non neoplastic lymph 
nodes, found that mir-155 was up-regulated in DLBCL as well. Moreover, this 
group demonstrated that miR-330, miR-17-5p, miR-106a and miR-210 
discriminate DLBCL, FL and RLNs (Roehle A. et al, 2008). In agreement with the 
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previous results, Lawrie et al. showed that ABC and GC subtypes of DLBCL have 
distinct miRNA expression profile. mir-155, mir-21 and mir-221 are highly 
expressed in ABC in comparison with GC DLBCL. These miRNAs were over-
expressed in clinical cases of DLBCL and FL as well as in DLBCL that had 
undergone transformation from FL. Univariate and multivariate analysis 
suggested that mir-21 expression is an independent prognostic indicator in de 
novo DLBCL and that high expression of this miRNA was associated with a better 
outcome (Lawrie C.H. et al, 2007). The aforementioned miRNAs (mir-155, mir-21, 
and mir-221) were compared in serum samples from DLBCL patients to healthy 
controls. The levels of these micro-RNAs were found to be up-regulated in 
patients’ serum. In addition, high levels of mir-21 in DLBCL patient serum was 
associated with improved relapse-free survival (Lawrie C.H. et al, 2008). A 
possible target of miR-155 is the transcription factor PU.1 that is a member of Ets 
domain-transcription factor family and is required for late differentiation of B 
cells (John B. et al, 2004). In addition, the mRNA of the transcription factor 
C⁄EBPb has a potential target site for miR-155 in its 3’-UTR (Eis P.S. et al, 2005). 
In addition, a correlation between miR-155 and NF-kB expression has been found 
in DLBCL cell lines and patient samples (Rai D. et al, 2008). Recently, miR-155 was 
found to directly target Src homology-2 domain-containing inositol 5-
phosphatase 1 (SHIP1), which acts in the PTEN⁄AKT pathway. miR-155 binds to 
3’-UTR of SHIP 1 and down-regulates SHIP 1 in vivo and in vitro. Down-regulation 
of SHIP 1 by mir-155 resulted in both myeloproliferative and lymphoproliferative 
disorder indicating a role of this pathway in myeloid and lymphoid cells 
(Costinean S. et al, 2009; O’ Connell R.M. et al, 2009). Primary effusion 
lymphoma (PEL) is a subtype of DLBCL associated with Kaposi sarcoma-
associated herpes virus (KSHV) while some of PELs are coinfected by EBV. PEL 
cells contain two types of miRNAs encoded by either cellular genes or by KSHV or 
EBV. A 68-miRNA-specific signature was identified containing KSHV and EBV 
miRNAs. mir-155 was found to be down-regulated in contrast to ABC DLBCL 
cases (O’ Hara A.J. et al, 2008). A recent study associates miRNA expression in 
DLBCL with immunophenotype, survival and transformation from FL. Lawrie et al. 
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studied 80 samples of DLBCL and 18 samples from FL with microarrays and found 
distinct expression patterns between these two lymphomas. Furthermore, 
miRNAs expression was associated with GC-like and non-GC-like 
immunophenotypes (supporting previous results), international prognostic index 
status and event-free survival in cyclophosphamide, doxorubicin, oncovin, 
prednisone (CHOP) and rituximab-CHOP treated patients (Lawrie C.H. et al, 
2009). These data indicate that miRNAs may be used in the future as prognostic 
and diagnostic tools in DLBCL. High expression of precursor miR-155⁄BIC RNA 
was described in pediatric Burkitt’s lymphoma (Metzler M. et al, 2004), but not in 
adult primary cases of the disease (Kluiver J. et al, 2006). Expression of BIC and 
miR-155 in three latency type III EBV-positive Burkitt’s lymphoma cell lines and in 
all primary posttransplantation lymphoproliferative disorder cases suggests a 
possible role for EBV latency type III-specific proteins, in the induction of BIC 
expression (Kluiver J. et al, 2006). Mantle cell lymphoma (MCL) represents 5–
10% of all non-HLs and has the worst prognosis among B-cell lymphomas. The 
t(11;14)(q13;q32) is characteristic of MCL and displays the cyclin D1 (CCND1) 
gene on chromosome 11 downstream to the enhancer region of the IgH gene on 
chromosome 14 resulting in CCND1 over-expression. Point mutations and 
genomic deletions in CCND1 create a truncated mRNA and result in increased 
proliferation and shorter survival (Wiestner A. et al, 2007). Cell lines, with 
increased ratio of truncated CCND1 have increased total mRNA levels, increased 
CCND1 protein expression. miR-16 is able to down-regulate CCND1 protein 
expression (Chen R.W. et al, 2008). However, the truncation of CCND1 mRNA 
lacks miR-16-1 binding sites within the CCND1 mRNA 3’-UTR and alters miRNA 
regulation in MCL suggesting a possible role of this miR-16-1 in CCND1 repression 
(Chen R.W. et al, 2008). The genetic locus 13q31, which is commonly found 
amplified in many B-cell lymphomas, such as DLBCL, MCL and solid tumors 
(Lawrie C.H. 2007), encodes the miRNA cluster mir-17-92, which includes mir-17-
5p, mir-18a, mir-19a, mir-20a, mir-19-b-1 and mir-92 (He L. et al, 2005). He et al. 
found that expression of the mir-17-92 cluster components in mice also over-
expressing MYC, enhanced lymphomagenesis while each miRNA of the cluster 
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did not (He L. et al, 2005). In addition, O’  Donnell et al. showed that the c-MYC 
oncogene activates the transcription of the mir-17-92 cluster (O’ Donnell K.A. et 
al, 2005). c-MYC also induces the expression of the transcription factor E2F1 
gene, which in turn can induce c-MYC by means of a positive feedback. mir-17-5p 
and mir-20a (members of the mir-17-92 cluster) directly down-regulate the 
transcription factor E2F1. By targeting E2F1, members of the mir-17-92 cluster 
can reduce the reciprocal activation MYC⁄ E2F1 and control c-MYC-mediated 
cellular proliferation (O’ Donnell K.A. et al, 2005). 
 
miRNA expression in T-cell lymphomas 
The role of miRNAs in T-cell lymphomas in human remains unclear. However, the 
available data suggest a role of miRNAs in the pathogenesis of T-cell lymphomas. 
Lum et al. found a high density of integrations upstream of the mir-106a miRNA 
cistron. In tumors containing integration, the primary transcript encoding the 
mir-106a cistron was over-expressed 5–20-fold compared with control tumors. 
The mature miR-106a, miR-363 and miR-17-92 were over-expressed too (Lum 
A.M. et al, 2007). Landais et al. confirmed pri-mir-106-363 over-expression in 
46% of human T-cell leukemias tested (Landais S. et al, 2007). 
 
miRNA expression in AML (acute myelogenous leukaemia) 
There is an increasing number of publications investigating the role of miRNAs in 
acute leukemia. Debernardi et al. analyzed the expression of miRNAs in 30 
samples from AML patients with normal karyotype. The levels of miR-181a 
(mentioned earlier as potential inhibitor of differentiation of all human 
hematopoietic lineages) (Georgantas R.W. et al, 2007) were elevated in M1 or 
M2 AML, compared with M4 or M5 AML. The elevated expression of mir-181a 
observed in AML implies its involvement in the leukemic process. Moreover, 
mRr-10a, miR-10b and miR-196a-1 were found to correlate with HOX gene 
expression (Debernardi S. et al, 2007). Cell lines treated with the differentiating 
agent all-trans-RA (ATRA) showed up-regulation of some miRNAs, including few 
known tumor suppressor miRNAs, such as mir-15a and mir-16-1, members of the 
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let-7 family and mir-223, mir-342 and mir-107. mir-181 was found to be down-
regulated after treatment with ATRA (Garzon R. et al, 2007). Isken et al. analyzed 
50 patient samples with AML and 12 control samples for the expression of 154 
human miRNAs. The expression level of mir-26a, mir-26b and mir-29b was 
intermediate between CD34+ cells and normal bone marrow (NBM) samples. 
There was a significant difference in the expression pattern of mir-23b, mir-34a 
and the mir-221⁄mir-222 cluster between AML and controls. Except for mir-23b, 
all these were up-regulated in AML samples compared to CD34+ and NBM 
samples. High levels of expression of mir-221⁄mir-222 cluster promote growth of 
several cancer cells lines, by inhibiting the expression of CDKN1B, an inhibitor of 
cell cycle progression and known tumor suppressor. In addition, they secondary 
affect KIT expression. Finally, mir-181a expression was reduced in samples with 
French-American-British (FAB) classification M4 and M5 compared to FAB M1 
and M2, supporting the results of the aforementioned study by Debernardi et al. 
(Debernardi S. et al, 2007; Vasilatou D. et al, 2009). More recently, Marcucci et 
al. studied samples of leukemia cells from adults under the age of 60 years who 
had cytogenetically normal AML and internal tandem duplication in the fms-
related tyrosine kinase 3 gene (FLT3-ITD), a wild type nucleophosmin (NPM1) or 
both using micro-RNA expression profiling. A signature of 12 miRNAs was 
associated with clinical outcome. Among them, members of mir-181 family are 
down-regulated in high risk AML, with their expression levels being inversely 
correlated with levels of proteins involved in pathways controlled by toll-like 
receptors and interleukin-1b (Marcucci G. et al, 2008). Moreover, there is 
evidence of a unique miRNA signature that distinguishes NPMc + AML (AML with 
NPM1 mutations and cytoplasmic NPM) from unmutated cases. This signature 
contains mir-10a, mir-10b, let-7 family and mir-29 family. Some of the miRNAs 
that are down-regulated, are associated with HOX genes indicating that HOX up-
regulation in NPMc + AML is attributed, at least in part, to the loss of miRNA 
regulation (Garzon R., Garofalo M., Martelli M.P. et al, 2008). In 240 AML patient 
samples with predominantly intermediate and poor cytogenetics, Garzon et al. 
found miRNA signatures, associated with balanced 11q23 translocation, isolated 
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trisomy 8 and FLT3-ITD mutations. In addition, miR-199a and miR-191 were 
found to have a prognostic value, because they were associated with reduced 
overall and disease-free survival (Garzon R., Volinia S., Liu C.G. et al., 2008).  
 
miRNA expression in ALL (acute lymphocytic leukaemia) 
A screening of deregulated miRNAs in acute lymphocytic leukemia (ALL) has been 
published, providing a list of miRNAs involved in leukemogenesis. The five highly 
expressed miRNAs in ALL were mir-128b, mir-204, mir-218, mir-331 and mir-
181b-1. The most commonly represented miRNA in ALL is mir-128b with a 436, 
fivefold difference compared to normal CD19+ B cells. The second most highly 
expressed miRNA in ALL is mir-204. On the contrary, the four miRNAs with the 
lowest expression levels are mir-135b, mir-132, mir-199s, mir-139 and mir-150. 
The mir-17-92 cluster was found to be up-regulated in ALL (Zanette D.L. et al, 
2007). Taking into consideration that the miR-17-92 antagonizes the expression 
of the pro-apoptotic protein BIM and favors the survival of B-cell progenitors 
(Ventura A. et al, 2008), the involvement of miR-17-92 in ALL is not surprising. 
Finally, Mi et al. performed a large-scale genome wide miRNA expression profile 
assay and identified 27 miRNAs that are differentially expressed between AML 
and ALL. Among them, mir-128a and mir-128b are significantly over-expressed, 
whereas let-7b and mir-223 are significantly down-regulated in ALL compared to 
AML. In addition, over-expression of mir-128 in ALL was at least partially 
associated with promoter hypomethylation and not with an amplification of its 
genomic locus (Mi S. et al, 2007). 
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1.2.10 miRNAs in dog 
 
It is known that many miRNAs are evolutionarily conserved among different 
organisms, so it is possible to predict orthologous genes (homologous genes 
present in different species, originating from gene duplication events and having 
different functions) of known miRNAs in different species due to the 
computational predictions (Shahi P. et al. 2006). The sequence similarities 
between dog and human allow to use primers and probes designed and 
commonly used in humans for the monitoring of miRNAs in the dog, when the 
respective sequences are perfectly conserved (Zhou D. et al. 2008). Until the 
beginning of my PhD program, only a few studies of miRNA in the dog have been 
reported. Zhou et al., in 2008, identified 357 miRNA candidates by computational 
prediction, starting from the dog genome, among them, 300 are known miRNA 
homologs in humans, the remaining 57 are not reported in any animal species. 
Of these 357 miRNAs, 125 are located in intronic regions of protein-coding 
genes, of which 75 are in the sense orientation and 50 anti-sense gene with 
respect to the host, and the other part in UTR, exons in mRNA or in intergenic 
spaces. Among all these miRNAs dog, 142 are organized into 53 clusters; 
alignment of the sequences shows that some clusters are formed by miRNA 
paralogs and others have multiple pairs. In Figure 13 the genes of miRNAs are 
schematically represented with colored rectangles and miRNA paralogs, in 
different clusters, have the same color (Zhou D. et al. 2008). 
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Figure 13. Schematic diagram of miRNA genes in C. familiaris (Zhou D. et al. 
2008)                                                                                                                                         
 
Using the sequences of miRNAs currently known in the dog, Zhou et al. analyzed 
the UTR of protein-coding genes in the genome of dog to identify potential 
target sites and predicted 865 miRNA target genes. Except for the transcript 
target 71, with 2 or more target sites, these genes have only one target site in 
UTRs conserved between dog, human and mouse. The majority of target genes 
predicted presents a imperfect complementarity with the corresponding miRNA 
and then it is presumed that are regulated through the repression of translation. 
Furthermore, it is interesting to note that 28 target genes have sites perfectly 
complementary to the miRNA, indicating that these miRNAs may work cutting 
the mRNA (Bentwich I. 2005). In the same study, has been analyzed the 
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functional annotations distribution of all conserved targets of miRNAs using 
Gene Ontology (GO) term and has been found that target genes play a wide 
range of biological functions including transcriptional regulation, stress response, 
metabolism biochemical processes related to cancer and signal transduction 
pathways (Bentwich I. 2005). Another study on miRNAs in dogs has been 
published in 2007by Boggs et al. In this study has been evaluated the expression 
of a cluster of seven miRNAs (miR-17-3p, miR-17-5p, miR-18, miR-19a, miR-19b, 
miR92, miR-20). These miRNAs were analyzed in five dog tissues (heart, lung, 
brain, kidney and liver) by means of qRT-PCR using assays designed on the 
corresponding human sequences, perfectly preserved in dogs, using the ΔΔCt 
method (Boggs R.M. et al. 2007). Moreover, in these study the expression data 
were analyzed by normalization with RNU6B, a small nucleolar RNA, without any 
assessment of the actual validity of this target as housekeeping under the 
experimental conditions of interest. Another important work concerning the 
miRNAs in dog has been published in 2008 by Boggs RM et al. This study was 
focused on oncomiRNAs, a subclass of miRNAs that includes genes whose 
expression, or the absence of expression, is associated with cancer (Boggs R.M. 
et al., 2008). Until the last decade, the domestic dog was little used as a model 
for the study of several human diseases with genetic components. However, the 
dog shows marked similarities in genetic and physiological with the man, so that 
makes him an excellent model for the study and treatment of various inherited 
diseases. In particular, it was discovered that some miRNAs can function at the 
same time as oncogenes and tumor suppressor in different types of cancer, 
therefore, in the work of Boggs et al, the pattern of expression of some miRNAs 
(miR-15a, miR-16, miR-17-5p, miR-21, miR-29b, miR-125b, miR-145, miR-155, 
miR-181b, let-7f), which were described in the literature to be associated with 
breast cancer human, was evaluated. The study showed that these miRNAs in 
breast cancer follow in dogs the same pattern of expression detected in humans. 
The genetic similarities observed between the two species indicate that, due to 
the preservation of the function of these miRNAs, they may target conserved 
genes in humans and dogs and be involved at the beginning of the 
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cancerogenesis and metastasis formation (Boggs R.M. et al. 2007). In conclusion, 
from the analysis of these works it is evident that in dogs a limited number of 
tissues, not including the hematopoietic tissues, was investigated and a 
systematic retrospective studies (for example, using samples embedded in 
paraffin) has not been realized yet. Furthermore, it has not been reported any 
study with proper validation of housekeeping genes in the different types of 
canine tissues. In the abovementioned two expression studies, the authors have 
a priori used as reference gene RNU6B, which cannot be considered a suitable 
normalizer gene for miRNA expression profiling. 
 
1.2.11 Lymphoma in dog as a model for human 
 
Lymphomas of the dog show histopathological, molecular and clinical features 
very similar to human non-Hodgkin's lymphoma (NHL). Most subtypes of 
lymphoma in humans have been recognized as histopathologically identical 
counterparts in dog, as well as striking similarities in molecular characteristics of 
the tumor between the two species. In fact, a spontaneous lymphoma in dogs 
has a clinical presentation, response to chemotherapy and clinical progression 
similar to the NHL in humans. This makes the dog a good animal model for the 
study of lymphoma in humans and for the search of new therapeutic agents, 
since dogs have body size bigger than rodents and genetic characteristics similar 
to humans, sharing with them the same environment and diet, and above all 
develop spontaneous tumors (and not artificially induced as usually happens in 
rodents). Until a short time ago, the use of spontaneous tumors in dogs as a 
model of human cancer has been limited by the poor availability of reagents and 
techniques that could be used also in dog. However, recent advances in genomic 
studies of the dog, including the sequencing of the canine genome, the 
availability of microarrays, the development of advanced techniques of 
hybridization and comparative cytogenetics and the development of flow 
cytometry species-specific, make possible now the use of most of these 
techniques that were previously used only in humans and in mice (Vail DM. et al, 
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2000; Kisseberth WC et al, 2007). Dog is a good comparative model for human 
cancer also due to the fact that it shares with humans the same environment, 
and therefore it is also chronically exposed to the same environmental 
pollutants, including carcinogens. It's interesting to note that dog can be even 
more exposed than humans to toxic and/or carcinogenic substances, because of 
the close contact with the soil, the surface water potentially contaminated with 
pesticides or other pollutants, and the greater physical proximity to the 
discharge of exhaust pipes of motor vehicles. Considering that dog has a half-life 
shorter than humans, it also has a shorter latency period between exposure to 
toxic substances and the appearance of the disease. Consequently, dog can play 
a very useful role of sentinel animal for diseases such as cancer, contributing to 
the early identification of carcinogens in the environment, the prediction of the 
risk to humans, and the assessment of the effects on public health. The 
epidemiological significance of the comparative study of canine cancer for 
human health has been highlighted by a recent study performed in some areas 
of the Campania region with a high degree of environmental contamination by 
carcinogens such as dioxin, showing that dog can anticipate the risk for man to 
develop cancer in resident population (Marconato et al., 2009). 
 
1.2.12 CLL in dog as a model for human 
 
Chronic lymphocytic leukemia (CLL) is a common hematologic disorder occurring 
in dogs as well as in humans. In people, CLL is prevalently an indolent B-cell 
neoplasm caused by the expansion of a subpopulation of CD5-positive B-cells. In 
dogs, case collections have been reported describing hematologic features and 
immunophenotype with T-CLL as the most frequent form (Vernau W. and Moore 
P.F. 1999; Adam F. et al., 2009; Tasca S. et al., 2009). However, some clinical and 
cytogenetic analogies have been reported between human and canine CLL. In 
particular, a deletion or the CFA 22q11.2 genomic region, harbouring also the 
mir-15a/miR-16 cluster, was reported in a case of canine CLL as homologue to 
the 13q14 deletion in human CLL leading to miR-15a and miR-16 
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underexpression with pathogenetic and prognostic significance (Calin G.A. et al., 
2002; Calin G.A. and Croce C.M. 2002; Breen M. and Modiano J.F. 2008). With 
regard to the human counterpart, no wide reports are available in dogs as far as 
prognostic factors for survival are concerned, even if some recent studies have 
compared canine B-cell and T-cell CLL and found a relationship between 
immunophenotyping and different prognosis (Williams M.J. et al., 2008; Comazzi 
S. et al., 2011). The possibility that at least some evolutionary conserved miRNA 
have a role in the pathogenesis and diagnosis of canine CLL as reported in 
humans should be thoroughly investigated. 
 
1.2.13 Splenic lymphoma in dog 
 
Splenic neoplasms can be broadly categorized into vascular neoplasms, non 
angiomatous non lymphomatous sarcomas and lymphomas. In dogs, 
angiosarcoma is the most common primary splenic tumor, while lymphoma is 
considered less common (Frey A.J. and Betts C.W., 1977; Spangler W.L. and 
Culbertson M.R. 1992; ; Day M.J. et al., 1995; Valli V.E. et al., 2006; Christensen 
N. et al., 2009; Eberle N. et al., 2012). On the contrary, lymphoma represents up 
to 40% of splenic malignancies in man (Bhatia K. et al, 2007; Kaza R.K. et al., 
2010). Splenic lymphoma may be primary or secondary however, primary forms 
account for 1% or less of all human lymphomas (Bhatia K. et al, 2007; Swerdlow 
S.H. et al., 2008; Kaza R.K. et al., 2010). These data do not seem clearly available 
in dogs (Valli V.E. 2007). 
In spleen, lymphomas are present as nodular or diffuse lesions (Bhatia K. et al., 
2007; Kaza R.K. et al., 2010; Valli V.E. et al, 2006, Valli V.E. 2007).  Primary 
nodular lymphomas have been described in humans (Thieblemont C. et al., 2002;  
Swerdlow S.H. et al., 2008; Kurtin P.J. 2009) and dogs (Valli V.E. et al 2006; Valli 
V.E. 2007; Stefanello D. et al., 2011; Flood-Knapik K.E. et al., 2012) as a group of 
mostly low grade tumors deriving from mature B cell lymphocytes. It has been 
estimated that 5.3–29% of all lymphomas in dogs are low-grade tumors and are 
characterized by indolent clinical course, incomplete response to chemotherapy, 
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but longer survival times compared to aggressive lymphomas (Carter R.F. et al., 
1986; Fournell-Fleury C. et al., 1997; Ponce F. et al., 2010). Histopathological 
subtypes of canine indolent lymphoma include marginal zone lymphoma (MZL), 
follicular lymphoma (FL) and mantle cell lymphoma (MCL), which are all of B-cell 
immunophenotype, and T-zone lymphoma (Valli V.E. et al., 2006; Valli V.E. et al., 
2011). Canine MZL and MCL develop more frequently in spleen than in lymph 
nodes (Valli V.E. et al., 2006; Valli V.E. 2007) while primary splenic follicular 
lymphoma (FL) has been reported but seems rare in both people and dogs 
(Pittaluga S. et al., 1996; Thieblemont C. et al., 2003; Valli V.E. et al., 2006; 
Swerdlow S.H. et al., 2008; Mollejo M et al., 2009; Shimizu-Kohno K. et al., 2012; 
Flood-Knapik K.E. et al., 2012). Diffuse primary splenic lymphomas seem less 
common than nodular lymphomas in dogs (Valli V.E. 2007) while diffuse 
sinusoidal splenic invasion by leukemic cells occurs on a regular basis (Workman 
H.C. and Vernau W. 2003; Vail D.M. and Young K.M. 2007). Primary diffuse 
splenic lymphomas most commonly reported in man are diffuse red pulp small B 
cell lymphoma, large B cell lymphoma and, hepatosplenic ɣ/δ T cell/NK 
lymphoma and hairy cell leukemia (Issacson P.G. 1997; Swerdlow S.H. et al., 
2008; Weidmann E. 2000). With the exception of hairy cell leukemia, lymphomas 
with a diffuse growth pattern are more aggressive (Weidmann E. 2000; Valli V.E. 
2007; Swerdlow S.H. et al., 2008). Diffuse large B cell lymphoma has been 
reported in dogs and seems to develop in spleen as a multifocal tumor that tends 
to become diffuse by the time of diagnosis (Valli V.E. 2007) but no data are 
available on its behaviour. Hepatosplenic lymphoma of ɣ/δ T cell origin has been 
described in dogs (Fry M.M. et al., 2003; Cienava E.A. et al., 2004; Keller S.M. et 
al., 2012). In these dogs primary diffuse involvement of the spleen together with 
severe splenomegaly are characteristic of this rapidly fatal disease.  Thus, while 
nodular lymphomas are generally indolent and slowly progressive tumours 
regarded to have a good prognosis, diffuse lymphomas are mostly associated 
with poorer prognosis in people and dogs (Valli V.E. 2006; Stefanello D. et al., 
2011; Flood-Knapik K.E. et al., 2012). Nevertheless, to date there are no accurate 
and complete works about classification and grading in canine splenic lymphoma. 
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1.3  MATERIALS AND METHODS 
 
1.3.1 Sampling procedures  
 
In this doctoral thesis the analyses were carried out on dogs suffering from 
different types of spontaneous hematopoietic malignancies, such as: 
 chronic lymphocytic leukaemia (T-CLL cells and B-CLL cells) 
 lymph nodes lymphoma (T cells and B cells) 
 splenic lymphoma  
 
For all types of tumor we used both fresh samples and stored samples, in 
particular:  
- peripheral blood for CLL and lymph node aspirates for lymph node 
lymphomas (both in RNA later),  
- cytologic glass smears for CLL and lymph nodes lymphomas,  
- sections of tissues fixed in formalin and embedded in paraffin (FFPE) for 
splenic and lymph nodes lymphomas.  
 
The fresh whole blood samples from canine CLL and from healthy dogs were 
collected in EDTA-coated tubes.  
The fresh-frozen lymph node samples were obtained from healthy dogs, or not 
suffering from neoplastic disease, and dogs with lymphoma by fine-needle 
biopsy (measure 22) of enlarged lymph nodes.  
The formalin-fixed and paraffin-embedded samples were provided by Prof. Paola 
Roccabianca, Department of Veterinary Sciences and Public Health, University of 
Milan, to the extent of 4 slices of 20 micron thickness for each sample.  
The cytologic glass smears were provided by Dr. Maria Elena Gelain, Department 
of Veterinary Sciences and Public Health, University of Milan.  
The samples were classified on the basis of clinical, haematological and 
cytological characteristics, and immunophenotyping data.  
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The lists of all the samples on which the analyzes were performed, divided by 
type of cancer and type of sample (fresh, FFPE and cytologic glass smears), are 
shown below. 
 
 FRESH-FROZEN LYMPH NODES LYMPHOMAS  
Sample 
code 
Sample type Phenotype Grade* Updated Kiel classification 
F1 Lymphoma T L Lymphocytic/small clear cell 
F2 Lymphoma T L Lymphocytic/small clear cell 
F3 Lymphoma T H Pleomorphic, medium and large 
cell 
F4 Lymphoma T H Pleomorphic, medium and large 
cell 
F5 Lymphoma T L Lymphocytic/small clear cell 
F6 Lymphoma T L Lymphocytic/small clear cell 
F7 Lymphoma T H Pleomorphic, medium and large 
cell 
F8 Lymphoma B H Centroblastic 
F9 Lymphoma B H Centroblastic 
F10 Lymphoma B H Centroblastic 
F11 Lymphoma B H Centroblastic 
F12 Lymphoma B H Centroblastic 
F13 Lymphoma B H Centroblastic 
F14 Lymphoma B H Centroblastic 
F15 Lymphoma B H Centroblastic 
F16 Non-
neoplastic 
   
F17 Non-
neoplastic 
   
F18 Non-
neoplastic 
   
 
Table 3. Fresh-frozen lymph node lymphomas samples list and classification. 
*L=low; H=high. 
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FFPE LYMPH NODES LYMPHOMAS  
Sample 
code 
Sample type Phenoty
pe 
Grade* Updated Kiel classification 
P1 Lymphoma T H Pleomorphic, medium and large 
cell 
P2 Lymphoma T L Lymphocytic/small clear cell 
P3 Lymphoma B L Macronucleolated medium-sized 
cells 
P4 Lymphoma B L Macronucleolated medium-sized 
cells 
P5 Lymphoma B H Centroblastic 
P6 Lymphoma B H Lymphoblastic 
P7 Lymphoma B H Immunoblastic 
P8 Non-neoplastic    
P9 Non-neoplastic    
P10 Non-neoplastic    
P11 Non-neoplastic    
P12 Non-neoplastic    
Table 4. FFPE lymph node lymphomas samples list and classification.  
*L=low; H=high. 
 
 CYTOLOGIC GLASS SMEARS LYMPH NODES LYMPHOMAS  
Sample code Phenotype Grade* Update Kiel 
C 1 T lymphoma L Lymphocytic (small cells) 
C 2 T lymphoma L Pro lymphocytic 
C 3 T lymphoma L Lymphocytic (small cells) 
C 4 T lymphoma H Pleomorphic (big cells) 
C 5 T lymphoma H Pleomorphic (medium- big cells) 
C 6 B lymphoma H Centroblastic 
C 7 B lymphoma H Centroblastic 
C 8 B lymphoma H Centroblastic 
C 9 B lymphoma H Centroblastic 
C 10 B lymphoma H Centroblastic 
C 11 B lymphoma H Centroblastic 
C 12 B lymphoma H Centroblastic 
C 13 B lymphoma H Centroblastic Pleomorphic 
C 14 B lymphoma H Centroblastic 
C 15 B lymphoma H Centroblastic 
Table 5. Cytologic glass smears lymph node lymphomas sample, list and 
classification. *L=low; H=high.  
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Table 6. Fresh/frozen CLLs samples, list and classification  
 
 
  
FRESH-FROZEN  CLLS 
Sample code Sample type Phenotype 
F 19 Non neoplastic blood  
F 20 Non neoplastic blood  
F 21 Non neoplastic blood  
F 22 Non neoplastic blood  
F 23 Non neoplastic blood  
F 24 Non neoplastic blood  
F 25 Peripheral blood T- CLL 
F 26 Peripheral blood T- CLL 
F 27 Peripheral blood T- CLL 
F 28 Peripheral blood T- CLL 
F 29 Peripheral blood T- CLL 
F 30 Peripheral blood T- CLL 
F 31 Peripheral blood T- CLL 
F 32 Peripheral blood T- CLL 
F 33 Peripheral blood B- CLL 
F 34 Peripheral blood B- CLL 
F 35 Peripheral blood B- CLL 
F 36 Peripheral blood B- CLL 
F 37 Peripheral blood B- CLL 
F 38 Peripheral blood B- CLL 
F 39 Peripheral blood B- CLL 
F 40 Peripheral blood B- CLL 
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CYTOLOGIC GLASS SMEARS CLLS  
Samples Immunophenotype 
C 16 T CLL  
C 17 T CLL  
C 18 T CLL  
C 19 T CLL  
C 20 T CLL 
C 21 T CLL 
C 22 T CLL 
C 23 B CLL 
C 24 B CLL  
C 25 B CLL 
C 26 B CLL 
C 27 B CLL 
C 28 B CLL  
C 29 B CLL  
 
Table 7. Cytologic glass smears CLLs samples, list and classification 
 
 
 
 
 
   A.  FFPE NON-NEOPLASTIC SPLEEN   
Sample 
code 
Sample type Updated Kiel classification Signalling 
P 13 
Non-neoplastic 
spleen 
 Boxer, F, 5 years 
P 14 
Non-neoplastic 
spleen 
 X, F, 6 months 
P 15 
Non-neoplastic 
spleen 
 X, Fs, 13 years 
P 16 
Non-neoplastic 
spleen 
 
King Charles, F, 4 
month 
P 17 
Non-neoplastic 
spleen 
 
Amstaff, F, 6 
months 
P 18 
Non-neoplastic 
spleen 
 X, M, 5 years 
P 19 
Non-neoplastic 
spleen 
 
Pomeranian, F, 3 
month 
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B. FFPE SPLENIC LYMPHOMA   
Sample 
code 
Sample type Updated Kiel classification Signalling 
P 20 Splenic lymphoma Splenic marginal zone lymphoma- extention X, F, 12 years 
P 21 Splenic lymphoma Follicular lymphoma grade 1 Boxer, F, 5 years 
P 22 Splenic lymphoma Splenic marginal zone lymphoma focal 
Cairn Terrier, M, 8 
years 
P 23 Splenic lymphoma Splenic marginal zone lymphoma focal X, F, 8 years 
P 24 Splenic lymphoma Nodular Mantle cell lymphoma 
Fox Terrier, Fc, 8 
years 
P 25 Splenic lymphoma Splenic marginal zone lymphoma focal X, F, adult 
P 26 Splenic lymphoma Splenic marginal zone lymphoma X, M, 11 years 
P 27 Splenic lymphoma Splenic marginal zone lymphoma focal X, M, 8 years 
P 28 Splenic lymphoma Splenic marginal zone lymphoma focal X, Fc, 14 years 
P 29 Splenic lymphoma Splenic marginal zone lymphoma multifocal X, M, 9 years 
P 30 Splenic lymphoma Splenic marginal zone lymphoma focal X, M, 7 years 
P 31 Splenic lymphoma Nodular Mantle cell lymphoma X, M, 9 years 
P 32 Splenic lymphoma Small lymphocytic lymphoma Cocker, F c 
P 33 Splenic lymphoma Follicular lymphoma grade 2 
Medium 
Schnauzer, F, 10 
years 
P 34 Splenic lymphoma Lymphocytic lymphoma Boxer, M, 7 years 
P 35 Splenic lymphoma 
Nodular lymphoma almost diffuse in blastic 
transformation 
Rottweiler, F, 8 
years 
P 36 Splenic lymphoma Nodular lymphoma almost marginal diffuse X, F, 6 years 
P 37 Splenic lymphoma Nodular lymphoma almost marginal diffuse X, F, 10 years 
P 38 Splenic lymphoma Diffuse Mantle cell lymphoma X, M, 10 years 
P 39 Splenic lymphoma Diffuse lymphoma (medium cells) 
Lagotto, M, 9 
years 
P 40 Splenic lymphoma Diffuse lymphoma (marginal) X, F c, 11 years 
P 41 Splenic lymphoma Peripheral T-cell lymphoma (PTCL) Boxer, F, 10 years 
P 42 Splenic lymphoma Diffuse lymphoma X, F, 8 years 
P 43 Splenic lymphoma Diffuse lymphoma (medium cells) 
German Shepherd, 
F, 10 years 
P 44 Splenic lymphoma Diffuse lymphoma (big cells) 
West Highland 
White Terrier, F, 7 
years 
P 45 Splenic lymphoma Peripheral T-cell lymphoma (PTCL) X, M, 8 years 
P 46 Splenic lymphoma Hepatosplenic lymphoma Boxer, M, 7 years 
P 47 Splenic lymphoma Diffuse lymphoma (big cells) 
Siberian Husky, M, 
11 years 
P 48 Splenic lymphoma Diffuse lymphoma (Plasmacytoma/Myeloma) 
Pyrenean 
mountain dog, F, 
11 years 
Table 8. FFPE splenic lymphomas, list and classification. 8A) FFPE non-neoplastic spleen 
samples. 8B) FFPE splenic lymphoma samples Legend: F = Female, M = male, X = mixed race 
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1.3.2 Cells sorting by flow cytometry 
 
Flow cytometry: technique and instrument 
Flow cytometry is a methodic that allows the measurement and characterization 
of cells suspended in a fluid medium. In particular, this methodic makes possible 
the measurement of multiple properties (size, graininess, etc. ..) of individual 
cells at high speed, allowing very detailed cytologic analysis. The appearance of 
the flow cytometry, around the 70s, resulting in a rapid and intensive 
development of cytochemical and histological techniques. The flow cytometry, 
thanks to the use of monoclonal antibodies labeled with fluorescein 
isothiocyanate (FITC), has brought great impetus to the study of the immune 
system. The great complexity of the immune system and the presence of 
different subpopulations that react with the same antibody, have stimulated the 
development of monoclonal antibodies ever more specific, the search for new 
fluorescent dyes coniugated to antibodies without altering their capacity of 
binding the antigen and the creation of multiparameter flow cytometers that 
using fluorophores with different emission spectra. A turning point in flow 
cytometry was the development of dyes such as phycobiliproteins; these 
fluorochromes are natural water-soluble, fluorescent at neutral pH, easily 
conjugated with monoclonal antibodies and with high quantum yields. The 
Phycoerythrin (PE), for example, is a fluorochrome which is excited by the same 
wavelength of FITC (488 nm) but has a different emission spectrum, and for this 
reason the two fluorochromes can be used together to provide a very sensitive 
double marking detecting system. The flow cytometry, as well as being a method 
now essential for cytological analysis qualitative and quantitative, also allows to 
separate physically, from heterogeneous cell populations, subpopulations of 
specific cells thanks to specific membrane structures, present on the cells 
surface, recognized by specific monoclonal antibodies. This procedure is called 
"cell sorting" and allows to obtain cell populations with a purity greater than 
95%. The operating principle of flow cytometry is based on the interaction of 
each cell with a beam of focused light from a laser or a mercury vapor lamp. The 
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meeting between the light beam and the cell, previously labeled with an 
antibody conjugated to a fluorochrome, generates signals that are related to the 
physical characteristics of the cell and the presence, on the cell surface, of 
specific fluorescent molecules.  
 
The instrument utilized in flow cytometry is called flow cytometer and it is 
composed of 5 functional units: 
1. fluidic system 
2. optical system 
3. electronic system 
4. mechanical system 
5. system software (SW) - data analysis 
 
The fluidic system 
The fluidic system brings the sample cells in the area of interaction with the light 
beam. The main part of the entire system is the flow cell, consisting of a "nozzle" 
(a cone that contains the needle for the injection) and a capillary. For set up 
individually the sample cells in columns, is necessary the presence of a laminar 
type of motion at the center of the capillary, guaranteed by a physiological 
solution (buffer) that acts as a dragging liquid for the sample. Liquid and sample 
arrive in the capillary where takes place the interaction with the light. 
 
The optical system 
The optical system consists of a series of diaphragms, lenses, filters and dichroic 
mirrors. All this to convey the beam of light as precisely as possible on the 
detector. The diaphragms improve the ratio between signal and background 
noise reducing scattered light; lenses serve to focus the laser beam and the 
fluorescence light; mirrors and filters are used to select the wavelengths of 
excitation spectra for emission continues and also the wavelengths that affect 
detectors. 
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The electronic system 
The electronic system consists of several subsystems: 
- Opto-detectors: convert light energy (photons) into electricity (electrons); 
- Photodiodes: collect the scattered light intensity, which is the parameter used 
for the determination of the size and granularity of the cell; 
- Photomultiplier tubes: detect the emitted fluorescence. 
In practice, the light incise on a photosensitive material (cathode), releasing 
electrons that are accelerated by different potential differences and  a series of 
electrodes in cascade which increase the flow of electrons, in order to have at 
the end a easily measurable current. The problem is that the eddy currents 
generated by background noise it also amplifies. For this reason a filter system is 
used. Then the electrical signals detected are measured in width, intensity and 
area. The data obtained are inserted into a channel that collects all the data 
within a certain range. Finally, a graph that shows the distribution of cells along a 
series of channels and for each channel (i.e., for a series of values) was made, 
and it provides a certain number of cells. 
 
The mechanical system 
The mechanical system allows to adjust the speed of release of the sample. 
 
The System software (SW) - data analysis 
Associated with the instrument there is a computer that stores, processes and 
presents data. Can be setted a threshold, or a regions (gates), that allows to 
capture only the parameters for some cell subpopulations or otherwise to 
exclude debris and impurities. The data already acquired can also be retrieved 
and reworked. 
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Cell subset purification: 
Peripheral mononuclear cells (PBMC) and polymorphonuclear (PMN) cells from 3 
healthy dogs were isolated over ficoll-hypaque discontinuous density gradient. 
Platelets (PLT) were recovered from plasma through centrifugation. The 
percentage of purity and the number of recovered cells were evaluated using 
Sysmex XT2000iV automated hematology analyzer (Sysmex, Kobe, Japan) and 
microscopically after cytocentrifugation and May Grünwald-Giemsa stain. To 
isolate lymphocyte subpopulations, PBMC were adjusted at 2 x 106 113 in 200 µl 
PBS and labelled with 200 µl of lineage specific antibody: anti-canine CD4-FITC 
and anti-canine CD8pe for T-cells, anti-CD21pe for mature B-cells. CD4, CD8, and 
CD21 positive cells were sorted using a fluorescent activated cell sorter (BD 
FACSVantage, BD Biosciences, San Jose, CA, USA). A minimum sorting yield of 1 x 
105 cells with more than 95% purity was considered suitable for molecular 
biologyinvestigation. 
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1.3.3 Classification of lymphoma and CLL samples  
 
A. Immunophenotyping by flow cytometry 
For all the fresh samples (peripheral blood and lymph node aspirates) a 
Immunophenotyping by flow cytometry of neoplastic cells using a FACSort 
instrument (Becton Dickinson) (Comazzi S. et al., 2006) was performed. In short, 
the following canine antigens were analysed using the corresponding antibodies: 
CD45 (clone mAb YKIX716.13 Serotec, Oxford, UK, all leukocytes), CD18 (clone 
mAb CA1.4E9, Serotec, all leukocytes), CD3-FITC (mAb clone CA17.2A12, Serotec, 
T lymphocytes), CD4-FITC, CD8-PE, CD21, CD11b (MAb clone CA163E10, Serotec, 
granulocytes and monocytes), CD34-PE (clone 1H6 mAb Pharmingen, BD 
Bioscience, cells blasts), and CD49d (clone mAb Ca4.5B3, PF Moore, Davis, CA, 
United States of America, T lymphocytes, myeloid cells). For unlabelled primary 
antibodies, indirect labeling was performed using secondary rabbit anti-mouse 
FITC-labeled polyclonal antibody (Serotec). Intracytoplasmic staining with anti 
CD79a-PE (clone HM57 Dako, Glostrup, Denmark, B cells, all stages) was 
performed after permeabilization using BD FACS permeabilizing solution 2 
(Becton Dickinson 
 
B. Immunophenotyping with immunohistochemistry 
The tissue samples were embedded in paraffin after formalin fixation. For 
histology, tissue sections of 5 micron in thickness were put on slides and stained 
with hematoxylin-eosin. For immunohistochemistry, sections of 5 microns were 
put on a glass slide coated with polylysine and colored according to the standard 
technique of peroxidase avidin-biotin. The antibodies used for phenotyping 
analysis of FFPE samples were: anti-CD18 to identify all leukocytes and used 
diluted 1:20 (Leukocyte Biology Laboratory, PF Moore, University of California, 
CA, USA), anti-CD79a and anti-CD20 (Dako) for recognizing the B cells and used 
diluted 1:40. Anti-CD3-epsilon (Dako) diluted 1:900 was used to identify the 
chain Y intracellular expressed in the majority of lymphocytes T. Negative 
controls consist of substitution of specific antibodies with an isotype specific 
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species, an irrelevant monoclonal antibody, or with the omission of the primary 
antibody. All samples of lymphoma were then analyzed under a microscope and 
classified according to the histological classification of hematopoietic tumors of 
domestic animals (Valli V.E. et al. 2002). 
 
C. Grading classification of FFPE splenic lymphoma samples 
For the splenic lymphoma FFPE samples a retrospective cohort study was 
performed. Dogs with confirmed primary splenic lymphoma were identified 
through medical record, biopsy and necropsy  database search of the electronic 
archives of the Anatomical Pathology service of the University of Milan, Italy.  A 
total of 29 cases of primary splenic lymphomas were evaluated and tissue from 7 
normal spleens from necropsy investigations  were included as controls.  Clinical 
data of the dogs were recorded.  Tissue samples were fixed in 10% buffered 
formalin, routinely processed, and 5 micron sections were stained with  
haematoxylin and eosin for histopathological evaluation. Lymphomas were 
classified according with the WHO classification (Valli V.E. et al., 2011); as part of 
the WHO classification, cell size and the number of mitoses were assessed. The 
pathologists classified the cell size as small (nuclei approximately 1 times the 
diameter of a red blood cell), intermediate (nuclei approximately 1.5–2 times the 
diameter of a red blood cell) and large (nuclei approximately 2.0–2.5 times the 
diameter of a red blood cell). Number of mitoses was evaluated by counting 
mitoses per 10 representative, artefact free fields at 400X magnification by three 
pathologists independently. If mitotic index differed among pathologists a mean 
of the three counts was calculated (Table 9). Grade was determined according 
with the WHO classification (cell size, diagnosis and mitotic index). On the basis 
of the grading, the samples were divided into two categories: Low (L) tumor 
samples and Intermediate/High (I/H) tumor samples. 
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SAMPLE IM Mitosis counts, 10 fields, 400X GRADE P 
P 20 0,2 0 0 1 0 0 0 1 0 0 0 L B 
P 21 0,4 0 0 0 1 0 2 1 0 0 1 L B 
P 22 0,1 1 0 0 0 0 0 0 0 0 0 L B 
P 23 0 0 0 0 0 0 0 0 0 0 0 L B 
P 24 0,3 0 0 0 0 0 1 0 2 1 0 L B 
P 25 0,7 2 0 0 0 1 1 1 0 2 0 L B 
P 26 0,3 1 1 0 0 0 0 0 1 0 0 L B 
P 27 0,3 0 1 0 0 1 0 0 1 0 0 L B 
P 28 0,2 1 0 0 0 0 0 1 0 0 0 L B 
P 29 0,2 0 0 1 0 1 0 0 0 0 0 L B 
P 30 0,2 1 0 0 0 0 1 0 0 0 0 L B 
P 31 0,4 0 1 1 2 0 0 0 0 0 0 L B 
P 32 0,3 1 0 0 0 0 0 0 0 2 0 L T 
P 33 0,8 2 1 0 1 0 1 1 2 0 0 L B 
P 34 0,9 0 0 0 1 3 0 2 2 0 1 L B 
P 35 0,9 0 0 6 0 0 1 1 1 0 0 L B 
P 36 0,6 1 1 2 0 1 1 0 0 0 0 L B 
P 37 0,4 0 0 0 0 1 1 0 1 1 0 L B 
P 38 0,2 0 0 0 0 0 0 1 0 1 0 L B 
P 39 1,7 2 1 5 1 3 2 1 2 0 1 L NK like 
P 40 1,5 1 3 2 2 0 0 1 3 2 1 L/I B 
P 41 3,3 10 5 2 7 6 3 0 1 2 2 I T 
P 42 5,3 9 6 3 7 5 4 6 4 3 6 I B 
P 43 7,9 12 5 6 7 1 7 9 14 9 9 I NK like 
P 44 2,3 2 1 0 2 2 4 2 3 2 5 I B 
P 45 3,6 5 3 3 4 4 2 2 4 2 7 I T 
P 46 3,5 4 3 5 4 3 4 6 0 3 3 I/H NK like 
P 47 11,4 13 11 6 14 11 17 8 13 10 11 H B 
P 48 27,3 14 35 33 38 32 28 28 29 22 14 H B 
 
Table 9. Sample grading of FFPE splenic tissue samples.  
IM= mitotic index, L= low, I= intermediate, H= high, P= phenotype 
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D. Phenotype assessment of FFPE splenic lymphoma samples 
For the application of the WHO classification for the tumoral cells, the phenotype 
was assessed. Briefly, 5 micron tissue sections were glued onto polylisine coated 
glass slides and were dewaxed and rehydrated before immunostaining. 
Immunohistochemical staining was performed utilizing monoclonal anti-human 
CD79a- (Dako, Glostrup, Denmark) at a 1:100 and polyclonal anti-human CD20 
(Neomarkers, Freemont, CA) at 1:400 were utilized for B cells recognition. 
Polyclonal anti-CD3- (Dako, Glostrup, Denmark) was utilized at 1:900 dilution for 
the identification of the intracellular epsilon chain expressed mostly in T cells. 
These antibodies recognize epitopes conserved in many species, including dogs 
(Jubala et al., 2005; Flood-Knapik et al., 2012; Stefanello et al., 2011). Heat 
induced antigen retrieval was performed by incubation in pH 6,4 citrate buffer 
and heated in a microwave oven at  maximum power for 1 minute and at 750 
watt for 3 minutes for two times and cooled for 20 minutes. Negative controls 
consisted of substitution of specific antibodies with an isotype-matched, 
irrelevant monoclonal antibody or omission of the primary antibody. Primary 
antibodies were incubated overnight in a humidified chamber at 4°C. Secondary 
detection was performed with the Avidin-Biotin enzyme Complex (ABC kit, 
Vectastain®, Burlingame, CA, U.S.A.) for 30 minutes. The  reaction was developed 
with the peroxidase Amino-9-ethyl-carbazole (AEC) substrate kit (Dako®, 
Glostrup, Denmark). Smears were counterstained with Mayer's hematoxylin for 3 
minutes and cover-slipped with an aqueous mounting media (Glicerine, Sigma-
Aldrich®, St. Louis, MO, U.S.A.). 
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1.3.4 RNA extraction 
 
1. From fresh/frozen samples  
The RNA was stabilized immediately after sampling by the addition of a 
stabilizing solution RNA (RNAlater ®, Ambion Inc., Austin, TX, USA) and storage at 
-80 ° until the extraction. Total RNA was extracted from whole blood samples 
with the miRNA Isolation Kit ™ Mirvana of Ambion, adapting the procedure for 
extraction of total RNA from tissue (whole blood is first centrifuged to remove 
the RNA later and then the pellet is lysed according to the procedure). The 
Mirvana ™ miRNA Isolation Kit has been developed for the purification of RNA 
suitable for studies of miRNA and siRNA. The kit uses organic extraction followed 
by immobilization of the RNA on a glass fiber filter to purify total RNA or RNA 
enriched for small species from cells or tissues samples. This extraction method 
presents considerable differences compared to classical chemical extraction 
method. In fact, the chemical extraction uses high concentrations of chaotropic 
salts with acid solutions of phenol or phenol-chloroform, to inactivate RNases 
and to purify RNA from other biomolecules. These methods lead to the recovery 
of pure RNA, however, provide an additional step of removal of salts and 
concentration with precipitation in alcohol. The latter step is not suitable for the 
recovery of miRNAs. The method of solid phase extraction using high 
concentrations of salts or salts and alcohol to decrease the affinity of RNA for 
water and increase it for the support of the solid phase. The Mirvana ™ miRNA 
Isolation Kit combines the advantages of the two methods, while avoiding their 
disadvantages.  
The kit consists on 2 steps: 
 Cells lysis and organic extraction: the sample is broken using a denaturant 
lysis buffer. Subsequently, the sample is subjected to extraction with 
phenol-chloroform, which allows a purification also removing most of the 
DNA. 
 RNA final purification on a glass fiber filter: absolute ethanol is added to 
sample which is then loaded onto the column containing the filter that 
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immobilizes the RNA. The filter is washed several times with special 
solutions, and finally the RNA is eluted with 100 µl of water previously 
heated to 95 ° C. 
 
2. From formalin-fixed and paraffin-embedded samples 
The samples of FFPE splenic tissue are extracted with the RecoverAll kit of 
Ambion, following the procedure for Total RNA. The RecoverAll ™ Total Nucleic 
Acid Isolation Kit is developed to extract total nucleic acid (RNA, miRNA and 
DNA) from tissues fixed in formaldehyde or paraformaldehyde or paraffin-
embedded (FFPE). In a single reaction sections of more than 20 µm can be 
processed. The FFPE samples are dewaxed using xylene attended by a series of 
washes in ethanol. Subsequently, the samples are subjected to digestion with a 
protease. The nucleic acids are then purified using a rapid methodology with 
glass fibers filter of which includes a treatment with nuclease directly on the 
filter, and finally are eluted with 60 µl of water previously heated to 95 ° C. 
 
3. From cytologic glass smears 
For cytologic glass smears we performed two different extraction protocols 
depending on the type of sample: peripheral blood or lymph node aspirate. The 
lymph node aspirate samples were incubated in xylene for 2-5 days in order to 
facilitate detachment of the coverslip and, subsequently, are subjected to two 
ethanol washes, first using 100% ethanol and then 70% ethanol. The smears are 
air dried and then the samples are retrieved from the surface of the slidse by 
means of scratching in 400 microliters of a solution of 75:25 RNA later-PBS: each 
sample is scraped from the coverslip, directly in the solution, in two steps from 
200 microliters each, using the blade of a sterile scalpel. The solutions after 
scratching are placed in an eppendorf. Each sample is then subjected to 
extraction and quantification of total RNA using miRNA Isolation Kit ™ Mirvana as 
described in the previous paragraph. On the other hand, on peripheral blood 
slides samples, given the smallest number of cells and the lowest quality of 
smears present, the RNA extraction is performed using a TRIzol protocol, 
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developed for the extraction of miRNAs from plasma (Laterza et al. 2009). In 
detail, the cytologic glass smears are incubated in xylene for 2-5 days and, 
subsequently, are subjected to two washings with 100% ethanol and 70% 
respectively. Then, the cytologic glass smears are air dried and the samples are 
retrieved from the surface of the slide by scratching in 1 ml of TRIzol: each 
sample is scraped from the slide, directly in the solution, in four steps from 250 
microliters each, using the blade sterile as scalpel. The solutions after scratching 
are placed in an eppendorf. Each sample is then incubated briefly at room 
temperature and then are added 200 µl of chloroform. The samples thus 
obtained are centrifuged at 12000 rpm for 15 minutes at 4 °C in order to 
facilitate the separation of the three phases: inferior (DNA), interphase (proteins) 
and upper aqueous phase (RNA). At this point the aqueous phases, containing 
the RNA, are recovered and 800 µl of isopropanol are added. After a further 
centrifugation (12000 rpm for 10 minutes at 4 °C) and elimination of the 
supernatant, 1 ml of 75% ethanol is added. The samples are then incubate at 
room temperature for 10 minutes and, after a final centrifugation (12000 rpm for 
10 minutes at 4 °C), the supernatants are removed and the samples are allowed 
to dry under chemical hood. Finally the RNAs are resuspended with 25 µl of 
water. 
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1.3.5 RNA quantification and quality control 
 
The concentration of RNA extracts was determined, in all cases with the 
exception of RNA obtained from CLL cytologic glass smears, by using a 
spectrophotometer ND-100 (NanoDrop® Technologies Inc., Wilmington, DE, USA) 
which expresses the concentration in terms of nanograms/microliter (ng/µl) 
accompanied by the ratio between absorbance at 260 nm and absorbance at 280 
nm (A260/A280 ratio). For RNA obtained by cytologic glass smears and from the 
corresponding fresh samples we carried out a quality control using Agilent 
Bioanalyzer 2100, in combination with the kit "RNA 6000 Nano LabChip ®" and 
the kit "Agilent Small RNA Chip".  
The Agilent Bioanalyzer 2100 is an instrument for the RNA quantitative and 
qualitative analysis. The quantification is relative because it is based on a 
comparison with a marker of known molecular weight. Each chip contains a 
series of tightly interconnected microchannels: the nucleic acid fragments are 
then separated according to their molecular weight as in a standard 
electrophoresis in agarose gel. The microchannels of each chip are filled with a 
matrix and a fluorochrome:  
 samples move through the microchannels from the hole of loading 
 each sample is inserted into the separation channel 
 samples are separated through an electrophoretic run  
 at the end of the electrophoresis, samples are read according to their 
fluorescence and this information is translated into a typical image of gel 
electrophoresis and electropherograms. 
The system, thanks to a dedicated software, is able to measure the quality and 
quantity of the RNA samples. At the end of the run, the instrument provides an 
electropherogram for each individual sample, the virtual image of a typical 
agarose gel and a tabulation with the results of quantification and 
contamination. In the case of Nano chip the instrument returns a value defined 
RIN (RNA Integrity Number) that allows to assign a quality index for the total RNA 
examined. This parameter has a scale that goes from 10, which indicates RNA of 
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excellent quality, to zero, which indicates that RNA is completely degraded. The 
Small RNA chips, however, is able to provide the percentage of enrichment of 
RNA fragments long about 20-40 nt, those corresponding to a population of 
miRNAs. 
 
1.3.6 Search of miRNAs in miRBASE  
 
Twelve computationally-predicted canine miRNA sequences (cfa-let-7a, cfa-miR-
15a, miR-16a-cfa, cfa-miR-17-5p, miR-cfa -21, cfa-miR-26b, miR-29b-cfa, cfa-miR-
125b, miR-150-cfa, cfa-miR-155, miR-cfa-181st and cfa-miR-223), known in 
humans as ubiquitous or typical of hematopoietic cells, were obtained either 
from miRBase (http://microrna.sanger.ac.uk) or from literature. The sequence 
identity of the mature miRNA sequence with the corresponding homologous 
human mature miRNA sequence was confirmed by BLAST alignment 
(http://blast.ncbi.nlm.nih.gov/bl2seq/wblast2.cgi). The corresponding precursor 
sequence were also checked to show a minimum 95% identity between the two 
species. Besides, the small nucleolar gene RNU6B was selected as a non-miRNA 
candidate EC since its previous use as unique EC gene in canine miRNA 
expression studies by other researchers (Boggs et al., 2007 and 2008). 
 
1.3.7 Specific gene reverse transcription of miRNAs 
 
For each sample, and for each miRNA of interest, 10 nanograms of RNA (CLLs) 
and 20 nanograms of RNA (lymphomas) were reverse transcribed to cDNA using 
the corresponding TaqMan ® MicroRNA Assay kit (Applied Biosystems Inc., Foster 
City, CA, USA) and TaqMan ® Assay snoRNU6B (Applied Biosystems Inc., Foster 
City, CA, USA). These kits are marketed specifically for humans but are also valid 
for the corresponding canine miRNA when the sequence is completely 
conserved. The RT reactions were performed with specific RT primers stem-loop 
for each miRNA and contained in the corresponding MicroRNA TaqMan ® Assay. 
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We used the reverse transcription kit microRNA TaqMan®, following the 
manufacturer's instructions. 
 
TaqMan MicroRNA Reverse Transcription General Procedure, Kit ABI 
The reverse transcription master mix is prepared as follows (amounts for 10 
reactions already include a round up of 10% to compensate losses due to 
pipetting): 
 
Component 1 sample 10 samples 
dNTP mix (100 mM) 0.15 μl 1.7 μl 
Multiscribe RT enz. (50 U/mcl) 1 μl 11 μl 
10x RT Buffer 1.5 μl 16.5 μl 
RNase Inhibitor (20 U/mcl) 0.19 μl 2.1 μl 
Water RNasi-free 4.16 μl 45.7 μl 
Total 7 μl 77 μl 
 
First, for every 7 µl of retrotranscription master mix, 5 µL of each sample total 
RNA (that contains 20 or 10 nanograms) are added, except for CLL cytologic glass 
smears where 5 microliters of the aqueous solution directly obtained after 
extraction with TRIzol, without prior quantification, are added. Then, an 
Eppendorf 0.5 µl for each reverse transcription reaction is prepared and 12 µl of 
master mix, already added of RNA, are aliquoted into each tube. After which, 3 µl 
of the reverse transcription primers, specific for a given target, are added to each 
tube. The retrotranscription reaction provides the following thermal protocol: 
incubation on ice for 5 minutes, followed by 30 minutes at 16 ° C, 30 minutes at 
42 ° C and 5 minutes at 85 ° C. 
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1.3.8 Standard curves construction for absolute quantification 
 
The miRNAs absolute quantification was calculated by interpolation of the 
corresponding threshold cycle (Ct) values with a reference curves obtained 
through miRNA-specific RT reaction followed by TaqMan real-time PCR 
quantification of 1:100 serial diluition points of the mirVana™ miRNA Reference 
Panel v9.1 (Ambion) following manufacturer’s instructions. The miRNA Reference 
Panel contains hundreds of miRNAs with known concentration. In particular, we 
used the following points of serial dilution for each miRNA of interest: 1 
femtomole, 10-2 femtomoles, 10-4 femtomoles, 10-6 femtomoles. The log ranges 
of the reference curves were chosen encompassing the putative amount of each 
target sequence that could be expected in cDNA prepared from our kind of 
samples. 
 
 
1.3.9 Standard curves construction for efficiency calculation and 
relative quantification  
 
To evaluate the efficiency of the MicroRNA TaqMan® Assay, serial amounts (125 
ng, 25 ng, 5 ng, 1 ng, 0.2 ng and 0.04 ng) of total RNA from non-neoplastic 
control tissue samples were used to obtain standard curves.  The 125 ng-0.04 ng 
range was designed to encompass the 20 ng and 10 ng of total RNA that is the 
amount used for expression profiling. No-template RT reactions were performed 
as negative control for each target. 
Relative expression of each miRNA was calculated using the comparative delta-
delta Ct method with the three most stable EC genes selected as described 
below. 
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1.3.10 qRT-PCR TaqMan  
 
The real time PCR reactions were performed utilizing the TaqMan MicroRNA 
Assay (Applied Biosystems) according to the instructions described by the 
manufacturer in 20 microliter total containing the following reagents quantities: 
 1.33 microliter RT product,  
 1X TaqMan® Gene Expression Master Mix, and  
 1X specific MicroRNA TaqMan® Assay.  
Each reaction was assayed in triplicate on a 96-well plate. The real time 
amplification reactions were run on an iQ™5 Real Time PCR Detection System 
(Bio-Rad, Hercules, CA, USA) following the thermal protocol recommended for 
MicroRNA TaqMan® Assays by the manufacturer. 
The absolute quantification for each miRNA retrotranscribed is calculated by 
interpolation of the corresponding threshold values with the straight line 
obtained from Reference Panel, while the relative quantification was determined 
by the comparative method ΔΔCT (Giulietti A. et al, 2001). 
 
1.3.11 Cloning of the amplifieds and DNA sequencing  
 
The specificity of each MicroRNA TaqMan® Assay for the corresponding canine 
target was assessed by amplicon cloning followed by DNA sequencing. The 
amplicons were run on 2.5 ethidium-bromide agarose gel followed by UV-
visualization and gel-purification by QiaquickTM Gel Extraction kit (Qiagen 
GmbH, Hilden, Germany). The concentration of purified amplicons was 
spectrofotometrically measured using a ND-100 Spectrophotometer (NanoDrop 
technology). Each quantitated amplicon was ligated into a P-GEM T-Easy plasmid 
(Promega Corporation, Madison, WI, USA) following manufacturer’s instructions. 
The constructs thus obtained were used to transform cells of E. coli DH5alpha. 
The colonies grown on the plate after processing were analyzed for the presence 
of the plasmid containing the insert by PCR using the primers T7 and SP6 specific 
for the plasmid. Two positive clones for each target were sequenced using T7 
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and SP6 primers and the DNA sequencer ABI PRISM 310 (Applied Biosystems). 
The obtained sequences were aligned with the expected target sequences using 
ClustalW. 
 
1.3.12 Housekeeping gene’s selection using NormFinder and 
geNorm algorithms  
 
The candidate reference genes Ct values, obtained by real-time qPCR, were 
analyzed in order to assess the stability of expression in all samples using the 
software NormFinder (Andersen C.L. et al., 2004), available at 
http://www.mdl.dk/publicationsnormfinder.htm, and the geNorm software, 
version 3.5 (Vandesompele J. et al., 2002), available at 
http://www.medgen.ugent.be/jvdesomp/genorm/. 
 
1.3.13 Calculation of ΔΔCt 
 
The miRNAs threshold cycle (Ct) values, obtained with the qRT-PCR, were 
analyzed utilizing the comparative ΔΔCT method (Giulietti A. et al, 2001). This 
method compares the Ct value of the test sample with the Ct value of the 
reference sample (the corresponding non-neoplastic tissue). The two Ct values 
are normalized according to the values of one or more endogenous control (EC) 
genes. The relative expression of the gene of interest in the different samples 
was calculated according to the following formula: 
 
ΔCt = Ct (target gene) - Ct (housekeeping gene) 
 
Ct target gene- indicates the value of the threshold cycle for the gene of interest, 
Ct housekeeping gene- indicates the value of the threshold cycle for the 
transcript used as reference.  
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Subsequently, the relative expression of all samples compared to a sample of 
non-neoplastic control was calculated as follows: 
 
Er = 2ΔΔCt     ;  ΔΔCt = ΔCt (sample) – ΔCt (control) 
 
Er indicates the relative expression, ΔCt (sample) indicates the difference of Ct 
values calculated for the individual sample, ΔCt (control) indicates the difference 
of Ct values calculated for the sample taken as a reference. 
Then, for each miRNA of interest of each sample was calculated the geometric 
mean of the values of differential expression obtained for each EC. 
 
1.3.14 Statistical analysis 
 
Significance analysis of expression data obtained in the present work were 
performed using the nonparametric Kruskal-Wallis test and Mann-Whitney test, 
using SPSS statistical package (version 13, SPSS, Chicago, IL, USA). Furthermore, 
to compare the extraction method from cytologic glass smears with the 
extraction method from fresh/frozen sample was used the test Passing-Bablok, 
which allows to detect the presence of correlations, also non-linear, followed by 
Bland-Altman test, which provide indications about a possible correlation and 
allows to detect the presence of errors proportional and / or constants. A p-value 
less than 0.05 was considered significant. 
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1.4  RESULTS 
 
1.4.1 Extracted RNA quantification and quality control 
 
The total RNA quantification procedure showed that the RNA extraction methods 
(miRNA Mirvana Isolation Kit ™ from fresh/frozen samples and Ambion 
RecoverAll kit from FFPE samples) has provided high quality RNA (ratio generally 
around 2) and in good concentration, largely sufficient for subsequent analysis. 
The tables below show the list of total RNA extracts, their concentrations and 
their A260/A280 ratio. 
 
A. Fresh/frozen lymph node aspirates:  
Sample code Sample type Concentration Ratio 
F 1 Lymphoma T 3140 ng/µl 2.03 
F 2 Lymphoma T 3245 ng/µl 2.04 
F 3 Lymphoma T 490 ng/µl 2.00 
F 4 Lymphoma T 685 ng/µl 2.06 
F 5 Lymphoma T 172 ng/µl 2.07 
F 6 Lymphoma B 304 ng/µl 2.02 
F 7 Lymphoma B 178 ng/µl 2 
F 8 Lymphoma B 2035 ng/µl 2.05 
F 9 Lymphoma B 155 ng/µl 1.97 
F 10 Lymphoma B 87 ng/µl 2.08 
F 11 Lymphoma B 336 ng/µl 2.06 
F 12 Lymphoma B 416 ng/µl 2.04 
F 13 Lymphoma B 237 ng/µl 2.09 
F 14 Lymphoma B 1224 ng/µl 2.03 
F 15 Lymphoma B 310 ng/µl 2.01 
F 16 Non neoplastic 913 ng/µl 2.01 
F 17 Non neoplastic 70 ng/µl 1.97 
F 18 Non neoplastic 410 ng/µl 1,97 
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B. FFPE lymph node aspirates: 
Sample code Sample type Concentration Ratio 
P 1 Lymphoma T 180 ng/µl 2.01 
P 2 Lymphoma T 228 ng/µl 1.98 
P 3 Lymphoma B 326 ng/µl 2 
P 4 Lymphoma B 63 ng/µl 2.06 
P 5 Lymphoma B 64 ng/µl 1.97 
P 6 Lymphoma B 1810 ng/µl 2.01 
P 7 Lymphoma B 223 ng/µl 1.99 
P 8 Non neoplastic 181 ng/µl 1.94 
P 9 Non neoplastic 42 ng/µl 2.05 
P 10 Non neoplastic 190 ng/µl 2.06 
P 11 Non neoplastic 92 ng/µl 2.03 
P 12 Non neoplastic 128 ng/µl 1.88 
C. Fresh/frozen CLLs: 
Sample code Sample type Concentration Ratio 
F 19 Non neoplastic blood 10 ng/µl 1.80 
F 20 Non neoplastic blood 50 ng/µl 2.02 
F 21 Non neoplastic blood 46 ng/µl 2.02 
F 22 Non neoplastic blood 123 ng/µl 1.91 
F 23 Non neoplastic blood 28 ng/µl 2.01 
F 24 Non neoplastic blood 120 ng/µl 1.98 
F 25 T- CLL 315 ng/µl 2.06 
F 26 T- CLL 740 ng/µl 2.09 
F 27 T- CLL 233 ng/µl 2 
F 28 T- CLL 275 ng/µl 2.03 
F 29 T- CLL 110 ng/µl 1.88 
F 30 T- CLL 82 ng/µl 2.07 
F 31 T- CLL 67 ng/µl 2.16 
F 32 T- CLL 118 ng/µl 2.07 
F 33 B- CLL 128 ng/µl 2.07 
F 34 B- CLL 71 ng/µl 2.00 
F 35 B- CLL 63 ng/µl 2.04 
F 36 B- CLL 329 ng/µl 2.08 
F 37 B- CLL 63 ng/µl 2.05 
F 38 B- CLL 57 ng/µl 2 
F 39 B- CLL 37 ng/µl 1.91 
F 40 B- CLL 107 ng/µl 2.1 
85 
 
D. FFPE splenic lymphomas: 
Sample code Sample type Concentration Ratio 
P 13 Non-neoplastic 45 ng/µl 1.93 
P 14 Non-neoplastic 91 ng/µl 1.89 
P 15 Non-neoplastic 78 ng/µl 1.95 
P 16 Non-neoplastic 158 ng/µl 1.99 
P 17 Non-neoplastic 157 ng/µl 2.03 
P 18 Non-neoplastic 25 ng/µl 2.19 
P 19 Non-neoplastic 60 ng/µl 1.99 
P 20 Splenic lymphoma 145 ng/µl 1.97 
P 21 Splenic lymphoma 313 ng/µl 2.01 
P 22 Splenic lymphoma 46 ng/µl 2.00 
P 23 Splenic lymphoma 55 ng/µl 1.85 
P 24 Splenic lymphoma 135 ng/µl 1.96 
P 25 Splenic lymphoma 1320 ng/µl 1.94 
P 26 Splenic lymphoma 40 ng/µl 2.05 
P 27 Splenic lymphoma 362 ng/µl 2.01 
P 28 Splenic lymphoma 130 ng/µl 1.88 
P 29 Splenic lymphoma 55 ng/µl 1.90 
P 30 Splenic lymphoma 103 ng/µl 1.89 
P 31 Splenic lymphoma 113 ng/µl 1.92 
P 32 Splenic lymphoma 362 ng/µl 2.02 
P 33 Splenic lymphoma 130 ng/µl 1.88 
P 34 Splenic lymphoma 55 ng/µl 1.90 
P 35 Splenic lymphoma 103 ng/µl 1.89 
P 36 Splenic lymphoma 153 ng/µl 1.92 
P 37 Splenic lymphoma 342 ng/µl 2.01 
P 38 Splenic lymphoma 130 ng/µl 1.88 
P 39 Splenic lymphoma 55 ng/µl 1.90 
P 30 Splenic lymphoma 103 ng/µl 1.89 
P 31 Splenic lymphoma 113 ng/µl 1.92 
P 32 Splenic lymphoma 362 ng/µl 2.00 
P 33 Splenic lymphoma 130 ng/µl 2.05 
P 34 Splenic lymphoma 58 ng/µl 1.90 
P 35 Splenic lymphoma 103 ng/µl 1.89 
P 36 Splenic lymphoma 113 ng/µl 1.92 
P 37 Splenic lymphoma 342 ng/µl 2.01 
P 38 Splenic lymphoma 128 ng/µl 1.90 
P 39 Splenic lymphoma 99 ng/µl 1.98 
P 40 Splenic lymphoma 49 ng/µl 1.89 
P 41 Splenic lymphoma 37 ng/µl 1.79 
P 42 Splenic lymphoma 65 ng/µl 2.01 
P 43 Splenic lymphoma 38 ng/µl 1.88 
P 44 Splenic lymphoma 167 ng/µl 1.80 
P 45 Splenic lymphoma 29 ng/µl 1.89 
P 46 Splenic lymphoma 136 ng/µl 1.92 
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P 47 Splenic lymphoma 267 ng/µl 2.02 
P 48 Splenic lymphoma 145 ng/µl 1.98 
 
Table 10. Results of NanoDrop quantification. List of total RNA extracts, with 
concentration nanograms/microliter (ng/µl) and ratio 260/280. A) lymph node 
aspirates fresh/frozen B) lymph node aspirates FFPE, C) Samples peripheral blood 
fresh/frozen, controls and CLL, D) splenic tissue samples embedded in paraffin, 
controls and lymphomas. 
 
As shown in Table 11, also the extraction protocols from lymph node aspirated 
cytologic glass smears were generally able to provide RNA in good concentration, 
not too far from that obtained from the corresponding frozen samples (which 
are extracted from an amount of sample significantly higher) and with high 
quality (the optimal ratio A260/A280 for RNA is between 1.8 and 2.1).  
 
Sample P Concentration (ng/µ) Ratio A260/A280 
  Smear Fresh/frozen Smear Fresh/frozen 
C 1/F 1 T 23 155 1,87 1,97 
C 2/F 2 T 60 304 2 2,02 
C 3/F 3 T 50 510 1,52 2,04 
C 4/F 4 T 24 60 1,84 1,61 
C 5/F 5 T 132 34 1,96 1,94 
C 6/F 6 B 158 3245 2,03 2,04 
C 7/F 7 B 55 685 1,97 2,06 
C 8/F 8 B 17 178 2 2 
C 9/F 9 B 50 2035 1,83 2,05 
C 10/F 10 B 66 416 1,91 2,04 
C 11/F 11 B 19 237 1,93 2,09 
C 12/F 12 B 107 920 1,94 2,03 
C 13/F 13 B 55 85 1,97 2,05 
C 14/F 14 B 48 1300 1,4 2,07 
C 15/F 15 B 55 74 1,78 2,05 
 
Table 11. Concentrations and relative A260/A280 ratios of RNA extracted from 
lymph node aspirates fresh/frozen and their equivalent cytologic glass smears 
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The total RNA obtained from peripheral blood cytologic glass smears of leukemic 
dogs was not sufficiently abundant to be adequately quantified with the micro 
spectrophotometer. This is not surprising considering the minimum volume of 
blood (few microliter) that is usually utilized to prepare a cytologic smear, and 
that this kind of samples naturally contains fewer cells rather than a similar 
volume of aspirated lymph node lymphoma. So, Agilent Bioanalyzer 2100 
instrument was utilized to analyze the total RNA extracted from cytologic glass 
smears and its corresponding fresh sample. For each sample is provided an 
electropherogram, the virtual image of an agarose gel, the total RNA 
quantification, the ratio between the two ribosomal RNA and the RIN (RNA 
INTEGRITY NUMBER). The value of the ratio between the two ribosomal RNA 
works as an indicator of the quality of RNA in question. As a result of the 
relationship existing between the two ribosomal RNA, the optimal value is 2. In 
the course of our project, unable to obtain RNA of such high quality, we decided 
to consider of good quality an RNA with a two ribosomal ratio included between 
1.2 and 2. In Figure 14 is shown an example of electropherogram and gel image 
of a lymphoma lymph node sample, both from cytologic glass smears that the 
respective fresh lymph node aspirate. From the observation of the 
electropherograms, we can note that the fresh sample (F 6), presents a total RNA 
of good quality since the 2 peaks representative 18S rRNA and 28S are visible. 
From the results obtained from the cytologic glass smears of the corresponding 
sample (C 6) we can note that the RNA is totally degraded because the RIN is 
N/A. This data is not surprising because the cytologic glass smears are stored in 
non-RNase free conditions and at room temperature, moreover the nucleic acid 
may be subject to further degradation during the step of mechanical removal of 
cells from cytologic glass smears. 
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Figure 14. Comparison results Agilent RNA 6000 Nano chip between a fresh 
lymphoma and its corresponding cytologic glass smears. 
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By the use of Agilent Bioanalyzer 2100 instrument and the appropriate small RNA 
chip, the percentage of enrichment of RNA fragments from 20 to 40 nt long (ie 
those that include miRNA) compared to total RNA, was calculated. From 
observation of the data shown in Table 12, we can see that the percentage of 
miRNAs in RNA extracted from cytologic glass smears is almost always higher 
than the percentage of those in the corresponding RNA extracted from fresh 
samples, this is probably due to the high chemical stability and to the small size 
of these molecules, which make them stable to the procedures of handling and 
preservation of cytologic glass smears with respect to the other nucleic acids. 
 
SAMPLE PERCENTAGE MIRNA AND  
CONCENTRATION pg/μl 
SMEARS FRESH/FROZEN 
C1=F1 36 % miRNA;  
Concentration: 6686.10 pg/μl 
23 % miRNA; 
Concentration: 3428.80 pg/μl 
C2=F2 33 % miRNA;  
Concentration: 11404.30 pg/μl 
27 % miRNA; 
Concentration:13106.60 pg/μl 
C3=F3 22 % miRNA;  
Concentration: 1266.80 pg/μl 
23 % miRNA;  
Concentration: 7146.40 pg/μl 
C6=F6 34 % miRNA;  
Concentration: 9253.40 pg/μl 
30 % miRNA; 
Concentration:13099.60 pg/μl 
 30 % miRNA;  
Concentration: 3543.50 pg/μl 
36 % miRNA; 
Concentration:186585.70 pg/μl 
C7=F7 50 % miRNA;  
Concentration: 13934.60 pg/μl 
35 % miRNA;  
Concentration: 5200.90 pg/μl 
C8=F8 62 % miRNA;  
Concentration: 8467.30 pg/μl 
33 % miRNA; 
Concentration:17999.60 pg/μl 
C9=F9 36 % miRNA;  
Concentration: 5415.20 pg/μl 
22 % miRNA; 
Concentration:9788.80 pg/μl 
 
Table 12. Results obtained with Agilent small RNA chip. Percentage and miRNA 
concentrations compared with total RNA extracted from fresh lymph node 
aspirates and corresponding cytologic glass smears. 
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1.4.2 Evaluation of the TaqMan assay for the canine miRNAs  
 
The sensitivity of the TaqMan® MicroRNA Assay, designed for human, was 
evaluated for some canine targets by 6 serial dilutions of cDNA obtained retro 
transcribing the total RNA extracted from canine lymph node aspirate and 
amplifyed utilizing the corresponding set of primers and probes. For each miRNA 
target, the relative straight line was obtained (Figure 15). The result shows that, 
for each miRNA, there is a linear reverse relationship between RNA input and 
threshold cycle (Ct), and efficiency values are close to optimal: indeed, the 
correlation values are in the range 0.997-1.000, and the efficiencies of PCR are 
included in the range 93.2-105% (Table 13). The dynamic range of each assay 
includes about four logarithms of concentration. 
 
 
Figure 15. Straight lines obtained from six serial dilutions of some cDNA obtained 
utilizing the TaqMan® MicroRNA Assay 
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Table 13. Dilution curves obtained for some miRNA assays:  
correlation values and PCR efficiency  
 
The sequencing of the amplicon after cloning, confirmed the amplification 
specificity for each miRNA target. As representative title, is shown below the 
clone sequence obtained after amplification with the assay for canine miR-26b 
(the sequence in bold refers to the sequence of the miRNA, which fully 
corresponds to the expected sequence, while the flanking sequences belong to 
the cloning site of the vector and the additional base resulting from the stem-
loop system amplification). 
 
CCTGCTCCCGGCCGCCATGGCGGCCGCGGGTAATTCGATTTGCAGGGNAC
CGAGGAACTGGATACGACAACCTATCCTGAATTACTTGAACGCGCCAATC
ACTAGTGAATTCGCGGCCGCCTGCAGGTCGACCATATGGGAGAGCTCCCA
ACGCGTTGGATGCATAGCTTGAGTATT  
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1.4.3 qRT-PCR TaqMan 
 
For each type of sample and neoplasia studied we proceeded to an accurate 
analysis and selection of suitable endogenous control (EC) genes in order to 
perform a correct normalization of target miRNA. The threshold cycles (CT) of the 
reference genes tested, obtained by real time, were analyzed using the 
algorithms geNorm, version 3.5 (Vandesompele J. et al. 2002), and NormFinder 
(Andersen C.L. et al. 2004). In all lymphoid malignancies studied, and for each 
miRNA target, after selecting the best housekeeping genes was performed a 
relative quantification, by calculating the delta-delta Ct to the endogenous 
control gene selected, and an absolute quantification, interpolating its Ct on 
standard curves obtained from serial dilutions of an equimolar pool of synthetic 
miRNAs (Mirvana ™ miRNA Reference Panel v9.1, Ambion). 
 
 
1.4.4 Selection of the best endogenous control (EC) genes 
 
A. Lymph nodes lymphomas 
In lymph nodes lymphomas, for choosing the best endogenous control (EC) gene, 
7 miRNA (cfa-let-7a, miR-16-cfa, cfa-miR-21, miR-26b-cfa, cfa-miR-125b, miR-
150-cfa, cfa-miR-223) and RNU6B were analyzed. The analysis were carried out 
on non-neoplastic lymph nodes and nodal lymphomas, both frozen and paraffin-
embedded. The candidate miRNA and RNU6B EC genes showed a wide 
expression range in non-neoplastic and neoplastic lymph node samples. Figure 
16 shows the arithmetic average of the threshold cycles obtained after 
amplification of each miRNA EC candidate for each sample (A non-neoplastic 
lymph nodes, B lymph node lymphomas), both frozen and paraffin-embedded. 
From the results obtained it was possible to distinguish two categories of 
expression: highly expressed genes had median Ct values below cycle 25, and 
lowly expressed genes had median Ct values below cycle 25. Although it 
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highlighted some general variability, it can be noted that some miRNAs (let-7a, 
miR-16-1, miR-26b) show a more constant level of expression in different types 
of samples. 
 
Figure 16. Median and range of Ct values of candidate genes as endogenous 
controls: (A) non-neoplastic lymph node samples and (B) lymph node samples 
with cancer. The arbitrary line drawn at 25 Ct defines two groups of candidate 
genes EC. 
 
In Table 14 are reported the results obtained by analyzing the data referring to 
the average of the threshold cycles of each miRNA both with the algorithm 
NormFinder that, for purposes of comparison and possible confirmation, with 
the algorithm geNorm. The samples were analyzed separately by type, or all 
together. From the general point of view, it can be deduced that, for the 
different types of samples, the rankings obtained with the two different 
statistical approaches coincide in absolute or almost absolute, confirming the 
validity of the experimental data. From a specific point of view, it should be 
noted that the samples of lymphoma, both frozen and embedded in paraffin, 
show an high stability of miR-16 and miR-26b and an high instability of miR-21 
and RNU6B, while in samples of lymph node control non-neoplastic, on the 
contrary, miR-21 is characterized by high stability of expression. Taking into 
account the totality of the samples, both control and neoplastic, both frozen and 
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embedded in paraffin, it appears that the best housekeeping gene is the miR-
26b, followed by let-7a and miR-16, while the genes characterized by greater 
instability of expression are the miR-150 and RNU6B (Figure 17). This latter fact 
has relevant importance, since the gene RNU6B was frequently used as 
housekeeping gene for the normalization in miRNAs quantification experiment  
(Boggs et al., 2007). 
 
 
Table 14. Ranking candidate genes EC obtained with the algorithms NormFinder 
and geNorm from lymph nodes neoplastic and non-neoplastic of dog: (A) 
fresh/frozen samples, (B) FFPE samples, and (C) fresh/frozen and FFPE samples. 
The values of stability of NormFinder shown are representative of both the 
intragroup variations which those of intergroup (control vs. tumors). GeNorm M 
values reported were calculated for the 8 candidates EC before the process of 
stepwise exclusion. 
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Figure 17. Average of stability expression of the endogenous control candidates 
obtained by geNorm. Gradual exclusion of the least stable gene in samples 
fresh/frozen and FFPE. (A) Controls and Lymphomas, (B) Only Lymphomas 
 
An important confirmation of the RNA extraction comparability from cytologic 
glass smears sample rather than from fresh/frozen samples was provided by the 
analysis in parallel of the 7 miRNA candidates EC using ranking algorithms 
geNorm and NormFinder, that classify miRNAs on the basis of their expression 
stability in order to select the best control gene endogenous. Table 15 shows the 
results obtained by analyzing the data referring to the average of the threshold 
cycles of each miRNAs with the algorithm NormFinder (both for fresh samples 
and cytologic glass smears). The rankings of stability between the two different 
kinds of samples is comparable, and in particular let-7a is the best candidate CEs 
in both cases, while miR-125b is revealed as the candidate EC less stable both for 
the cytologic glass smears that for frozen. In Figure 18 is shown the high level of 
correlation between the stability values obtained for each miRNAs from the 
analysis of two different kinds of samples (cytologic glass smears and 
fresh/frozen). 
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Gene name Stability value 
 Smears Fresh/frozen 
let-7a 0,338 0,421 
miR-16 0,526 0,629 
miR-26b 0,436 0,663 
miR-125b 1,478 2,042 
 
Table 15. Stability values of the candidates genes of endogenous control in the 
two kinds of samples. 
 
 
Figure 18. Correlation degree between the stability values obtained for each 
candidate EC in the two kinds of samples. 
 
The miRNAs stability values obtained by cytologic glass smears samples show a 
quite similar stability compared to the corresponding  fresh/frozen samples 
(Table 15). This result confirms that the intrinsic variability of the amplification 
yield obtained from cytologic glass smears samples is not greater than other kind 
of archive’s sample. In this regard, it should be noted that the stability ranking of 
the different candidates EC genes is similar for both kind of samples (Table 15), 
with an inversion between miR-16 and miR-26b, presumably due to the 
oscillation of stability values very close to each other. Furthermore, the linearity 
degree between the two kind of samples is very high (Figure 18). This confirms 
the validity of the extraction procedure from cytologic glass smears sample with 
respect to the extraction from samples of conventional archive, and finally the 
possibility of using lymph node aspirate cytologic glass smears for miRNAs 
expression analysis as a supplement or replacement of fresh/frozen samples. 
Normfinder
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B. Chronic lymphocytic leukemia (CLL) 
In CLL, to choose the best candidate EC gene, were analyzed 12 miRNAs (let-7a-
cfa, cfa-miR-15, miR-16-cfa, cfa-miR-17-5p, cfa -miR-21, miR-26b-cfa, cfa-miR-29, 
miR-125b-cfa, cfa-miR-150, miR-155-cfa, cfa-miR-223) and RNU6B. Analyses were 
carried out on non-neoplastic peripheral blood samples and blood samples of 
subjects suffering from CLL with different immunophenotype. Initially, the 
analysis for the evaluation of miRNAs expression levels have been carried out 
only on fresh/frozen samples, later the same investigations were made also in 
peripheral blood cytologic glass smears of leukemic dogs. As in the nodal 
lymphomas, even in CLL the analyzed miRNAs and the gene nucleolar RNU6B 
showed variable levels of expression between neoplastic samples and control 
samples (Figure 19). 
 
 
Figure 19. Median and range of Ct values of candidate EC genes in: (A) non-
neoplastic peripheral blood samples, (B) T-CLL samples, (C) B-CLL samples. 
The arbitrary line drawn at 25 Ct defines two groups of candidate EC genes. 
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Figure 20. Best EC gene selection in peripheral blood samples with geNorm.  
(A) The average value of stability of expression (M) was calculated for each 
candidate EC. Comparison comparative two by two, which in turn eliminates the 
less stable miRNA and recalculates the stability among the remaining miRNA, 
thus giving as result a single pair of miRNA reference (the most stable).  
(B) Determination of the optimal number number of EC genes for normalization. 
Is calculated the value of systematic variation (v) between two normalization 
factors in a sequential manner. V 4/5 shows the variation of the normalization 
factor with 4 vs 5 EC genes 
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GeNorm analysis of the whole sample set identified let-7a and miR-17-5p as the 
most stable pair of candidate EC genes, followed by miR-26b and miR-223 (Figure 
20A). Noticeably, RNU6B was the least stable candidate EC. Pairwise variation 
analysis showed that a value (0.173) close to the recommended threshold value 
(0.15) was achieved when the top 4 candidate EC genes were selected as 
normalizers, and that the observed trend of V values did not change significantly 
after inclusion of additional genes (Figure 20B). 
Based on geNorm analysis results, four EC genes (let-7a, miR-17-5p, miR-26b and 
miR-223) were selected for optimal normalization of miRNA expression in canine 
normal and leukemic whole blood samples. The remaining eight miRNAs have 
been studied as target miRNA in CLL. 
 
C. Splenic lymphomas 
In splenic lymphoma, to choose the best endogenous control (EC) gene, we 
analyzed the 6 miRNAs (let-7a-cfa, cfa-miR-16, cfa-miR-21, cfa-miR-26b, cfa-miR-
150, cfa-miR-223) resulting as better endogenous control genes in lymph nodes 
lymphomas. The assayed miRNA genes showed a wide expression range in 
normal and neoplastic spleen samples. According to NormFinder algorithm 
(Table 16) the most stable gene is miR-16 in both sample types, followed by let-
7a, miR-26b, miR-150, miR-223 and miR-21. According to geNorm algorithm 
(Figure 21) the most stable pair of miRNAs result to be let-7a and miR-16 while 
the less stable is, once again, miR-21.  
 
RANK miRNA Stability value 
1 miR-16 0.108 
2 let-7a 0.242 
3 miR-26b 0.310 
4 miR-150 0,485 
5 miR-223 0.623 
6 miR-21 0.686 
 
Table 16. Stability values of the candidates genes of endogenous control 
obtained with NormFinder algorithm. 
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Figure 21. Average of stability expression of the endogenous control candidates 
obtained by geNorm. Gradual exclusion of the least stable gene in splenic 
lymphoma samples. 
 
Based on these results, we chosed miR-16 as endogenous control gene as it 
shows the more stable expression levels in both algorithms. It can be noted that 
some miRNAs (let-7a, miR-16, miR-26b) show a greater stability of the level of 
expression in various samples, regardless of their type. 
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1.4.5 Assessment of miRNAs levels in canine blood cell 
subpopulations  
 
Analysis of miR-15a, miR-16, miR-29b, miR-150, miR-155 and miR-181a 
expression was performed in canine CD4+ and CD8+ T cells, CD21+ B cells, PMN 
cells, PMBC and PLTs purified from three healthy subjects. The presence of all 
tested miRNAs was confirmed based on the amplification results. The expression 
data of blood line subpopulations were normalized to the miR-26b because it has 
comparable levels of expression in different cell subpopulations. Indeed, miR-26b 
was found to be the most suitable housekeeping miRNAs for the lymphoid 
tissues. 
Absolute quantification of each miRNA was performed through interpolation of 
the CT values, obtained with the qRT-PCR, on the corresponding Reference Panel 
curve. The expression ratio (molar ratio) between femtomoles of the single 
miRNA and miR-26b (normalization gene) was then calculated for each sample, 
including platelets, and the corresponding mean and standard deviation gene 
ratios for each dog were calculated (Table 17).  
A cell-type specific expression in peripheral blood cells was clearly detected, and 
each cell lineage was characterized by a specific miRNA expression pattern with a 
predominantly expressed gene. MiR-150 showed the maximal expression in T-
lymphocytes, and especially in CD4+ cells compared to CD8+ cells, and a low 
expression in PMN. The same was detected, on a lesser extent, for miR-29b and 
miR-155. The most expressed miRNAs in B-lymphocytes were miR-29b and miR-
150. Within lymphoid cell subpopulations, the expression level of miR-150 in B-
lymphocytes was appreciably lower compared to T-lymphocytes, whereas miR-
29b, miR-155 and miR-181a expression was rather similar in both cell types. Mir-
181a expression in lymphocytes was comparable to expression in PMN. MiR-15a 
showed preferential expression in PMN, whereas miR-16-1 was expressed in all 
cell types at a comparable level. MiR-15a was also the only miRNA showing 
higher expression in B-lymphocytes compared to T-lymphocytes. PBMC showed 
an intermediate expression profile between lymphocyte and PMN. PLT showed 
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the lowest expression level of miR-29b, miR-150, miR-155 and miR-181a, 
whereas miR-15a and miR-16-1 were expressed in a way comparable to other 
cell subpopulations. 
 
A 
Sample N 15a/26b 16-1/26b 29b/26b 150/26b 155/26b 181a/26b 
  m sd m sd m Sd m sd m sd m sd 
              
CD4+ 3 0.24 ±0.10 1.04 ±0.02 2.13 ±0.72 11.22 ±2.71 1.01 ±0.63 0.70 ±0.34 
CD8+ 3 0.29 ±0.17 0.88 ±0.16 2.58 ±0.30 5.13 ±0.65 0.69 ±0.11 1.00 ±0.38 
CD21+ 3 0.49 ±0.25 0.42 ±0.11 1.57 ±1.23 1.66 ±0.91 0.49 ±0.24 0.42 ±0.24 
PMN 3 4.12 ±0.69 2.28 ±1.52 0.34 ±0.06 0.14 ±0.02 0.05 ±0.01 0.76 ±0.27 
PBMC 3 0.62 ±0.16 0.62 ±0.15 0.37 ±0.07 0.29 ±0.17 0.13 ±0.07 0.20 ±0.02 
PLT 3 0.53 ±0.05 0.60 ±0.05 0.03 ±0.003 0.01 ±0.002 0.01 ±0.004 0.12 ±0.02 
 
B 
Sample N 150/223 150/15a 150/181a 
  M sd m sd m Sd 
        
CD4+ 3 229.74 ±210.05 48.17 ±8.47 17.48 ±4.94 
CD8+ 3 59.12 ±51.66 26.63 ±23.03 5.50 ±1.47 
CD21+ 3 3.55 ±1.03 3.31 ±1.07 4.02 ±1.23 
PMN 3 0.005 ±0.0037 0.03 ±0.01 0.20 ±0.07 
PBMC 3 0.32 ±0.25 0.52 ±0.35 1.43 ±0.43 
PLT 3 0.02 ±0.008 0.01 ±0.002 0.05 ±0.01 
 
Table 17. Comparison of the expression levels of miRNA target, expressed as 
mean and standard deviation A) ratio of the number of copies of the target 
miRNA and miRNA housekeeping cfa-mir-26b B) ratio of the number of copies of 
two different target genes, calculated in canine leukocyte subpopulations 
purified from three healthy subjects. PMN: polymorphonuclear PBMC: peripheral 
blood mononuclear cells; PLT: platelets. 
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1.4.6 Expression of targets miRNA in canine hematological 
malignancies 
 
A. Lymph nodes lymphomas 
 
1. Fresh/Frozen and FFPE samples 
Relative quantification of four miRNAs (miR-17-5p, miR-29b, miR-155 and miR-
181a), selected as target, was performed for all lymphoma samples (both in 
fresh/frozen samples than in FFPE samples) with reference to a representative 
non-neoplastic fresh-frozen (sample code F16) and FFPE (sample code P12) 
lymph node respectively (Table 18). Besides, based on the results obtained with 
NormFinder and geNorm analysis, let-7a, miR-16 and miR-26b were choosed as 
normalizing genes. 
 
 
miR-17-5p miR-29b miR-155 miR-181a 
F P Mean F P Mean F P Mean F P Mean 
T-cell 
lymphoma 
1.4 1.2 1.3 0.3 1.4 0.8 0.8 0.5 0.7 27.7 41.5 34.6 
B-cell 
lymphoma 
6.6 5.7 6.1 0.7 1.9 2.8 1.1 0.8 1 0.7 1 0.8 
 
Table 18. Relative quantification of the four miRNA target in all lymph nodes 
lymphomas. F= fresh/frozen, P= FFPE 
 
The relative expression (RE) values obtained for each miRNA versus F16 and P12 
reference samples showed excellent correlation, with the exception of those 
relative to miR-155 (Figure 22). 
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Figure 22. Correlation between the relative expression data of miRNAs target 
normalized to the let-7a, miR-16 and miR-26b and with reference to the control 
sample F16 (non-neoplastic lymph node aspirate fresh) and P12 (non-neoplastic 
lymph node embedded in paraffin). (A) miR-17-5p, (B) miR-155, (C) miR-29b, and 
(D) miR-181a. 
 
Non-parametric Kruskal-Wallis test of relative expression data, using either fresh-
frozen or FFPE non-neoplastic lymph node as reference sample, showed 
significant overexpression of miR-181a (p-value < 0.01) and downregulation of 
miR-29b (p-value < 0.05) in T-cell lymphoma cases compared to B-cell 
lymphomas, and significant (p-value < 0.01) overexpression of miR-17-5p in B-cell 
lymphomas compared to T-cell lymphomas. No significant (p > 0.05) difference in 
expression between T-cell lymphomas and B-cell lymphomas was detected for 
miR-155 (Figure 23). 
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Figure 23. Relative expression of target miRNAs (miR-17-5p, miR-29b. miR-155 
and miR-181a) in fresh/froze and paraffin-embedded samples of canine 
lymphoma, normalized to the EC genes miR-16, miR-26b and let-7a. The 
expression values were calculated in relation to the average of the lymph nodes 
of non-neoplastic control. (A) fresh/frozen control, (B) FFPE control. 
 
Absolute quantification of miR-181a and miR-17-5p in femtomoles was then 
performed for each sample through interpolation of the obtained Ct values on 
the corresponding Reference Panel curve. In order to derive a molecular 
parameter useful for the differentiation of B-cell lymphomas compared to T-cell 
lymphomas, the gene ratio between absolute quantities of miR-181a and miR-
17-5p was then calculated for each lymphoma sample (Figure 24). Non-
parametric Mann-Withney test showed significant (p-value <0.01) difference of 
mean miR-181a/miR-17-5p gene ratio between T-cell lymphomas and B-cell 
lymphomas. No statistical differences were found between high and low grade 
lymphomas either when all samples were analysed or considering different 
phenotypes. 
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Figure 24. Analysis of Ratio miR-181a/miR-17-5p in canine neoplastic lymph node 
sample divided by immunophenotype. 
 
 
2. Cytologic glass smears samples 
In order to highlight the usefulness of the miRNAs analysis from cytologic glass 
smears and to derive a molecular parameter useful for the differentiation of B-
cell lymphomas compared to T lymphomas, the absolute expression of miR-181a 
and let-7a was calculated even in this type of sample. After that, the ratio of 
expression (molar ratio) between the absolute quantities of miR-181a and the 
let-7a, for each cytologic glass smears sample, was calculated. The result is a 
clear distinction of molar ratio values between T lymphoma compared with B-cell 
lymphomas, with an average ratio of 9.11 in lymphoma type T and 3.4 in 
lymphoma type B (Figure 25). 
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Figure 25. Ratio miR-181a/miR-17-5p in B-cell lymphomas and T lymphomas 
from cytologic glass smears 
 
Non-parametric Mann-Withney test showed significant (p-value = 0.008) 
difference of mean miR-181a/miR-17-5p gene ratio between T-cell lymphomas 
and B-cell lymphomas from cytologic glass smears samples. Figure 26 shows the 
Bland-Altman test result regarding the molar ratio miR-181a/let-7a of the two 
types of samples (cytologic glass smears and frozen). Based on this test, it should 
be noted that the results of the two methods of extraction are sufficiently 
concordant despite a minimum constant error next to the proportional error. 
 
 
 
Figure 26. Results of the Bland-Altman test for the ratio miR-181a/let-7a in 
lymphomas samples. 
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Figure 27 shows similarly the result of the Passing-Bablok test regarding the 
molar ratio miR-181a/let-7a of the two types of samples. Based on this test, it 
should be noted that the two methods of extraction show sufficiently concordant 
results despite a moderate error of proportional type about the frozen samples 
(relatively to the cytologic glass smears samples) with a higher value of molar 
ratio. In particular, the results of the statistical analysis show an intercept very 
close to the expected value of zero (-0.14) and a slope of the straight estimated 
at 1.87 (ideal value equal to 1), however in the range of confidence between 0.69 
and 3.51. 
 
 
Figure 27. Results of Passing-Bablok test for the ratio miR-181a/let-7a in 
lymphomas samples. 
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B. Chronic lymphocytic leukemia (CLL) 
 
1. Fresh/Frozen and FFPE samples 
Relative expression (RE) of the eight miRNA not selected as ECs was calculated in 
the CLL whole blood sample set after normalization with the four EC genes, and 
expressed as fold change (FC) with reference to a representative normal whole 
blood sample (Figure 28).  
 
 
Fig 28. Relative expression of miRNA target in fresh/frozen samples of canine 
CLL, normalized to the genes miR-17-5p, miR-26b, miR-223 and let-7a. The 
expression values were calculated compared to the average of non-neoplastic 
blood samples. FC values of each miRNA were plotted on a log scale. T-1 to T-7: 
T-CLL whole blood samples. B-1 to B-7: B-CLL whole blood samples. 
 
The histogram above shows that miR-21 and miR-150 were overexpressed in T-
CLL while miR-125b and miR-155 were overexpressed in B-CLL (Table 19). 
Analysis of RE data by non-parametric Kruskal-Wallis test showed a significant (p-
value=0.007) overexpression of miR-125b in B-CLL compared to T-CLL (Table 19). 
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 Av. FC T-CLL Av. FC B-CLL KW test, p-value 
miR-15a 0.57 0.70 0.902 
miR-16 0.53 0.71 0.318 
miR-21 3.42 1.63 0.318 
miR-29b 9.83 7.36 0.620 
miR-125b 0.79 4.63 0.007 
miR-150 48.78 32.30 0.535 
miR-155 4.93 21.46 0.209 
miR-181a 0.26 0.47 0.805 
 
Table 19. Average fold change (av. FC) of target miRNAs in canine CLL whole 
blood samples with reference to normal whole blood, calculated from the data 
reported in Figure 24. KW, non-parametric Kruskal-Wallis test. 
 
Absolute quantification of the eight targets miRNA was then performed for each 
normal and neoplastic whole blood sample through interpolation of the obtained 
Ct values on the corresponding Reference Panel curve. In order to obtain a 
molecular parameter useful for immunophenotyping of CLL in dog, the gene ratio 
between absolute quantities of each miRNA pair was then calculated for each 
normal and CLL sample. Statistical analysis performed through non-parametric 
Kruskal-Wallis and Mann-Whitney tests showed significant difference of mean 
miR-150/miR-125b and miR-150/miR-155 gene ratios among samples of different 
leukemic status (Table 20). No statistical differences were found regarding gene 
ratios of the remaining miRNA pairs (data not shown). 
 
 
 
Table 20. Averages of the ratio miR-150/miR-125b and miR-150/miR-155 in 
samples with different stages of leukemia. p-value calculated using the 
nonparametric Kruskal-Wallis (KW) for all independent samples and the 
nonparametric Mann-Whitney (MW) for two independent samples. 
 
 miR-150/miR-125b miR-150/miR-155 
Normal samples (N) 5.3 4.6 
T-CLL samples (T) 318,7 60.1 
B-CLL samples (B) 43.2 17.3 
N vs B vs T (KW test, p-value) 0.004 0.002 
N vs T (MW test, p-value) 0.003 0.003 
N vs B (MW test, p-value) 0.048 0.018 
T vs B (MW test, p-value) 0.038 0.017 
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2. Cytologic glass smears samples 
As though for fresh/frozen samples, the molar ratio between miR-150 (more 
expressed in CLL T-type) and miR125b (more expressed in CLL B-type) was 
calculated also for cytologic glass smears CLL samples. The result is a clear 
distinction, also in cytologic glass smears, of molar ratio in T- CLL compared to B-
CLL (average ratio miR-150/miR-125b: 15788 in CLL T-type, and 145 in CLL B-
type) (Figure 29). 
 
 
Figure 29. Ratio miR-150/miR-125b in B-CLL and in T-CLL 
 
Non-parametric Mann-Withney test showed significant (p-value = 0.015) 
difference of mean miR-150/miR-125b gene ratio between T-CLL and B-CLL from 
cytologic glass smears samples.  
As a control of the actual specificity of the target amplification from CLL cytologic 
glass smears (in the absence of the possibility of properly quantify the total RNA 
subjected to reverse transcription, and then extract information about the RNA 
purity from the ratio of absorbance), the retrotranscription for miR-125b and 
miR-150 of a RNA sample from CLL cytologic glass smears, in the absence of the 
reverse transcriptase enzyme, was carried out. This control samples had not 
amplified, and so it was possible to exclude any nonspecific amplification due to 
genomic DNA contaminating. 
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C. Splenic lymphomas 
 
On the basis of the grading, the samples were divided into two categories: Low 
(L) tumor samples and Intermediate/High (I/H) tumor samples. Relative 
quantification of the four target miRNAs (miR-17-5p, miR-29b, miR-155 and miR-
181a) was performed for all splenic lymphoma samples, to analyze the 
expression levels of the above miRNAs in L and I/H splenic tumor samples with 
reference to a representative non-neoplastic spleen FFPE sample, code P15 
(Figure 30). The normalization was performed using miR-16, previously identified 
as the best endogenous control. 
 
 
 
Figure 30. Relative expression of miRNA target in FFPE samples of canine splenic 
lymphoma (y-axis), normalized to the miR-16 gene. X-axis, miRNA relative 
expression (fold changes) compared to non-neoplastic spleen. 
 
Analysis of relative expression (RE) data by non-parametric Kruskal-Wallis test 
showed a significant (p-value=0.0015, two-tailed test) overexpression of miR-17-
5p and a non-significant (p-value=0.22, two-tailed test) overexpression of miR-
181a in the I/H samples compared to the L samples. Furthermore, a significant 
(p-value= 0.0025, two-tailed test) downregulation of miR-155 was shown in I/H 
samples compared to the L samples. Finally, a stable expression of miR-29b in 
the two types of samples was detected (Figure 31). 
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Figure 31. Mean differential expression (fold changes, y-axis) of the four miRNAs 
in Low grade (L) samples compared to Intermediate (I)/High (H) grade samples.  
 
Absolute quantification of miR-17-5p and miR-155 was then performed for each 
sample through interpolation of the obtained Ct values on the corresponding 
Reference curve. In order to validate a new molecular parameter useful to 
support the grading of canine splenic lymphoma samples, the gene ratio 
between absolute quantities of miR-17-5p and miR-155 was then calculated for 
each lymphoma sample (Figure 32 and 33).  As we can see in figure 33, non-
neoplastic samples have the lowest ratio, followed by L samples, while the I/H 
samples have the highest ratio.  
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Ratio miR-17-5p/miR-155 
 
 
Figure 32. Ratio miR-17-5p/miR-155 obtained with absolute quantification in L 
and I/H splenic lymphomas samples. 
 
 
 
Figure 33. Mean miR-17-5p/miR-155 ratio in the non-neoplastic samples 
(controlli), the Low grade (L) samples and the Intermediate/High grade (I/H) 
samples. 
 
Non-parametric Mann-Withney test showed significant (p-value <0.001) 
difference of mean miR-17-5p/miR-155 gene ratio between L and I/H tumoral 
samples.  
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Finally, we performed a correlation between the ratio miR-17-5p/miR-155 and 
the mitotic index of the same tumoral samples (Table 21). This correlation was 
statistically significant (Pearson’s coefficient= 0,74). 
 
SAMPLE 
CODE 
GRADING IM RATIO 17-5p/155 
P 20 L 0,2 0,05 
P 21 L 0,4 0,09 
P 22 L 0,1 0,03 
P 23 L 0 0,03 
P 24 L 0,3 0,02 
P 25 L 0,7 0,04 
P 26 L 0,3 0,05 
P 27 L 0,3 0,12 
P 28 L 0,2 0,07 
P 29 L 0,2 0,05 
P 30 L 0,2 0,05 
P 31 L 0,4 0,08 
P 32 L 0,3 0,05 
P 33 L 0,8 0,05 
P 34 L 0,9 0,39 
P 35 L 0,9 0,18 
P 36 L 0,6 0,08 
P 37 L 0,4 0,03 
P 38 L 0,2 0,02 
P 39  L 1,7 0,07 
P 40 L 1,5 0,32 
P 41 I 3,3 0,15 
P 42 I 5,3 0,13 
P 43 I 7,9 0,84 
P 44 I 2,3 0,27 
P 45 I 3,6 0,65 
P 46 I/H 3,5 0,63 
P 47 H  11,4 1,02 
P 48 H  27,3 0,84 
 
Table 21. Correlation between the ratio miR-17-5p/miR-155 and the mitotic 
index (IM) of the tumoral samples. 
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1.5  DISCUSSION AND CONCLUSIONS 
 
The main results obtained in this thesis are: 
 
1. The detection of a panel of miRNAs expressed in canine hematological 
malignancies  
In the recent years, bioinformatic studies on dog genome predicted a large 
number of canine miRNAs, but expression studies are still lacking of almost all of 
them. In particular, accurate expression data regarding normal and neoplastic 
canine lymph node samples, canine splenic lymphoma samples and normal and 
leukemic whole blood samples were still missing at the time of this study. The 
present work provided basic information regarding the expression in these 
canine haematological malignancies of some miRNAs that are used for diagnosis 
and prognosis of human hematopoietic tumors. Furthermore, the analysis was 
extended from fresh-frozen samples to FFPE samples and cytologic glass smears 
in order to increase sample size and to compare three different tissue sources 
procured independently by one another.  
The MicroRNA TaqMan® Assays originally designed for human miRNAs let-7a, 
miR-16, miR-17-5p, miR-21, miR-26b, miR-29b, miR-125a, miR-150, miR-155, 
miR-181a and miR-223 were successful in the amplification of the corresponding 
canine mature miRNAs extracted from normal lymph node with high sensitivity 
and specificity over a four-logs diluition range,  from normal and leukemic whole 
blood samples, and from normal and neoplastic canine spleen samples. This 
result is a further confirmation of the outcome of previous studies where the 
MicroRNA TaqMan® Assays originally designed for several human miRNAs were 
validated for the corresponding canine miRNAs (Boggs et al., 2007; Boggs et al., 
2008). The accumulating evidence that the stem-loop TaqMan® assay is suitable 
for investigation of heterologous miRNA expression, provided perfect sequence 
identity with the concerning human mature miRNAs, opens interesting 
perspectives for comparative expression studies in organisms, especially 
mammals, for which dedicated commercial miRNA assays are not available.  
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2. The identification and validation of suitable ECs for miRNA analysis in canine 
lymph node and splenic lymphoma and in canine CLL 
A very important issue for qRT-PCR expression experiments is the variability 
associated with the various steps of the procedure: different amounts and 
quality of starting material, variable extraction and retrotranscription 
efficiencies, or differencies between tissues or cells in bulk transcriptional 
activities (Ginzinger D.G. 2002). The identification of proper internal 
normalization genes is considered a valid strategy to remove as much technical 
and biological variation as possible between samples except for that difference 
that is consequence of a disease status. To be considered as reliable controls for 
a defined sample type, the genes should exhibit stable expression across all 
samples under investigation as empirically evaluated within a panel of candidate 
normalizers from a representative number of the sample population if not the 
entire sample set. Moreover, having a gene that is stable in one tissue type or 
disease state does not necessarily mean that the same gene will be stable 
enough in a different tissue type or disease to represent suitable EC. Various 
softwares are now available to assess the degree of variation in candidate 
reference genes and identify the most stable one(s) for the tissue(s) of interest. 
Expression studies on a new molecular class like miRNAs with peculiar properties 
should include the careful selection of appropriate normalization gene(s) in the 
tissue of interest. It is well recognized that empirical validation of ECs is the 
optimal strategy for ensuring accurate quantification of miRNAs by RT-qPCR. 
Recently, the few studies that have been published regarding the selection of 
miRNA reference genes in human normal and cancerous samples using geNorm 
and NormFinder applets (Xi Y. et al, 2006; Davoren P.A. et al, 2008). To our 
knowledge, no information have been published until now on the selection of 
suitable ECs for qRT-PCR analysis of miRNAs in any canine tissues. The two 
pivotal studies in canine miRNA analysis employed the non-miRNA gene RNU6B 
as a single EC gene, without any validation of its expression stability (Boggs et al., 
2007; Boggs et al., 2008). 
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 lymph node lymphoma samples  
With the present work we provided experimental justification for the selection of 
three suitable ECs, such as let-7a, miR-16 and miR-26b, for miRNA analysis in 
canine lymphoma samples from three different archival sources using the two 
more widely used, complementary algorithms NormFinder and geNorm. The 
wide range in stability values observed in the non-neoplastic and neoplastic 
lymph node sample sets reflects the high variability detected in candidate ECs 
gene stability. This could be partly due to the different tissue source and 
preparation method of the analysed samples (fresh-frozen, FFPE and cytologic 
glass smears samples). On the other hand, the observed overall conservation in 
miRNA stability across the three kind of samples confirmed the possibility to 
effectively normalize RT-qPCR miRNA expression data using very different tissue 
preparation methods. This finding was consistent with recent studies suggesting 
miRNA stability is less affected by FFPE or cytologic glass smears sample 
preparation compared to mRNA, due to the smaller size (Xi Y. et al, 2006;  Peltier 
H.J. et al, 2008). Another relevant finding of the present study was that RNU6B 
turned out to be an unstably expressed candidate EC with both algorithms. This 
was consistent with a recent miRNA expression study performed in normal and 
cancerous human solid tissues, where RNU6B was among the least stable 
candidate ECs evaluated [27]. Taken together, these results strongly suggest that 
the default use of non-miRNA EC genes for miRNA expression studies should be 
carefully evaluated. 
 
 CLL samples 
In this study let-7a, miR-17-5p, miR-26b and miR-223 were ranked as the best 
candidate ECs for normal blood and CLL samples and again, RNU6B was the least 
stable, consistently with a study performed in normal and cancerous human solid 
tissues (Peltier H.J. et al, 2008). Taken together, these results strongly suggest 
that let-7a and miR-26b should always be included in the panel of candidate ECs 
when dealing with miRNA analysis in canine lymphoid  cancer, and the use of non 
miRNA EC genes, like RNU6B, should be carefully evaluated. 
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 splenic lymphoma samples  
In this work, to choose the best endogenous control (EC) gene were analyzed, 
using the complementary algorithms NormFinder and geNorm, the 6 miRNAs 
that result as better EC genes in lymph nodes lymphomas. The assayed miRNA 
genes showed a wide expression range in normal and neoplastic spleen samples. 
For both algorithms the most stable pair of miRNAs result to be let-7a and miR-
16 while the less stable is miR-21. It can be noted that some miRNAs (let-7a, miR-
16, miR-26b) show a greater stability of the level of expression in various 
samples, regardless of their type. 
 
3. Identification of differentially expressed miRNAs that can be used as 
potential new molecular targets for diagnosis and prognosis in canine 
leukemias and lymphomas  
The quantification of miRNAs expression in canine lymphoma and leukemia 
profiling and progression is an attractive perspective for veterinary clinical 
oncology and also, from a comparative point of view, since the similarities in 
both genetics and physiology and considerable overlap in treatment regimens, 
make dog an ideal model for many human diseases (Boggs R.M. et al, 2008; 
Paoloni M. and Khanna C. 2008). Moreover dogs share the same environment 
with human beings, being cronically and sequentially exposed to outdoor 
pollutants, yet they do not indulge in occupational activities or lifestyles which 
can confound interpretation of epidemiological studies (Marconato L. et al, 
2009). 
In humans, miRNA analysis has provided new possibilities in hematopoietic 
tumor classification, disease prognosis, early cancer detection and therapeutic 
decision making: for instance altered miRNA expression associated to ZAP-70 and 
IgH mutations reflect the survival or proliferation of neoplastic cells in B-CLL 
(Cummins J.M. and Velculescu V.E. 2006; Calin G.A. et al, 2005). Identification of 
valid targets in canine cancers with direct association with human tumor targets 
could provide significant rationale for the study of new diagnostic and 
therapeutic approaches both in dogs and humans. 
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 Ratio miR-181a/miR-17-5p as a marker for the immunophenotype in canine 
lymph node lymphomas 
Normalization of the expression data to the three most stable miRNA and to 
fresh-frozen and FFPE non-neoplastic lymph node both supported the 
statistically significant identification of miR-181a upregulation in canine T-cell 
lymphoma and miR-17-5p upregulation in canine B-cell lymphoma. When 
absolute quantification was performed, the molar ratio between miR-181a and 
miR-17-5p clearly distinguished between T-cell and B-cell lymphoma samples, 
but not between high grade and low grade tumors. The correlation of miR-181a 
and miR-17-5p transcript disregulation to tumor immunophenotype, and not to 
tumor grade, directs future research toward hypothetical correlations with 
particular pathogenetic features or cancer biomarkers at the phenotypic level in 
neoplastic lymph nodes. Noteworthly, in other canine hematopoietic tumors like 
chronic lymphocytic leukaemia (CLL) and splenic lymphoma the expression 
pattern of miR-17-5 and miR-181a is not related to the immunophenotype. The 
results of the present study are in accordance with what already performed in 
humans, that described very different miRNA expression patterns in a variety of 
hematopoietic tumors. In particular, the miR-181 family is generally considered 
to be oncogenic, with observed overexpression in breast, pancreas and prostate 
cancers (Calin G.A. and Croce C.M. 2006). Besides, miR-181a shows enhanced 
expression in leukaemia cell lines, and miR-181 family is upregulated in 
cytogenetically normal, molecular high risk acute myeloid leukaemia 
(Ramkissoon S.H. et al, 2005; Marcucci G. Et al, 2008). On the other hand, the 
miR-181 family has reported to be a tumor suppressor in human B-CLL and 
glioma (Pekarsky Y. Et al, 2006; Marton S. Et al, 2008;  Shi L. Et al, 2008). In 
particular, both miR-181b and miR-29b regulate the expression of the oncogene 
TCL1 and are downregulated in human aggressive B-CLL with high Tcl1 
expression (Pekarsky Y. Et al, 2006). The dual nature of miR-181 family 
(oncogenic/tumor suppressor) could depend on the specific cellular context 
(Fabbri M. et al, 2008). MiR-17-5p is encoded within the miR-17-92 polycistron, a 
cluster of seven miRNAs associated with a broad range of human tumors 
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including lymphoma (Lawrie C.H. et al, 2009). Due to its capability to interact 
with a number of known promoters of cellular proliferation, miR-17-5p is able to 
act as both an oncogene and a tumor suppressor in different cellular contexts, 
dependant on the expression of other transcriptional regulators (Cloonan N. Et 
al, 2008). 
There are a number of limitations in the present study that can be addressed in 
future work. One relates to the functional verification of the observed 
differences in miRNA levels affecting any specific outcomes in canine lymphoma, 
for example, modulation of target genes. Further studies should also be 
performed on purified neoplastic cells, since in clinical samples as lymph node 
aspirates the relative abundance of each cell subpopulations in neoplastic cases 
is usually different from normal range and this could affect a precise evaluation 
of miRNA expression status. However, even if the percentage of purity of 
neoplastic cells was difficult to evaluate in our samples, canine lymphomas are 
mostly characterized by a diffuse pattern in contrast with human medicine in 
which follicular or mixed pattern are often recognized. For this reason the 
population of neoplastic cells was considered almost pure in our samples as also 
shown in flow cytometry by the limited (less than 10%) percentage of residual 
non-neoplastic cells in most samples. Finally, large scale studies including long-
term follow-up monitoring after diagnosis are needed in order to obtain a proper 
evaluation of the potential utility of miR-181a and miR-17-5p as new molecular 
tools for the clinical monitoring of canine T- and B- cell lymphoma. 
 
 Ratio miR-150/miR-125b as a marker for the immunophenotype in canine 
CLL  
The utility of immunophenotyping to predict survival in CLL affected dogs has 
been recently reported (Comazzi S. et al., 2010) and analysis of relevant miRNAs 
should also allow to detect immunophenotype in archival samples problematic 
for standard immunophenotyping methods, like cytologic glass smears (Comazzi 
S. et al., 2010). In this study the least stable miRNAs in canine CLL were miR-29b, 
miR-125b, miR150 and miR-155. In particular, statistically significant 
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disregulation of miR-125b was shown depending on CLL immunophenotype. This 
findings could direct future research toward hypothetical correlations of miR-
125b with particular pathogenetic features or cancer biomarkers at the 
phenotypic level in canine B-CLL. Notewhorty, in humans miR-125b influences B-
cell differentiation in germinal center lymphocytes, and is upregulated in acute 
myeloid leukemia with t(2;11)(p21;q23) chromosomal traslocation and 
PML/RARA rearrangement (Bousquet M. et al., 2008; Malumbres R. et al., 2009; 
Zhang H. et al., 2009). In this work, miR-155 was upregulated in 4/7 B-CLL 
without reaching statistical significance. In humans, miR-155 is upregulated in 
diffuse large B-cell lymphoma and in CLL with differential expression linked to 
chromosome 17p deletion status (Lawrie C.H. 2007; Garzon R. and Croce C.M. 
2008;  Visone R. et al., 2009; Rossi S. et al., 2010). The analysis of purified blood 
cell subpopulations showed that miR-155 is basically a lymphoid miRNA with 
preferential expression in normal T-lymphocytes. This finding enforce the 
hypothesis that the observed increase expression in some B-CLL cases compared 
to T-CLL may not be an accidental result and could imply pathogenetic 
significance in canine B-CLL similarly to human CLL. Further analysis of larger 
sample sets could clarify if a real disregulation of miR-155 with any diagnostic 
and prognostic significance exists in (sub)population of canine B-CLL. The highest 
fold changes in canine CLL samples compared to normal blood were observed for 
miR-150, followed by miR-29b. MiR-150 is highly expressed in mature B- and T-
cells, controls B lymphopoiesis in mice and is overexpressed in human CLL (Fulci 
V. et al., 2007; Zhou B. et al., 2007). In canine blood cell subpopulations, miR-150 
is strongly expressed in lymphoid cells, with preferential expression in T cells 
compared to B-cells. This result could justify the hypothesis that the observed 
upregulation of miR-150 in T-CLL samples compared to B-CLL, without statistical 
significance, could be at least partly linked to a biased T vs B cellular ratio in the 
leukemic samples. The same could apply, on a lesser extent, to the observed 
miR-29b upregulation in T-CLL.  
The oncosuppressive miR-15a and miR-16, that target the antiapoptotic gene Bcl-
2, in humans are cotranscribed from the same cluster and are frequently 
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downregulated in CLL due to a deletion of the corresponding 13q14 genomic 
region (Calin G.A. et al., 2002; Calin G.A. et al., 2008). Deletion of the 
corresponding CFA 22q11.2 genomic region was reported in one case of canine 
CLL, but no extensive studies are available at this regard. The comparable 
deletion in canine CLL, in which T-cell phenotype is prevalent compared to 
human CLL, that are almost B-cell, suggested that miR-15a and miR-16-1 could be 
essential factors in the pathogenesis of the CLL regardless the immunophenotype 
(Breen M. and Modiano J.F. 2008). In this thesis work, it was not detected any 
significant variation of miR-15a and miR-16 in leukemic samples compared to 
normal blood. The analysis of canine blood cell subpopulations showed that miR-
15a, and on a lesser extent miR-16, are strongly expressed in PMNs compared to 
lymphoid cells. In CLL samples at least 80% of leukocytes were found to be 
lymphocytes but it can’t be excluded that even slighty differences in PMN 
abundance could have masked disregulation of these two miRNAs in leukemic 
cells. Finally, the expression pattern of miR-17-5 and miR-181a, that can 
distinguish between T-cell and B-cell lymphoma in lymph nodal lymphoma 
samples, in CLL is not related to the immunophenotype. 
The limitations of the present study, which can be  addressed in future work, are 
mainly relate to the functional verification of the observed differences in miRNA 
levels affecting any specific outcomes in canine CLL, for example, modulation of 
target genes. Moreover, definitive evaluation of leukemia-specific miRNA 
expression status should be performed on purified neoplastic cells, even if 
leukemic cells in CLL whole blood samples are usually overrepresented and they 
could be considered almost pure in our samples as also shown in flow cytometry 
by the limited percentage of residual non-neoplastic cells in most samples. 
Finally, large scale studies including long-term follow-up monitoring after 
diagnosis are needed to obtain a proper evaluation of the potential utility of miR-
125b, miR-150 and miR-155 as new molecular tools for the possible clinical 
monitoring of canine T- and B- CLL. 
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 Ratio miR-17-5p/miR-155 correlates with grading in canine splenic 
lymphoma 
To date there are no accurate and complete works about classification and 
grading in canine splenic lymphoma. We performed for the first time a 
comprehensive grading as follows. Splenic lymphoma samples were classified 
according with the WHO classification (Valli et al., 2011). Grade was determined 
according with the WHO classification (cell size, diagnosis and mitotic index). 
On the basis of the grading, we divided our samples into two categories: Low (L) 
tumor samples and Intermediate/High (I/H) tumor samples. Relative 
quantification of the four target miRNAs (miR-17-5p, miR-29b, miR-155 and miR-
181a) was used to analyze the expression levels of the miRNAs target in L and I/H 
splenic tumor samples. miR-17-5p is significantly overexpressed in I/H samples 
compared to L samples. miR-155  is significantly downregulated in I/H samples 
compared to L samples. miR-181a is upregulated in I/H samples compared to L 
samples but this up-regulation is not statistically significant. Finally, miR-29b 
doesn’t vary appreciably its expression profile in the two types of samples.  
Absolute quantification of miR-17-5p and miR-155 was then performed and the 
molar ratio miR-17-5p/miR-155 was obtained for each sample. The miR-17-
5p/miR-155 ratio clearly distinguished between low and high-grade tumors. 
Finally, marked correlation between the ratio miR-17-5p/miR-155 and the 
mitotic index of the same tumoral samples was evidenced. The molar ratio miR-
17-5p/miR-155, then, was validated as a new grading marker for L/H canine 
splenic lymphoma (since the two types of neoplasms have a different course and 
prognosis) and can be considered a useful research product of this thesis 
complementing the corrently used classification tools.  
 
4. Development and validation of methods for extraction and analysis of 
miRNAs from archive’s samples, such as formalin-fixed and paraffin-embedded 
(FFPE) tissue and cytologic glass smears 
This goal of the thesis has a significant importance because the techniques 
classically used for the determination of the phenotype and expression analysis 
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(flow cytometry, immunohistochemistry, RT-PCR and related techniques) often 
require fresh material in abundance, or biopsy. Therefore, it would be very useful 
to achieve the same result by analyzing miRNA from small amounts of archival 
material deposited on glass slides as cytological smears, or embedded in paraffin 
after formalin fixation. Furthermore, compared to human oncology, in veterinary 
medicine the availability of a sufficient number of fresh samples for validation 
studies of molecular markers is often very limiting. This is because of the smaller 
number of cases and  the difficulty to obtain material suitable for subsequent 
studies. Hence the importance of being able to use different types of archive’s 
samples that can be normally available for clinical types such as lymphoma and 
leukemia. In general, it is known that miRNAs are characterized by high chemical 
stability such as to remain virtually unaffected, even in case of procedures for 
handling and storage of the biological material that irreparably damage other 
types of nucleic acids (eg. messenger RNA). In addition, fixed and stained 
cytologic glass smears are frequently prepared in veterinary clinics and can be 
easily stored for many years after preparation. 
In lymph nodal lymphoma, yield and stability of some representative miRNAs 
from smears and FFPE samples was comparable to the standard sample type that 
is currently used for expression studies, i.e. the frozen sample. Furthermore, for 
both lymphoma and CLL, it was possible to establish the immunophenotype, i.e. 
an information of diagnostic and prognostic relevance, by monitoring the 
expression of certain miRNAs from cytologic glass smears and FFPE samples, with 
the same result compared to frozen samples. This validation procedure for the 
expression data obtained by the miRNA extracted from the smear is an 
undoubted progress in the technology of analysis of these important cancer 
markers. The possibility to use material from smears allows to implement the 
number of cases for retrospective studies of dog’s hematological malignancies 
(and even neoplasms of different origin). It also allows to manage and maintain, 
in a simple and affordable way for every veterinarian, the material on which to 
perform analysis for diagnosis and prognosis. 
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Chapter 2:  
 
High Resolution Melting Analysis 
(HRMA) of genic polymorphisms for 
diagnostic purposes 
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2.1  High Resolution Melting Analysis (HRMA) 
 
High Resolution Melting Analysis (HRM or HRMA) is a recently developed 
technique for fast, high-throughput post-PCR analysis of genetic mutations or 
variance in nucleic acid sequences. It enables researchers to rapidly detect and 
categorize genetic mutations (e.g. single nucleotide polymorphisms (SNPs)), 
identify new genetic variants without sequencing (gene scanning) or determine 
the genetic variation in a population (e.g. bacterial diversity) prior to sequencing. 
The first step of the HRM protocol is the amplification of the region of interest, 
using standard PCR techniques, in the presence of a specialized double-stranded 
DNA (dsDNA) binding dye. This specialized dye is highly fluorescent when bound 
to dsDNA and poorly fluorescent in the unbound state. This change allows to 
monitor the DNA amplification during PCR (as in quantitative PCR). After 
completion of the PCR step, the amplified target is gradually denatured by 
increasing the temperature in small increments, in order to produce a 
characteristic melting profile; this is termed melting analysis. The amplified 
target denatures gradually, releasing the dye, which results in a drop in 
fluorescence. When set up correctly, HRM is sensitive enough to allow the 
detection of a single base change between otherwise identical nucleotide 
sequences. HRM uses low-cost dyes and requires less optimization than similar 
systems based on TaqManR and fluorescence resonance energy transfer (FRET) 
probes. Compared to these methods HRM is a simpler and more cost-effective 
way to characterize multiple samples (High Resolution Melt Analysis, Application 
Guide, www.kapabiosystem.com).  
 
  
128 
 
Overview of the Melting Profile Principle 
Amplification product melting analysis is not a novel concept and exploits a 
fundamental property of DNA, called melting: the separation of the two strands 
of DNA with heat. PCR product melting analysis in combination with real-time 
PCR was first introduced with the LightCyclers and the  stability of DNA duplexes 
was monitored using SYBRR Green I dsDNA intercalating dye to detect primer-
dimers or other non-specific products (Wittwer et al., 1997). This procedure, 
called Low Resolution Melting has been performed for over a decade. A Low 
Resolution Melt curve is produced by increasing the temperature, typically in 0.5 
°C increments, thereby gradually denaturing an amplified DNA target. Since 
SYBRR Green I is only fluorescent when bound to dsDNA, fluorescence decreases 
as duplex DNA is denatured. The melting profile depends on the length, GC 
content, sequence and heterozygosity of the amplified target. The highest rate of 
fluorescence decrease is generally at the melting temperature of the DNA 
sample (Tm). The Tm is defined as the temperature at which 50% of the DNA 
sample is doublestranded and 50% is single-stranded. The Tm is typically higher 
for DNA fragments that are longer and/or have a high GC content. The 
fluorescence data from low resolution melting curves can easily be used to 
derive the Tm by plotting the derivative of fluorescence vs. temperature (-dF/dT 
against T) as shown in Figure 34 (High Resolution Melt Analysis, Application 
Guide, www.kapabiosystem.com). 
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Figure 34. Low Resolution Melt profile derivative plot (-dF/dT against T).  
The steepest slope is easily visualized as a melt peak. In this example the Tm of 
the amplicon is 77 °C (High Resolution Melt Analysis, Application Guide, 
www.kapabiosystem.com). 
 
The principle of HRM is the same as a Low Resolution Melt, except that the 
temperature difference between each fluorescence reading is reduced. During a 
Low Resolution Melt curve analysis, the temperature increases are typically in 
0.5 °C steps, but for HRM this is reduced to 0.008 - 0.2 °C increments, depending 
on the instrument. This allows a much more detailed analysis of the melting 
behavior. HRM sensitivity and reliability has been improved with the use of a 
variety of new dsDNA intercalating dyes and the availability of new instruments 
and more sophisticated analysis’ software. 
 The introduction of HRM has revived the use of DNA melting for a wide range of 
applications, including: SNP genotyping, mutation discovery (gene scanning), 
heterozygosity screening, DNA fingerprinting, haplotype blocks characterization, 
DNA methylation analysis, DNA mapping, species identification, viral/bacterial 
population diversity investigation, HLA compatibility typing, association study 
(case/control). 
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The Intercalating Dyes  
There are various types of dsDNA intercalating dyes, which have distinctly 
different properties. The requirements of the dyes used for HRM are different 
from dyes typically used for standard quantitative PCR (qPCR) assays. Factors 
critical in qPCR, such as the signal-to-noise ratio and amplification efficiency, are 
not essential requirements for HRM. Instead, the dye must provide detailed 
information on the melting behavior of an amplified target. Ideally the dye 
should not bind preferentially to pyrimidines or purines, change the Tm of the 
amplicon, or inhibit DNA amplification (High Resolution Melt Analysis, 
Application Guide, www.kapabiosystem.com). The three main classes of dsDNA 
binding dyes currently available are: 
 Non-saturating dyes. SYBR® Green I is the most common non-saturating 
dsDNA intercalating dye. It is generally unsuitable for most HRM 
applications. At high concentrations, SYBR® Green I stabilizes the duplex 
DNA and inhibits the DNA polymerase. To allow reliable amplification, 
low concentrations of SYBR® Green I must therefore be used. At lower 
concentrations, SYBR® Green I is able to redistribute from the melted 
regions of single-stranded DNA back to the regions of dsDNA, which 
results in poor base-difference discrimination, as detailed in Figure 35. To 
overcome this limitation, saturating dyes have been developed. 
 Saturating dyes. A new class of dsDNA intercalating dyes that do not 
inhibit DNA polymerases, or alter the Tm of the product, have recently 
been developed; these dyes can be added at higher concentrations than 
non-saturating dyes, ensuring more complete intercalation of the 
amplicon. The dye is not able to redistribute during melting because the 
dsDNA is saturated. More precise examination of the melting behavior is 
therefore possible, as indicated in Figure 35. Dyes such as SYTO9® and 
LCGreen® can be used at the saturating concentrations required for HRM. 
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 Release-on-demand dyes. The “release-on-demand” class of dyes, which 
include EvaGreen®, can be added at non-saturating concentrations. This 
is due to the novel method of fluorescence emission, where the 
fluorescent signal is quenched when the dye is free in solution. Upon 
binding to duplex DNA, the quenching factor is released and the dye 
emits high fluorescent signal. This allows non-saturating concentrations 
of the dye to be used, ensuring that there is no PCR inhibition, whilst the 
unique dye chemistry provides highly sensitive HRM analysis. 
 
 
Figure 35. Non-saturating, saturating and ‘release-on-demand’ dsDNA 
intercalating dyes (High Resolution Melt Analysis, Application Guide, 
www.kapabiosystem.com). Melting of the duplex as the temperature increases 
releases the intercalated dyes. At non-saturating concentrations the dye rapidly 
rebinds to regions that remain double stranded; consequently there is no drop in 
fluorescence. Saturating and ‘releaseon-demand’ dyes do not redistribute from 
the melted regions of single-stranded DNA back to dsDNA, resulting in a 
reduction of fluorescence. This difference gives dyes such as EvaGreenR the high 
sensitivity required for HRM analysis. 
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Instruments and software 
The power of any HRM analysis depends upon the sensitivity of the instrument 
and the nature of the PCR reagents used. Certain instruments have been 
designed specifically for HRM analysis. These can be summarized into two 
distinct classes: 
1. Block based instruments – Samples are placed in a block for cycling and a 
scanning head or stationary camera is used for detection. 
2. Rotary – Samples reside in a single chamber and spin past an optical detector. 
There are advantages and disadvantages with each class, and the user should 
choose the type of instrument that best suits their needs. As a general rule, for 
high sensitivity and reproducibility a rotarybased instrument should be used, 
whilst for high-throughput and ease-of-handling, block-type instruments are 
optimal. The HRM run can vary considerably between instruments; some take 
considerably longer than others. Every instrument should be calibrated regularly 
(as recommended by the manufacturer, typically every 6 months), kept in a clean 
area on a secure and stable benchtop, and checked daily for dust buildup around 
the optics. The computer hardware and software must be capable of handling 
the large quantities of data usually generated during a HRM experiment. Analysis 
of the data is relatively easy with the appropriate software. HRM specific 
software uses various algorithms to analyze the data and display the results in 
easily accessible formats to help discriminate between sequence variants. 
Additional software packages, designed for more detailed analysis, are available 
from the instrument manufacturer (High Resolution Melt Analysis, Application 
Guide, www.kapabiosystem.com). 
In this work of thesis we used the Eco™ Real-Time PCR System instrument, 
Illumina Inc. (9885 Towne Centre Drive San Diego, CA 92121 USA), a block based 
instrument whose technical characteristics are shown in Table 22. The main 
instrument specifications are: 
- Thermal system: silver block with Peltier-based system 
- Block format: 48-well block 
- Samples volumes: validated for 5-20 µl 
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- Average ramp rate: 5.5°C/sec 
- Temperature range: 40-100°C 
- Temperature uniformity : ± 0.1°C 
- Optical system: dual LED excitation ($%”-486 nm and 542-582 nm), four 
emission filters (505-545 nm, 562-596 nm, 604-644 nm, and 665-705 nm) and 
CCD camera 
- Calibrated dyes at shipment: SYBR Green, FAM, HEX, ROX, Cy5.  
- Passive reference dyes: use of ROX is supported, but optional 
- Data collection: data collection in all four filters for all wells regardless of 
plate setup; plate setup for data analysis can be altered after run completion. 
- Melt curve analysis supports continuous data acquisition in a single filter to 
provide increased data point collection and reduced run times 
- Real-Time PCR run time (40 cycles): less than 40 minutes 
  
Table 22. Specifications and Environmental Requirements of Eco™ Real-Time PCR 
System, Illumina. 
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HRM assay and reagent optimization  
Due to the highly sensitive nature of HRM analysis, proper assay design is critical. 
Factors such as genomic DNA (gDNA) quality, primer design, MgCl2 
concentration and carryover of inhibitors will all affect the melting behavior. 
Small differences in the initial setup can greatly affect the final results. Achieving 
specific amplification is critical to the success of an assay, since any non-specific 
amplification will greatly impair the melt analysis. Some important aspects to 
consider are (High Resolution Melt Analysis, Application Guide, 
www.kapabiosystem.com): 
 
1. DNA quality and quantity 
One of the major factors that can detract from the quality of results is the 
carryover of buffer from template DNA samples/preparations. Unsuitable DNA 
purification techniques can exacerbate this problem. Salt carryover can subtly 
change the melting behavior of the PCR product, and can result in low sensitivity, 
poor reproducibility and incorrect genotype calls. Buffer carryover from the 
template DNA will not only modify the Tm and melting behavior during the HRM, 
but can also encourage nonspecific amplification during the PCR. For optimum 
results the following is recommended: 
- ideally, all DNA samples to be analyzed (including genotype controls) should be 
extracted using the same DNA extraction method or kit. 
- some kits use high concentrations of salt for elution of DNA from columns. All 
template samples should be eluted with low salt buffers, ideally 10 mM Tris-HCl, 
pH 8.5. 
- the DNA sample should be as concentrated as possible after purification. This 
helps to reduce buffer variation between samples. 
- addition of a low volume of template DNA will reduce the carryover salt in the 
reaction; ideally the lowest volume of template that can be accurately added 
should be used (1 - 2 μl). 
- all samples should have a similar final concentration of DNA in each assay. Table 
23 details the recommended concentration of DNA for different types of 
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template. At low template concentrations, there is a greater chance of 
incorporating a mutation early in the PCR which will affect the melting behavior; 
high concentrations of DNA will result in high background fluorescence due to 
increased intercalation of dye into dsDNA.  
- positive control(s) for all genotypes should be included where possible, 
preferably at the same concentration as their corresponding test samples. 
Control DNA should also be eluted and/or diluted in the same buffer as the 
samples. 
 
Table 23. Recommended concentration of DNA for different types of template 
(High Resolution Melt Analysis, Application Guide, www.kapabiosystem.com) 
 
2. Primer design 
The design of primers for HRM analysis can be a challenge, due to the fact that 
small amplicon sizes are required for maximum sensitivity. The short amplicon 
lengths required for HRM restricts the number of potential primer locations; 
well-designed primer sets will improve the quality of the final result. Potential 
primer sets and full-length amplicons can then be tested for specificity using a 
BLAST search. Factors such as the position of the primer, the need for a GC 
region on the 3’ end, the presence of any secondary structures in the primers or 
target, and the predicted specificity of amplification should be carefully 
considered. Some commercial primer design software program such as Primer3 
or Primer3Plus may be helpful. This software assists in positioning primers such 
that specific regions are included or excluded, and amplicon size can be 
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specified. Figure 36 shows an example of the input page of the Primer 3 design 
package, when used to design primers for amplification of a human SNP. 
 
Figure 36. Design of primers for amplification of a human SNP using Primer 3 
(http://frodo.wi.mit.edu/primer3/). The target SNP is shown in square brackets 
(e.g. ... TTAA[A]TGTC...) and the product size is set to 50 – 300 (bp).  
Selection of the mispriming library ‘HUMAN’ helps reduce the chances of non-
specific amplification (High Resolution Melt Analysis, Application Guide, 
www.kapabiosystem.com). 
 
After the primers have been designed, the following factors must be checked: 
• The presence of a GC ‘clamp’ on the 3’ end. This is not essential, but usually 
improves amplification. 
• The specificity of the primers and the presence of known sequence variations. 
A BLAST search with both primer sets and the expected amplification product 
should be performed. If possible, sequence variations should also be checked.  
• The secondary structure of the primers and the expected amplification 
product. This should be examined using appropriate software for example, m-
fold, http://mfold.rna.albany.edu/?q=mfold/dna-folding-form,  or operon, 
http://www.operon.com/tools/oligo-analysis-tool.aspx. Amplification of any 
secondary structure within the product may result in unusual melting profiles. 
Primers may need to be redesigned to avoid areas of secondary structure. 
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• Amplicon size. This must be optimal for the specific application, typically 
between 100 - 300 bp. 
 
3. Primer concentration and purification  
The primer concentration should not greatly affect the overall HRM result. Minor 
changes are possible, but are likely to be amplicon specific. The recommended 
primer concentration to avoid nonspecific amplification is between 0.05 and 0.5 
μM final. We used the final concentration of 0.3 μM as recommended by the 
Evagreen’s manufacturers.    
 
4. Effect of MgCl2 on HRM analysis  
The concentration of MgCl2 in PCR is known to greatly affect amplification 
efficiency. For some targets, adjusting the MgCl2 concentration will result in 
reduced non-specific amplification, allowing clearer distinction of sequence 
variations; however, MgCl2 concentration has other, notable effects on HRM. It 
is important to realize that the optimum MgCl2 concentration for amplification 
efficiency is not necessarily optimal for HRM sensitivity. The effect of MgCl2 is 
shown in Figure 37. As the MgCl2 concentration is increased, the HRM difference 
graphs change distinctively. 
 
5. Amplicon length  
The optimal length of an amplicon is dependent upon the nature of the assay. 
The longer the amplicon, the more difficult it is to obtain clear discrimination 
between sequence variants. For single base changes or SNPs, and for single base 
insertions/deletions, it is recommended that amplicons be 50 – 300 bp. The 
clearest discrimination is usually seen with the shortest amplicons. As the 
amplicon size increases, a more complex melting pattern can develop, making it 
more difficult to distinguish between single nucleotide variants. The use of 
smaller amplicons may result in low fluorescence values, presumably due to 
reduced dye incorporation. However, this is usually not a problem unless the 
assay is run alongside a longer amplicon assay. When screening for unknown 
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sequence differences, longer amplicons (typically 200 – 500 bp) can be used. This 
is useful in gene scanning or determining the variation within a population (e.g. 
viral) and reduces the number of primer sets required. Furthermore, too short 
amplicons are difficult to sequence. 
 
6. Effect of PCR enhancers on HRM analysis 
PCR enhancers are commonly added to end-point PCR in order to help reduce 
non-specific amplification, reduce the number of required cycles and increase 
yield. These enhancers function by assisting the melting and annealing of primers 
and templates, and can affect HRM performance. For GC-rich amplicons, the 
addition of DMSO appears not to affect the HRM significantly, and is 
recommended if amplification is difficult. Overall, the addition of PCR enhancers 
is not recommended as they usually detract from HRM performance. 
 
Figure 37. Effect of increasing MgCl2 on melting behavior. Three Difference 
Graphs are overlayed to demonstrate the dependence of amplicon melting on 
MgCl2 concentration. The effect of MgCl2 is most pronounced in the 
heterozygote samples (blue), a result of the magnesium stabilizing the annealing 
of mispairs. The MgCl2 concentrations are 1.5 mM, 2.5 mM and 3.5 mM final. 
G/G = green, G/A = blue, and A/A = red (High Resolution Melt Analysis, 
Application Guide, www.kapabiosystem.com). 
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Analysis of results 
 With the correct software, data analysis is typically straightforward, allowing 
multiple samples to be analyzed simultaneously. It is important to know what to 
look for when interrogating results; unforeseen errors made during setup can be 
identified at this point. Low resolution melt plots are often viewed as a derivative 
plot (−dF/dT against T); however, HRM raw melting curves must be analyzed 
differently. This section concerns how to analyze the HRM results; a 124 bp 
product covering a Type IV SNP (rs641805) is used as an example (High 
Resolution Melt Analysis, Application Guide, www.kapabiosystem.com). 
Amplification plots. Reproducibility of amplification is more important for HRM 
analysis than the efficiency of amplification (as compared to qPCR). For example, 
HRM analysis can still be performed if the product amplifies later than expected 
(i.e. due to limitations in primer design), provided that all the samples are 
consistent, the no template control (NTC) does not amplify and the product is 
specific. 
Raw data melt curve. The data collected during the HRM analysis has a range of 
initial (pre-melt) fluorescence readings. This variance makes it difficult to 
properly analyze results, even though different genotype groups may be visible. 
Figure 38A illustrates how the selection of pre-and post-melt regions is used to 
align data. Pre- and post-melt regions must be selected for each primer set, by 
positioning the parallel double-bars as shown. It is important to adjust these bars 
so that the melt region is not selected. If the preor post-melt regions are not 
clearly defined, it is possible to repeat the HRM run only (without repeating the 
amplification step), and adjust the temperature range as required. 
Normalization data. If the data is normalized correctly, it will appear as shown in 
Figure 38B. This is termed ‘Normalization Data’. Here the fluorescence variance 
seen in Figure 38A has been eliminated, and only the temperature range 
between the outer bars of the pre- and post-melt regions is shown. The 
genotypes are now more distinct, but the two homozygote samples (in red and 
blue) are still difficult to distinguish. 
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Difference graph. Some HRM software applications allow calculation of the 
difference plot. This is achieved by subtracting the normalized fluorescence data 
of a user-defined genotype from that of each of the other samples in the HRM 
analysis. In Figure 38C, the A/A genotype has been selected as a baseline (any 
genotype can be selected, but usually one of the homozygotes is used). The 
position of each sample relative to the baseline is plotted against the 
temperature. This form of HRM analysis is an aid for visualizing the 
Normalization Data. Automatic calling of genotypes of sequence variants can 
usually be performed with the software; sometimes confidence ratings are given. 
However, checking the difference to confirm the genotype is recommended. 
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Figure 38. Analysis of HRM data from a type 4 SNP (A/T). Different genotypes are 
highlighted in different colors. A/A = red, A/T = green, and T/T = blue.  
A. Raw data showing the pre-melt, melt and post-melt regions. Notice the 
fluorescence variance and the positioning of the pre- and post-melt identification 
bars. B. Normalization Data derived from the raw data plots in A. Positioning of 
the pre-melt, and post-melt bars provides a more detailed view of the melt 
region. C. Difference Graph derived from the Normalization Data (High 
Resolution Melt Analysis, Application Guide, www.kapabiosystem.com). 
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2.2 HRMA of gyrA Ser84Leu mutation conferring 
resistance to fluoroquinolones in Staphylococcus 
pseudintermedius isolates from canine clinical 
samples 
 
2.2.1 Introduction 
 
Staphylococci: General information and Taxonomy 
The genus Staphylococcus belongs to the family of Micrococcaceae, and is the 
only of its kind that includes pathogens with medical and veterinary concern. It is 
Gram-positive, spherical in shape (cocci), a diameter of about 0.5-1,5 μm aerobic 
and facultative anaerobic, motionless, catalase-positive and oxidase-negative 
(Poli G. And Cocilovo A., 2005). The taxonomic classification of staphylococci has 
changed a lot over the years thanks to improvements in microbiological and 
enzymatic techniques but especially in molecular methods. We can then identify 
the different species on the basis of different criteria: 
 Phenotype (colony morphology, cell wall composition, molecular 
structure and activity of various enzymes, nutritional and oxygen 
requirements, composition of cellular fatty acids, products of the 
fermentation of carbohydrates, products of glucose metabolism, electron 
transport system, sensitivity to bacteriophages, resistance to specific 
antibiotics such as novobiocin)  
  Genotype (chromosome size, composition and homology of the DNA, 
ribotype) 
Staphylococci are now classified into forty different species on the basis of 
genotype, habitat, and the pathological process caused (Martino P.A. et al., 
2005). A good criterion to classify staphylococci is the production of coagulase. In 
fact the various species can be divided, according to their ability to coagulate 
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rabbit plasma, in coagulase-positive and coagulase-negative. Coagulase is an 
enzyme considered by many authors as a factor closely related to pathogenicity, 
as it promotes the spread and survival of the bacteria in the body. It is present in 
many staphylococci and its main action is to coagulate the plasma resulting in 
activation of fibrinogen and its subsequent transformation into fibrin. The 
formed clot protects the bacteria from the immune system that fails to reach, for 
which bacteria who develop this enzyme are more resistant to the immune 
defenses of the host (Cox H.U. 2006). The coagulase is also defined free 
coagulase to distinguish it from clumping factor, an enzyme that bound to the 
bacterial cells and which has the same function. 
Staphylococci are ubiquitous bacteria widely distributed in the environment. 
They can be found in water, air, soil, dust, and a wide variety of inanimate 
objects (Martino P.A. et al., 2005). They can also be considered the most 
common saprophytic of humans and animals skin. As well as on the skin, 
Staphylococci can be isolated from mucous membranes of various apparatuses, 
including the respiratory, gastrointestinal and urogenital tracts. Many people can 
be healthy carriers which are then considered a likely source of infection for 
themselves and for others (Cox H.U. 2006). Moreover, given their strong 
environmental resistance, they can survive the toughest conditions, persisting 
for months outdoors (protected from sunlight), and in the laboratory after 
transplantation in fresh medium or freezing. They are also relatively resistant to 
heat (about thirty minutes at 60 °C), drying and also to the common disinfectants 
if properly protected from organic material (pus, mucus, milk, serum, debris) 
(Martino P.A. et al., 2005; Cox H.U. 2006). In addition to being very resistant 
these bacteria have developed several factors which allow the colonization and 
infection of host tissues. Each species of staphylococcus can therefore be 
considered as potentially pathogenic, although each shows a wide and varied 
spectrum of virulence as well as host and seat preference. These bacteria then 
act as opportunistic pathogens (except Staphylococcus aureus a real pathogen). 
They in fact, after a decrease in immune function, invade the epithelium. This 
colonization can be stimulated by various conditions such as: mechanical insults 
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of the skin (eg., wounds, abrasions, etc.), other infections / infestations (eg., 
demodicosis, dermatophytosis, pyoderma, etc.) or even particular changes (eg., 
seborrhea, hypothyroidism, Cushing's disease and Addison’s disease). In 
addition, subjects persistently immunosuppressed are more affected and 
develop more violent and persistent clinical forms. When bacteria invade the 
skin may cause local infections, from light (acne, impetigo) to severe 
(furunculosis) or, as a result of colonization of the bloodstream with bacteremia, 
develop purulent processes of various kinds (especially abscesses) in different 
locations: liver, kidneys, lungs, joints. In dogs they can be attributed to specific 
diseases such as otitis, pyoderma and metritis (Cox H.U. 2006). 
 
Staphylococcus pseudintermedius 
Staphylococcus pseudintermedius is a bacterium that is commonly found on the 
skin or in the nose or intestinal tract of 50% of more of healthy dogs, and a 
smaller percentage of healthy cats. Typically it causes no problems at all, but it is 
an opportunistic pathogen. This bacterium can infect almost any tissue, but skin 
and soft tissue infections are more common, particularly when the skin has been 
damaged by something else (e.g. allergies, scratching, chronic wetness, wounds, 
surgery). Ear infections are also very commonly caused by S. pseudintermedius. 
Infections of other body sites and organs are much less common, but can be very 
severe. Staphylococcus pseudintermedius can also be found in the nose of up to 
4% of healthy pet owners. MRSP stands for methicillin-resistant S. 
pseudintermedius, which is highly resistant to many antibiotics, including most of 
the drugs that are commonly used to treat bacterial infections in dogs and cats. 
Non-MRSP strains of S. pseudintermedius are methicillin-susceptible (MSSP). 
People and animals that carry MRSP without any signs of infection at all are said 
to be colonized. When infection with S. pseudintermedius (either MRSP or MSSP) 
occurs, this causes signs of inflammation (e.g. heat, pain, swelling, discharge, 
fever) (www.wormsandgermsblog.com).  
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Staphylococci: classical methods of isolation and identification 
Staphylococci easily grow on common growth media, without the need of 
particular substances or pH indicators; they form colonies with color from gray to 
yellow to orange (Figure 39) (Cox H.U. 2006). 
 
Figure 39. Colonies of Staphylococcus aureus in a growth medium common Agar 
(ASM Microbel library.org®) 
 
However, due to the great resistance of these bacteria, specific selective media 
to disadvantage the growth of contaminants and promote the purity of the 
colony are often used. In particular, since staphylococci are halophilic, they are 
able to withstand high concentrations of sodium chloride (up to 10%), and they 
can grow on culture medium (MSA-Mannitol Salt Agar-) that contains a large 
percentage of this salt (approximately 7.5%). Being staphylococci mesophilic 
bacteria, their growth temperature is between 18 and 40 ° C with an optimum at 
37 ° C, and also being aerobic-anaerobic facultative, they can grow both under 
normal oxygen conditions and in modified atmosphere (10% of carbon dioxide) 
(Martino P.A. et al., 2005; Cox H.U. 2006). 
With regard to the macroscopic appearance of the colonies, in liquid media a 
uniform turbidity is obtained, while in solid media, after incubation for 24 hours 
at 37 ° C, are present as large colonies roundish of about 2-3 mm in diameter, 
opaque, smooth and convex; encapsulated strains can form colonies of mucoid 
appearance (Martino P.A. et al., 2005). The staining of these colonies may vary as 
146 
 
already mentioned from gray to yellowish, to orange depending on the 
pigmentation of the cell membrane, being the colour not associated with 
pathogenicity. Isolation of the bacterium on soil Agar-blood can be useful for 
identification, because some staphylococci, according also to the type of red 
blood cells used for the ground, show a well clear  halo of hemolysis (Figure 40). 
 
Figure 40. Clear area of hemolysis around the colonies of S. aureus on blood-Agar 
(ASM Microbel library.org®) 
 
After isolation of blood-Agar colonies, identification by various cultural and 
biochemical methods can be done: 
 Examination of the morphology. The morphological characteristics (size, 
shape, color, odor, presence of hemolysis, etc.) of the colonies already 
provide some important information useful for a first partial 
identification. Staphylococci tend to aggregate in irregular clusters, but 
occasionally can be found arranged individually, in pairs (diplococci) or in 
groups of four (tetrads) (Figure 41) (Martino P.A. et al., 2005). 
 
Figure 41. Staphylococci in electron microscopy arranged in small clusters 
of several subjects. (ASM Microbel library.org®) 
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 Bacterioscopic examination of stained preparations. This test provides 
further information on the morphological characteristics of the isolated 
bacteria and also on how they react to certain differentials colors (eg, 
Gram, Ziehl-Neelsen). In the case of staphylococci the examination with 
an optical microscope is preceded by Gram stain, which, for Gram-
positive bacteria, allows detection of blue-violet microorganisms (Figure 
42). 
 
Figure 42. Staphylococci with Gram stain 
 
 Proof of the catalase. This test is used to highlight the presence or 
absence of this enzyme and to easily distinguish staphylococci (catalase-
positive) from streptococci (catalase negative). There are several 
commercial kits but more simply is to dissolve a colony in one drop of 
water 3% hydrogen peroxide placed on a glass slide. In case of positivity 
we note the presence of bubbles due to the formation of free oxygen, 
within a few seconds (Poli G. and Cocilovo A., 2005). 
 Proof of the oxidase. For this test a colony of the bacteria in question is 
dissolved in a drop of saline placed on a glass slide; the suspension is 
subsequently immersed in a disk of paper, impregnated with a solution of 
tetramethyl-p-phenylenediamine dihydrochloride (the disks are 
commercially available). In case of positive reaction, within 10-20 seconds 
is observed the appearance of an intense purple color. There are also 
commercial kits, which allow the simultaneous execution, in vitro, of the 
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catalase and oxidase tests. Obviously, in the presence of colonies of 
staphylococci, this test must be negative (Figure 43) (Poli G. and Cocilovo 
A., 2005).  
 
Figure 43. Outcome of the catalase test: on the right a positive sample, on the 
left a negative sample (www.mesacc.edu) 
 
 Proof of coagulase. For the determination of the coagulase presence 
several techniquescan be used: the test in a single tube, for the detection 
of free and bound coagulase, performed on colonies from selective and 
differential media, for example MSA. A sub-culture of the strain in 
question is prepared in a generic liquid medium, like BHI Broth (Brain-
Hearth Infusion Broth), for the cultivation and maintenance of a wide 
variety of microorganisms. After approximately 6-12 hours of incubation, 
when appreciates microbial growth, the test is carried out, taking 0.05 ml 
of culture broth and adding 0.5 ml of rabbit plasma. The anticoagulant 
used in commercial preparations of rabbit plasma can be lyophilized 
citrate or EDTA, we must remember that the citrate can be metabolized, 
with consequent risk of false positives caused by nonspecific plasma 
coagulation, when free calcium ions previously chelates. After incubation 
at 37 ° C, the observation is carried out at 1, 2, 4, 8 and 24 hours. If the 
bacteria is coagulase-positive, coagulation is observed within 24 hours. 
Beyond this time, there may be a spontaneous fibrinolysis, with the risk 
of false negatives. The test slide (for the detection of bound coagulase or 
clumping factor) is presumptive and the negative result must be 
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confirmed by the test tube. A drop of rabbit plasma is deposited on a 
glass slide and a colony is dissolved; the occurrence, within 5 seconds, of 
microscopic flakes is a sign of positivity (Poli G. and Cocilovo A., 2005).  
 Biochemical tests and API-System®. The microorganisms differ from each 
other for the differential ability to use certain substrates or to produce 
certain substances. It is possible to identify and classify them according to 
the final products or intermediates of various biochemical reactions of 
which they are capable. API-System® (bioMérieux) is a miniaturized and 
standardized system for the identification of microorganisms by 
biochemical tests. It is used when the first phase of identification has 
narrowed down the possibilities to a few genera or it only remains to 
identify the species. It consists of a gallery with 20 wells, each containing 
a different soil and appropriate chromogenic indicators; therefore allows 
the simultaneous execution of 20 biochemical tests. Some reactions are 
read immediately, according to the spontaneous color changes of the 
substrates used in the individual well; in other cases, only after the 
addition of specific reagents. Is thus possible to detect simultaneously the 
ability of the microorganism to metabolize various sugars to produce 
acids or gas, to liquefy the gelatine, to use citrate, to reduce nitrate, etc. 
There is a version of this identification system, called API-Staph® 
specifically targeted to the genera Staphylococcus and Micrococcus. 
 
Figure 44. Example of a biochemical test API-System ® 
(www.jlindquist.net) 
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Antibiotic resistance 
Antibiotic resistance is a phenomenon by which a bacterium is immune to the 
effects of one or more antimicrobial drugs. This phenomenon can be considered 
as an evolutionary and adaptive biological process that bacteria carry out to 
escape the selection (Levin B.R. et al., 2000). The selection pressures reach 
maximum levels when bacteria are exposed to sub-optimal doses of the drug. 
The resistance may be natural or acquired: the first is determined by the innate 
characteristics of the microorganism, for example a Gram-negative bacterium is 
naturally resistant, thanks to the porosity characteristics of their membrane, to 
glycopeptide antibiotics such as vancomycin. The second appears when occurring 
genetic modifications that allow to changed subjects the survival and 
transmission of the modifications (Levin B.R. et al., 2000).  
The changes are divided into chromosomal and plasmidic. The chromosomal 
mutations, also known as endogenous, occur primarily at the level of nuclear 
DNA by spontaneous phenomena of substitution, insertion and deletion of base 
pairs (point mutations) or more pairs of bases repeated (mutations for repeated 
sequences) within the colony to each replication cycle with a frequency of 1:103 
- 1:109 for cell division. This type of mutation occurs more slowly and rarely 
compared to plasmid-mediated mutations but usually gives to the changed 
population a permanent resistance to antimicrobial agents. Obviously, being this 
mutation spontaneous and random, it does not mean that, once completed, a 
mutation affects exactly the portion of DNA that contains sequences related to 
molecules or structures that are antibiotic targets. The genic modifications 
mediated by plasmids, however, are caused by fragments of double-stranded 
circular cytoplasmic DNA. This type of filament is common in bacteria and 
promotes the exchange of genetic information between phylogenetically related 
micro-organisms. The plasmids are small DNA fragments of different size: the 
smaller ones (approximately 10kb) are generally present in large number in the 
cytoplasm (10-20); those more bulky (100-150kb) are usually present in single or 
double copy. The plasmids replicate with the aim of specific proteins and are 
divided among the daughter cells during binary fission. They are able to transmit 
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genetic information that are used to develop new features dangerous for the 
host: virulence factors, the production of new proteins or enzymes for the 
survival, detoxification, antibiotic-resistance (Smillie C. et al., 2010).  
 
There are mainly three other mechanisms that bacteria can use for the exchange 
of genetic material, with both chromosomal and plasmid nature: 
- Conjugation: it is a process in which takes place the direct exchange of 
genetic material from a donor cell to a recipient through the formation of a 
particular structure called pilo sexual, which allows the horizontal passage of 
chromosomal DNA or, more frequently, plasmid. 
- Transformation: during this process the genes are acquired by the recipient 
cell in the form of naked extracellular DNA. Basic assumption is the death of 
another microorganism which, after analysis of their structures, releases the 
DNA into the surrounding environment. The recipient cell adsorbs the free 
DNA through the cell wall and, as a result of recombination with a 
homologous segment, it incorporates into its DNA acquiring new characters. 
- Transduction: in this process, the gene transfer is mediated by 
bacteriophages (or phages), i.e. from viruses that infect bacteria. A phage  
infects a bacterium, basically, and takes control of the genetic processes of 
the bacteria to replicate. During this process, inadvertently, bacterial DNA 
(genomic or plasmid) can replace and/or become incorporated into the newly 
formed phage DNA, a phenomenon called transduction (only the phages 
characterized by dsDNA can be transducing). After bacterial death, which 
follows the lysis, the new phages are released and go on to infect other 
bacteria, carrying to them genetic material from previously infected bacteria 
(an example of transfer by transduction regards the plasmid carrying the 
gene for β-lactamase in S. aureus). 
 
In any cases the appearance of antibiotic resistance is linked to three main 
categories of mechanisms: alteration of the binding site between the target 
protein and antibiotic; production of enzymes that destroy the drug; decrease in 
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the concentration of the antibiotic in the cytoplasm (Walsh C. 2000). The 
alteration of the binding site occurs via genetic mutations both chromosomal 
ande plasmid-mediated, which alter the affinity for the drug by changing the 
nucleotide sequence of a certain protein. In this way even if the antibiotic 
reaches the cytoplasm, it fails to exert its bacteriostatic action or bactericidal 
activity. Examples of this mechanism are provided by PBPs (Penicillin Binding 
Proteins), that are target enzymes of β-lactam antibiotics. The production of 
enzymes that break down the drug is definitely one of the most studied and 
known mechanisms of antimicrobial resistance. The best known case is 
undoubtedly that of beta-lactamase enzymes produced by many microorganisms 
that destroy the antibiotic belonging to the group of β-lactam (penicillins and 
cephalosporins). These enzymes are encoded both by plasmids, such as the R 
plasmid which also contains the TEM-lactamase, and by chromosomal sequences 
such as AmpC, characteristic of many Gram-negative bacteria (Nikaido H. 2009). 
The beta-lactamases cause hydrolysis and subsequent destruction of antibiotics 
and have become increasingly refined and perfected by the great use of β-lactam 
antibiotics. These antibiotics are increasingly improved over the years to escape 
the enzymes produced by bacteria, but inexorably microorganisms develop 
resistance by producing and adapting their defense mechanisms. The production 
of pumps for the cytoplasmic efflux is a very refined mechanism of resistance 
whose transmission to other bacteria is quite difficult because of the complexity 
of the genes that encode them. Antibiotics enter into the cell through pores of 
the membrane, but can be extruded from the cytoplasm due to  the presence of 
these pumps which are nothing more than transmembrane proteins that actively 
expel the drug. This system, developed by both Gram-positive and Gram-
negative bacteria, has been particularly studied in E. coli, but also in 
staphylococci, especially S. aureus, and is responsible for resistance to multiple 
antibiotics, especially the fluoroquinolones (NorA), tetracyclines, macrolides and 
β-lactam antibiotics (Nikaido H. 2009). 
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Evaluation of antibiotic susceptibility 
All chemoantibiotics compounds are effective only towards certain bacterial 
species while have no effect on others species. Furthermore, the emergence of 
resistance makes immune some bacterial strains that commonly fall in the 
spectrum of action of the antimicrobial. For this reason when infection by a 
pathogenic micro-organism is suspected, before embarking on empirical therapy, 
at least one antibiogram should be performed since it gives not only information 
about the involved strain, but also general information about the antibiotic 
resistance. The antibiogram, performed according to the Kirby-Bauer technique, 
is certainly one of the most used techniques in clinical practice and is a 
standardized method regarding the amount of bacteria seeded (using a bacterial 
inoculum equal to Section 0.5 of the McFarland scale, i.e. to 5 x 108 CFU / ml) 
and the type of media used (Mueller-Hinton, devoid of para-amino acid -benzoic 
acid). The inoculums are seeded for inclusion in agar or slithered on the surface 
by swab. Then a number of cellulose diskettes impregnated with known amounts 
of antibacterial drugs are deposited on the surface of theplates. Since the 
chemoantibiotics spread by disks into the surrounding media and, if effective, 
inhibit bacterial replication in a much larger area, after the incubation period of 
the plates (typically 37 ° C for 24 hours) it is thus observed the appearance of 
zones of inhibition of growth around the diskette antibiotic, whose diameter is 
proportional to the antibacterial activity of the antibiotic content (the greater is 
the halo, the greater is the antibiotic activity). The absence of a halo is, instead, a 
sign of ineffectiveness of the drug. With this technique it is therefore possible to 
classify the bacteria as susceptible, intermediate or resistant to several 
antibiotics tested (Figure 45). 
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Figure 45. Antibiogram performed according to the Kirby-Bauer technique 
(www.wikipedia.org) 
 
 
MIC (Minimum Inhibiting Concentration), is the minimum concentration of 
antibiotic capable of inhibiting bacterial growth. The most common technique of 
execution involves dilution in liquid media (or broth): the technique can be 
performed in a test tube (macromethod) or in 96-well plates (micromethod). It 
starts from a bacterial inoculum with a concentration equal to 100 CFU/ml, 
which is mixed at scalar concentrations of antibiotic. The technique performed in 
a test tube provides the twofold serial dilution, starting from 128 micrograms/ml 
of the antibiotic, in volumes of 1 ml. The micromethod instead is performed by 
mixing 100 µl of BHI for growth of the bacterium, 100 µl of bacterial suspension 
and, in the first tube, 100 µl of stock solution of antibiotic (equal to 1 mg/ml, 
obtained by dilution of the powder of the principles active in distilled water and 
filtration), or two-fold serial dilutions of the same antibiotic solution for the 
remaining tubes. Following incubation at 37 ° C for 18-24-48 hours, the MIC is 
obtained as the highest dilution, i.e. the smallest amount of antibiotic, capable of 
visibly inhibiting bacterial growth. 
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Fluoroquinolones: Historical background and generality 
Quinolones are a class of chemotherapy (i.e. generated by chemical synthesis) 
antibiotics discovered at the end of the Fifties of the last century, whose 
progenitor may be considered the nalidixic acid. Given their spectrum of activity, 
i.e. Gram-negative aerobes and anaerobes, their rapid renal excretion and the 
achievement of high urinary concentrations, they were usually used to treat 
infections of the genito-urinary tract. However, given their narrow spectrum of 
activity and the emergence of significant resistance phenomena, they have 
slowly fallen into disuse. In more recent years, starting from quinolones, novel 
compounds called fluoroquinolones have been synthesized that, due to the 
presence in their structure of a fluorine atom, have a broader spectrum of action 
and smaller phenomena of resistance. These drugs have a good intestinal 
absorption, good tissue distribution and prolonged half-life of elimination (Carli 
et al., 2009). Lately there is a growing series of antibiotic resistance even against 
this class. Currently, in Italy, some fluoroquinolones are registered for use in 
veterinary medicine (i.e. enrofloxacin, danafloxacin, difloxacin, flumequine, 
marbofloxacin and norfloxacin). 
 
Fluoroquinolones: Chemistry and mechanism of action 
The fluoroquinolones are synthesized starting from the same chinolonic 
structure, from time to time amended with different chemical substituents (such 
as fluorine) and side chains. These modifications, as a rule, do not change the 
spectrum of action of fluoroquinolones but instead affect the kinetic 
characteristics, in particular the bioavailability, the ability of tissue distribution 
and excretion rhythms (Carli et al., 2009). The mechanism of action of these 
chemotherapeutic type is bactericidal, very rapid and dose-dependent. It is 
carried out at the level of two enzymes of the class of topoisomerase: DNA 
gyrase and topoisomerase IV. The DNA gyrase, an enzyme composed of two 
GyrA subunit and two GyrB subunits transcribed respectively by gyrA and gyrB 
genes, is crucial as it is the only enzyme able to rotate the DNA windings 
negative; this ability is important during the step of replication and synthesis of 
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the DNA (Drlica K. and Malik M. 2003). The topoisomerase IV is an isomerase 
type II and is the main enzyme responsible to the separation of DNA strands at 
the end of the replication process. It also consists of two subunits ParC (calls grlA 
in Staphylococcus aureus) and two subunits ParE. The main targets of 
fluoroquinolones are GyrA and parC; the bond with these molecules hampers the 
separation and rejoining of DNA strands and this results in inhibition of DNA 
synthesis, poor reparative ability of the genetic material and cell death (Drlica K. 
and Malik M. 2003). More precisely, the link between drug, enzyme and open 
DNA, called ternary complex, prevents the progression of replication and 
transcription, and causes fragmentation of the chromosome which will lead to 
cell lysis. The high selective toxicity that these compounds have towards 
prokaryotic cells is justified by the fact that the eukaryote DNA-gyrase is 
inhibited at much higher concentrations than those of the bacterial cell (about 
100-1000 micrograms/ml against 0.1-10 micrograms/ml) (Carli et al., 2009). For 
Gram-negative the primary target of fluoroquinolones is the DNA gyrase enzyme, 
while for the Gram-positive is the topoisomerase IV enzyme. 
 
Fluoroquinolones: Resistance 
The resistance against these drugs is predominantly chromosome-linked, then 
stable, and its appearance is directly related to the concentrations of the 
chemotherapeutic in the site of infection. A repeated exposure to sublethal 
concentrations of fluoroquinolones can then produce a dangerous and stable 
resistance; which usually, being of cross-type, makes ineffective the other drugs 
of the same class (Carli et al., 2009). The onset of this phenomenon assumes the 
appearance of defensive mechanisms against the quinolone by the bacterial cell, 
which can implement two main strategies: the formation of transmembrane 
pumps that actively expel the drug outside of the cytoplasm, and the 
modification of target enzymes of the antibiotic. The first resistance mechanism 
is provided by several efflux systems associated to genes with chromosomal and 
extra-chromosomal localization coding for transmembrane proteins that are able 
to reduce the cytoplasmic concentration of the drug (Table 24). 
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Antibiotic drug Working 
Resistance 
genes 
Genes 
location 
Bacteria 
Tetracyclines Outflow tet P, T, C 
Gram-positive 
Gram-negative 
Macrolides Outflow mefA P, T, C 
Salmonella spp 
E.coli 
Chloramphenicol, 
Fluoroquinolones 
Outflow blt, norA C 
Bacillus spp. 
Staphylococcus spp. 
Chloramphenicol, 
Fluoroquinolones,  
β-lactams, Macrolides, 
Tetracyclines 
Outflow 
MexA, MexB 
AcrA, AcrB, 
oprM, tolC 
C 
Pseudomonas spp. 
E.coli 
Salmonella spp. 
 
Table 24. Examples of microbial resistance through development of 
transmembrane pumps. P= Plasmids, T= Transposons, C= Chromosomes.  
(Carli et al., 2009). 
 
Over the years, many bacteria have also developed a tenacious resistance to 
these chemotherapeutic thanks to the modification of the target enzymes of 
these antibiotics. Obviously, the microorganisms have not followed a single 
common process but have adapted their strategy according to their features. As 
remembered above, the resistance is usually linked to stable modifications in the 
chromosomal genome, and its appearance is directly proportional to the 
concentrations of the drug in the site of infection. This occurs more frequently 
when the microorganism is exposed to sub-lethal concentrations of the drug for 
a long time. Typically the resistance is of cross-type, for which its appearance 
makes the bacterial strain immune, or at least not very sensitive, to all drugs in 
the same category. 
Fluoroquinolone resistance in S. pseudintermedius and other Staphylococci is 
predominantly mediated by a mutation located at position 84 of the gyrA subunit 
of DNA gyrase enzyme (Ser84Leu), together with a mutation located at position 
80 of the grlA subunit of topoisomerase IV enzyme (Intorre L. et al., 2007; 
158 
 
Descloux S. et al., 2008). All these amino acid substitutions are caused by point 
mutations (substitution of a single nucleotide) on particular chromosomal genes, 
gyrA and parC, which encode for the production of these enzymes. This causes a 
different reading of the nucleotide triplet and then the change in the aminoacid 
sequence of the enzyme. The modification of the enzyme structure decreases 
the binding affinity between target enzyme and quinolone that fails to form the 
ternary complex and thus to cause cell death (Intorre L. et al., 2007; Descloux S. 
et al., 2008). 
 
2.2.2 Application of the HRMA  
 
Since the standard methods for determining FQ resistance based on the CLSI 
guidelines (www.clsi.org) are tedious and time consuming, and the molecular 
techniques currently used to characterize FQ resistance usually require 
sequence-specific probes or post-amplification processing such as gel 
electrophoresis and DNA sequencing (Kaltenboeck B. and Wang C., 2005) which 
are expensive, there is a need for reliable and accurate methods allowing fast 
identification of gyrA-mediated FQ resistance in S. pseudintermedius strains 
isolated during clinical routine. Furthermore, since the appearance of resistance 
to fluoroquinolones in staphylococci is mediated primarily by a point mutation, 
we decided to use the HRM technique to detect single nucleotide polymorphisms 
in the gyrA gene, related to the antibiotic resistance, in strains of Staphylococcus 
pseudintermedius isolated from dogs with pyoderma. 
 
Materials and methods 
 
1. Samples isolation, species identification and evaluation of fluoroquinolones 
resistance 
In this study, 16 S. pseudintermedius strains were screened for the presence of 
gyrA Ser84Leu mutation through a specific real time PCR-HRMA protocol. The 
strains were obtained as the unique or prevalent bacterial isolate from canine 
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skin, external ear and conjunctive clinical samples submitted for microbiological 
examination to our Department during 2009. Isolation was performed through 
cultivation on tryptone soy agar plates containing 5% sheep blood (Oxoid S.p.A, 
Rodano, Italy) for 24 h at 37°C under aerobical conditions. Isolates were 
identified as S. pseudintermedius by morphology, Gram staining, catalase 
activity, growth in mannitol salt agar selective medium, and API-Staph® analysis.  
The strains were tested for FQ susceptibility to enrofloxacin and marbofloxacin 
by the disc diffusion method on Muller Hinton agar (Oxoid).  
 
2. Design of primer set 
Coding sequence of S. pseudintermedius gyrA gene was obtained from NCBI 
(http://www.ncbi.nlm.nih.gov; accession number: NC_014925.1). Since 
nucleotide polymorphisms not related to resistance status can affect 
interpretation of HRMA results, we choose as target a portion of gyrA gene that 
is reported to undergo only mutations causing amino acid substitutions in FQ-
resistant S. pseudintermedius, and no silent mutations or mutations causing 
amino acid substitutions in both FQ-resistant and FQ-susceptible strains 
(Descloux S. et al., 2008). Degenerate primer sequences available in literature for 
gyrA amplification in Staphylococci (Intorre L. et al., 2007) were adapted to S. 
pseudintermedius as follows: GyrAsmod forward primer 5’-
ATGAGTGTTATCGTATCTCGTGC-3’ and GyrAasmod reverse primer 5’-
CCATCGAACCGAAGTTACCTTG-3’, for the amplification of a gyrA 262 bp 
fragment. 
 
3. Sample processing and DNA extraction 
For gyrA sequence analysis, each S. pseudintermedius isolate was tip-sampled 
from a single colony and placed in an 0,5 ml Eppendorf containing 50 microl of 
water. Samples were then subjected to three alternate cicles of 5’ at 95 °C and 5’ 
at -80°C to obtain bacterial cell lysis and DNA extrusion.  
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4. Conventional PCR and sequencing 
The bacterial lysates were then subjected to PCR amplification in a Mastercycler® 
Gradient thermal cycler (Eppendorf AG, Hamburg, Germany). The PCR reactions 
were carried out in duplicate in a total volume of 20µl containing 1µl of bacterial 
lysate, 1X Taq buffer containing 1.5mM MgCl2 and 0.2mM dNTPs, 1.25 U Taq 
Promega and 0.5µM of GyrAsmod forward and GyrAasmod reverse primers. The 
thermal profile for the amplification was 94 ◦C for 90 sec; 35 cycles of 94 ◦C for 
45sec, 51 ◦C for 30sec, 72 ◦C for 90sec and final elongation step at 72 ◦C for 
300sec. Amplification products were run on 2% agarose gel and purified using 
Qiaquick™ Gel Extraction kit (Qiagen GmbH, Hilden, Germany). The purified 
amplicons were then sequenced using standard Applied Biosystems technology. 
 
5. Real-time PCR amplification and HRM analysis 
The same primer pair used for conventional PCR was then used for real time PCR-
HRMA on an Eco™ Real-Time PCR System (Illumina, Inc., San Diego, CA, USA) 
carrying out each amplification reaction with 1µl of bacterial lysate, 7.5µl 
Supermix SsoFast EvaGreen Biorad, 0.3µM of each primer and H2O to reach a 
total volume of 15µl. The thermal protocol for the PCR was 95 °C for 10min, 40 
cycles of 95 °C for 5sec and 60°C for 5sec. The melting protocol was 95 °C for 
15sec, 55 °C for 15sec, ramping to 95 °C with fluorescence data acquisition each 
0.1 °C and a final step at 95 °C for 15sec. Sample melt curves were subjected to 
normalization and temperature shifting. The difference plot for each sample was 
generated for subsequent grouping analysis. A S. capitis strain of human origin, 
conserving the primer annealing sequences, was used to generate a gyrA 
external control curve, in order to check sequence specificity of the melting 
profile.  
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Results and discussion 
 
1. Evaluation of fluoroquinolones resistance by antibiogram  
The disc diffusion method on Muller Hinton agar showed that 5 S. 
pseudintermedius isolates were resistant to enrofloxacin and marbofloxacin, 
while the remaining 11 isolates resulted sensitive to both FQs. 
 
2. Sequencing results 
After conventional PCR, the purified amplicons were then sequenced using 
standard Applied Biosystems technology. The obtained sequences were aligned 
to the expected sequence for gyrA gene of S. pseudintermedius using ClustalW 
(http://www.ebi.ac.uk/clustalw). The 5 FQ-resistant strains showed a C to T 
transition at position 251 leading to substitution from Ser to Leu at codon 84, 
whereas all the 11 FQ-sensitive strains showed no mutation at the same position. 
None of the strains showed any other mutations in the amplification target. 
 
3. Real-time PCR amplification and HRM analysis 
The HRMA, with the protocol we developed, has been proven to be able to 
discriminate two sequences that differ by a single nucleotide, thus allowing to 
recognize strains of S. pseudintermedius presenting the single nucleotide 
mutation (fluoroquinolones resistant) than wild-type (fluoroquinolones sensible).  
Furthermore, the results obtained through HRMA coincide perfectly with those 
obtained with the classical microbiology and with the sequencing.  
Figure 46 shows the results obtained with HRMA: the 11 S. pseudintermedius 
that have gyrA wild-type (sensitive to fluoroquinolones), contain a codon TCG 
and are highlighted in blue. The 5 S. pseudintermedius that have gyrA mutant 
(resistant to fluoroquinolones) contain a codon TTG and are highlighted in red. A 
strain of S. capitis (gray) was analyzed as a control. The three different curves are 
clearly distinguishable. 
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Figure 46. Results of HRMA shown in normalized mode (46.A) and in differential 
mode (46.B). The strains of S. pseudintermedius susceptible to fluoroquinolones 
(in blue) and the strains resistant to fluoroquinolones (in red) are clearly 
distinguishable. In gray the strain of S. capitis analyzed as control. 
 
 
 
A 
B TTG 
TCG 
TTG 
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A 
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S. capitis 
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Conclusions 
 
The real time PCR-HRMA protocol was able to discriminate among FQ-sensitive 
and FQ-resistant strains on the basis of the corresponding melt curves, with 
complete agreement with data obtained by DNA sequencing of the same gene as 
a reference technique and by FQ susceptibility testing (Figure 45). In this study 
we validated as proof of concept a HRM analysis-based approach for rapid 
identification of gyrA-linked FQ resistance in S. pseudintermedius clinical isolates 
at molecular level without the need to perform DNA sequencing or to use 
mutation-specific probes. We also confirmed previous reports that in S. 
pseudintermedius, the main mutation site associated to FQ resistance is at 
position 251 (Ser84Leu) of gyrA as detected in all the five resistant strains. 
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2.3 HRMA for detection and discrimination of 
Dirofilaria immitis and Dirofilaria repens in canine 
peripheral blood 
 
2.3.1 Introduction 
 
Filariasis: General information and Taxonomy 
The etiological agents of disease defined generally "filariasis" fall into two 
subfamilies of parasites belonging to the Onchocercidae family and to the 
Filarioidea superfamily (Table 25). These subfamilies are represented by: 
Dirofilarinae, which includes Dirofilaria immitis and Dirofilaria repens (Nochtiella 
repens), and Onchocercinae, which includes Dipetalonema reconditum 
(Acanthocheilonema reconditum), Dipetalonema dracunculoides 
(Acanthocheilonema dracunculoides) and Dipetalonema grassii (Cercopithifilaria 
grassii) (Chauve C.M., 1990; Euzeby J., 1990; Urquhart G.M. et al., 1996). 
 
Kingdom Animalia 
Phylum Nemathelmintes 
Class Nematoda 
Order Spirurida 
Suborder Spirurina 
Superfamily Filarioidea 
Family Onchocercidae 
Subfamily Dirofilarinae 
Gender Dirofilaria 
Species Immitis e Repens 
 
Table 25. Classification of D. immitis and D. repens.  
(Urquhart G.M. et al., 1996) 
165 
 
Morphology of the parasite 
The present study deals only with parasites belonging to the subfamily of 
Dirofilarinae. Here below the morphology of both the adult parasites and  
microfilariae, which is of great diagnostic value, is described. 
 
Morphology of adult parasites 
Dirofilaria immitis (Figure 47) is a filiform parasite that  measures approximately 
20-30 cm in length and 1 mm in diameter; the male can be distinguished by the 
female for the smaller size and the caudal ends wound in a spiral. The mouth is 
surrounded by eight median and two lateral papillae. The caudal area of the 
male presents 4 to 6 pairs of voluminous, pedunculated and ovoid papillae, of 
which 2-4 are pre-cloacal and 2 post-cloacal and fingerlike, and 3-4 pairs of 
conical small papillae, located in terminal position. The spicules measure 
respectively 315 and 200 microns. In the caudal edge of the female, in sub-
ventral position, there is a conical and papilliforme structure facing backwards 
(Euzeby J., 1990). 
 
 
Figure 47. Adult specimens of D. immitis 
(cal.vet.upenn.edu/merial/hrtworm/hw_1a.htm) 
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Dirofilaria (Nochtiella) repens has smaller dimension than D. immitis: in fact the 
female measures 10-17 cm long and 460-650 microns wide, while the male 
measures 5-7 cm long and 370-450 microns wide. The male has 2 to 4 pre-anal 
papillae on one side (with spicules measuring 465 to 590 microns) and 5 or 6 on 
the other (with spicules which measuring 185 to 206 microns). In the female the 
vulva is distant 1.15 to 1.60 mm from the front end (Chauve C.M., 1990). 
 
Morphology of microfilariae 
The larval forms of the parasite are represented by the microfilariae (L1): these 
are found in the circulating blood of the definitive host and, like the adult 
parasites, their characterization is necessary to reach a proper etiologic 
diagnosis. The morphological elements that allow the identification of 
microfilariae are the length and the shape of the cephalic and caudal end. 
The microfilariae of Dirofilaria immitis (Figure 48) measure 300-330 x 5-7 
microns and are not equipped with sheath: the caudal part is straight and sharp 
while the cephalic end is tapered and blunt-ended (Figure 49) (Chauve C.M, 
1990; Euzeby J., 1990; Manfredi M.T., 1998; Urquhart G.M. et al., 1996). 
The microfilariae of Dirofilaria (Nochtiella) repens (Figure 48) measure 207-360 
microns in length and 5-8 microns in width; they do not exhibit sheath, the 
cephalic end is rounded and the caudal end has a shape similar to an umbrella 
handle (Figure 50) (Chauve C.M., 1990; Manfredi M.T., 1998). 
The microfilariae are identified, as well as on the basis of morphology, also with 
histochemical and immunological methods; such investigation method are 
described later in this thesis work. 
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Figure 48. Microfilaria of D. immitis (left) and D. repens (right). (Photo kindly 
provided by Dr. Marco Genchi). 
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Figure 49. Tapered cephalic-end of D. immitis.  
(Photo kindly provided by Dr. Marco Genchi). 
 
 
Figure 50. Caudal ends with shape of umbrella handle of D. repens. 
(http://www.personalweb.unito.it/ezio.ferroglio/atlante/parassiti_cane/dirofilari
a/d_repens/foto/coda_rep1.jpg) 
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Biological cycle of the parasite 
Dirofilaria immitis, like the other members of the superfamily Filarioidea, is a 
dixenic parasite, and it depends on insect vectors for the completion of the cycle, 
for transmission to the definitive hosts and for its dissemination (Euzeby J., 1990; 
Urquhart G.M. et al., 1996). D. immitis is a hematophagous parasite that can 
remain for years within the definitive host, continuing to produce microfilariae 
(Euzeby J., 1990). It is a viviparous parasite: the female lays the microfilariae that 
circulate in the blood of the host. The microfilariemia has a monthly and 
seasonal circadian periodicity that is highest in July and August and lowest in 
winter. To become adult, the larvae make various moults and part of their 
evolutionary cycle takes place in a hematophagous Diptera (mosquitoes of the 
genera Aedes, Anopheles, Coquillettidia, Culex, Culiseta and Mansonia) which 
acts as  carrier and as intermediate host (Cancrini G., 1998). The first stage larvae 
(L1, microfilariae) are taken from the Diptera during the blood meal and remain 
viable in its gut. Subsequently, they migrate towards the Malpighian tubules and 
are transformed, through two moults, into larvae of the second stage (L2) and 
third stage (L3). These become infesting in two weeks, after reaching the 
cephalic space and the labium. The infesting ability depends on the temperature: 
if this is too low, larval development stops and may then resume in more 
favorable climatic conditions. The cycle in the final host begins when L3 are 
inoculated by the mosquito during a blood meal. The L3 remain in the skin for 
about six days, then moults in the fourth stage larva (L4) that is localized in the 
capillaries of the abdominal wall (about 20 days after the bite of the insect) and 
thoracic wall (after about 40 days from inoculation of L3). Within 60-80 days, it 
moults into the fifth stage larva (L5) that migrates through the venous system to 
localize in the pulmonary artery (between 70 and 120 days after infestation). It 
persists in this location up to a length of 8-11 cm and subsequently performs, 
about 110 days after infestation, a retrograde migration into the right ventricle, 
where it becomes an adult individual (Euzeby J., 1990; Urquhart G.M. et al., 
1996). The prepatent period, i.e. the interval between infection of a host by a 
parasitic organism and the first ability to detect a diagnostic stage of the 
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organism from that host, is about 6 months, after which the adult females begin 
to produce the microfilariae. The infestation of the final host (mostly dogs) can 
take place between June and October; during the first infestation, usually L5 
reach the pulmonary artery in late August and persist here until December, and 
then migrate into the right ventricle and start producing microfilariae. In an 
already parasitized subject, however, the larvae can be found in the blood 
throughout the year. In the pregnant dog, microfilariae can cross the placenta 
and reach the fetus (in this case microfilariae are not able to evolve because it 
must spend part of their cycle in the mosquito) , while the infesting larvae (L3) 
are not able to perform this migration (Euzeby J., 1990) (Figure 51). 
 
  
Figure 50. Biological cycle of D. immitis. (http://www.capcvet.org/capc-
recommendations/canine-heartworm) 
 
Dirofilaria (Nochtiella) repens, like D. immitis, to evolve to adult parasite needs a 
phase of development in an intermediate host (the mosquito) in which parasite 
development takes place from L1 to L3. This is followed by the final inoculation 
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into the final host (dog, cat, man, other canids and wild felines) where the 
parasite is localized in the subcutaneous connective tissue and connective bands 
of skeletal muscle. In these locations it makes two moults, becoming first L4 and 
subsequently L5 and reaching then the sexual maturity (Chauve C.M., 1990). 
 
Epidemiology and geographical spread 
The epidemiology of canine heartworm, and in particular the cardiopulmonary 
pathology by D. immitis, is a complex problem because there are several factors 
involved, which interact with each other, that lead to the spread of the disease in 
dogs, the main reservoir of the parasite, and increase the risk of human 
infections. Although the number of dogs subjected to specific prevention is more 
and more increasing, the prevalence of this disease is still high (Vayna de Pava 
M., 2002).  
The areas which best allow the diffusion of heartworm have a climate 
characterized by high temperatures for a few months of the year, with high 
humidity and poor oxygenation. All these conditions are, in fact, favorable to the 
development of the intermediate host and in particular, are to be considered at 
high risk especially the river areas. Dirofilariasis is an endemic disease in the 
United States of America, Japan and north eastern Australia. D. immitis has also 
been reported in Asia, Africa and in South America (Figure 52). The situation in 
Europe shows that the most involved species are D. immitis and D. repens. In 
Spain, the south-central area is characterized by a high prevalence of infection 
with D. immitis and a low prevalence of that by D. repens; distribution is 
sporadic, and prevalence rates vary widely, ranging from 0 to 5% in northern 
areas to over 37% in the western regions and the Canary Islands. In France, D. 
immitis is present in the west and D. repens occupies the same territory as well 
as the central part of the nation; the infestation is found mostly along the coasts 
of the Mediterranean, and dogs positive for the parasite are mainly found at the 
mouth of the Rhone, Vaucluse, Haute-Garonne, Dordogne, Pyrenees Atlantiques 
, Gard, Var, Alpes-Maritimes and in Corsica. In Portugal, the disease is reported 
mainly in the southern regions, with prevalence rates between 10% and 30% of 
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the canine population. In Greece there are both species of heartworm (Cancrini 
G. et al., 2000; Chauve C.M., 1997; Muro A. et al., 1999). With regard to Eastern 
Europe, few data are available, which show that the prevalence ranges between 
2% and 17% in Slovenia, Bulgaria and Turkey, while more than 65% in Romania, 
where some regions are considered endemic for heartworm (Leuterer G. and 
Goethe R., 1993). Finally, in northern Europe, particularly in Germany, Austria 
and Switzerland, there have been some cases of dirofilariasis, but they are 
considered imported, i.e. are attributed, according to available anamnestical 
information, to infestations contracted in countries where the disease is endemic 
(Figure 52) (Leuterer G. and Gothe R., 1993). 
 
Figure 52. Geographic distribution of heartworm disease in the world. 
(http://www.stanford.edu/group/parasites/ParaSites2005/Dirofilariasis/Pages/E
pidemiology.htm) 
 
The largest endemic area of Europe is along the middle and lower course of the  
Po river and Oglio river, in the Po Valley, between 45 and 46 degrees North 
Latitude. It has, in fact, the more favorable characteristics to the development of 
the carrier: it is surrounded and protected by the Alps and Apennines, 
characterized by abundant rainfall, high relative humidity and extensive 
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monoculture cropping systems (Maffi S. et al. 1999). It would sound restrictive to 
consider dirofilariasis as a parasitic infection "confined" in certain areas with 
special environmental characteristics and climate. The infestation, in fact, has a 
tendency to stabilize in canine populations where the presence of the parasite 
was in the past considered sporadic, and to spread into areas once considered to 
be free. The expansion of areas at risk for the parasitosis can be considered, in 
part, as a consequence of the ability of the vector to adapt to various situations. 
The expansion occurs in the foothill areas surrounding the Po Valley to the south, 
also, to the northeastern edge, localized in the provinces of Veneto and Friuli 
Venezia Giulia, where the infection can now be considered endemic with reports 
of prevalence of medium-high level (28% ). Filariasis is rising almost everywhere 
in Italy, colonizing new habitats substantially, such as hilly areas and foothills (up 
to a height of about 900 meters above sea level), Maremma, the upper valley of 
the Arno River and other areas of Central Italy. In southern Italy most cases of 
dirofilariasis are due to parasites different from D. immitis: in Campania showed 
a high prevalence of infections with D. reconditum, while in Sicily the parasite is 
more involved D. repens (Giannetto S. et al., 1997) (Figure 53). 
In recent years several epidemiological studies to establish the prevalence and 
spread of heartworm disease in the dog population in Italy have been 
performed. The infection is spreading from endemic areas in the Po Valley to 
peripheral areas once considered to be free. It should be emphasized that there 
is an interaction between the two species of Dirofilaria (D. immitis and D. repens) 
in dogs and this may hinder the spread of D. immitis to areas where D. repens is 
extremely widespread and vice versa. In this regard, the mosquito species 
involved in the transmission, their biology, and competence as vectors of 
Dirofilaria species should be considered. The introduction in Europe of a new 
species of mosquito as Aedes albopictus, and the recent highlighting of its role as 
a vector for heartworm, may influence the risk and spread of infection (Cancrini 
G. et al., 2003; Cancrini G. et al., 2007). This species of mosquito could spread 
from south to north European countries in the near future, changing the 
epidemiological models of heartworm disease in both humans and animals 
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(Genchi C. et al., 2005). It was stated that the prevalence of heartworm infection 
is increasing in dogs non treated with preventive drugs, and that there is a risk 
that infested host from outside will trigger cycles in indigenous regions 
previously free, as reported about several regions of the United States. In this 
regard, climate change can be considered a key factor responsible for the spread 
of vectors to the north and their ability to transmit pathogens. In addition to 
climate change and global warming, it is also important to consider the effects of 
the global movement of animals, as an important factor for the spread of vector-
borne diseases (Genchi C. et al., 2009) 
 
 
 
Figure 53. Distribution of Dirofilaria immitis in Italy. Outbreaks of canine 
heartworm disease by Dirofilaria immitis in the area until 1990 endemic of the Po 
Valley (blue dots) and outside the endemic area (blue symbol). New outbreaks 
(red points) reported in non-endemic areas, after 1990, until 2009. 
(www.parasitesandvectors.com/content/2/S1/S2) 
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Pathogenesis and clinical signs 
The principal location of D. immitis are pulmonary arteries and heartworm must 
be considered as a pulmonary disease, that during the last stage also affects the 
heart chambers (Figure 54). A few days after the arrival of the parasite in the 
caudal pulmonary arteries, the endothelial cells become swollen, the 
intercellular junctions become dilated in response to trauma and activated 
neutrophils adhere in the space between endothelial cells. Adhesion and platelet 
activation are also found. The damaged arterial wall allows albumins, fluid 
plasma and blood-cells to reach the perivascular space inducing a persistent 
perivascular inflammatory edema. After the endothelial changes, the tunica 
intima thickens and leukocytes invade the smooth muscular wall; the smooth 
muscle cells multiply within the tunica media and migrate to the surface 
endovascular as a response to the growth factor released from platelets. The 
proliferation and migration of smooth muscle cells determines the presence, on 
the inner surface of the arteries, of villi and collagen lined by endothelial cells. 
The surface of the arteries of infected dogs and cats appear to be strongly rough 
and smooth and the lumen of the pulmonary arteries is decreased. Lung disease 
is secondary to vascular changes; the leakage of liquids and proteins through the 
wall of the affected arteries produces an edema in the parenchyma. Moreover, 
the spontaneous death of some filariae is capable of producing pulmonary 
thromboembolism and severe inflammatory reactions. The reduction of 
conformation and caliber of the pulmonary arteries, which may also be occluded 
by a thromboembolism or severe villous proliferation, causes a state of 
pulmonary hypertension and, consequently, an increase of the post load in the 
right ventricle, which can induce the cor pulmonale syndrome and congestive 
heart failure. The leaking of fluid and proteins through the wall of the affected 
arteries produces further swelling and inflammation in the lung parenchyma.  
The clinical evolution of heartworm disease in dogs is usually chronic. Most 
infected dogs have no symptoms of the disease for a long time, months or years, 
depending on the amount of heartworms, the individual reactivity and physical 
exercise, as there is more serious damage in dogs that perform strenuous 
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exercise compared to other dogs. The disease can begin with occasional 
coughing and develops gradually. The cough may be followed by dyspnea, 
moderate to severe, weakness, and sometimes fainting after exercise or 
excitement. Sound of crackling can be found at lung auscultation. Later, when 
congestive heart failure is developing occur: swelling of the abdomen and legs, 
fluid accumulation, anorexia, weight loss and dehydration. At this stage, there is 
a cardiac murmur on the right side of the chest, because of insufficiency of the 
tricuspid valve, and the heart rhythm is altered because of atrial fibrillation. 
Sudden death occurs rarely and usually as a result of respiratory distress or 
cachexia. In the course of this chronic disease, sometimes there is an acute 
symptomatology due to a severe thromboembolism following the natural death 
of heartworms, and dogs may show acute dyspnea and hemoptysis (Genchi C. et 
al., 2007). In small dogs, the movement of adult worms from the pulmonary 
artery to the right chambers of the heart due to pulmonary hypertension and a 
sudden drop in right cardiac output is also common. In this case, the affected 
dogs show the so-called superior vena cava syndrome. This syndrome shows 
dyspnea and cardiac murmur due to the presence of microfilariae in the vicinity 
of the tricuspid valve. This syndrome is also called intravascular hemolytic, being 
accompanied by hemolytic anemia and hemoglobinuria due to mechanical 
intravascular hemolysis (red blood cell fragmentation occurs due to the 
continuous movement between atrium and ventricle of filarial intertwined). This 
implies a systemic hemodynamic decompensation and shock with consequent 
death of the affected animal (Venco L., 1993). Disseminated intravascular 
coagulopathy often accompanies the superior vena cava syndrome, being 
secondary to hemolysis and metabolic acidosis. In addition, the dog may 
experience liver lesions characterized by hepatomegaly, with expansion venous 
thrombosis, centrilobular necrosis and fibrosis. Finally, there may be a serious 
kidney disease, resulting from the hemoglobinuria with renal tubular necrosis 
and cylindruria. 
In subcutaneous filariasis, caused by D. repens, the adult parasite is localized in 
the subcutaneous tissues of the dog and cat. This disease presents with minor 
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clinical signs such as itching, swelling of the skin, subcutaneous nodules or 
remains asymptomatic (Genchi C. et al., 2007).  
 
 
Figure 54. Adult of Dirofilaria immitis in dog heart. 
(http://www.stanford.edu/group/parasites/ParaSites2001/dirofilariasis/Synony
ms.html) 
 
Diagnosis 
Knott test to microfilariae search in the peripheral blood 
The circulating microfilariae can be detected with the Knott test. The 
microfilariae are detected and identified under the microscope on the basis of 
morphological criteria, and this is considered as a definitive proof of infection 
(specificity 100%). However up to 30% of dogs may be oligo-or amicrofilaremic, 
despite presenting adult worms, for the presence of worms only of the same sex 
(quite unusual in dogs), for a host immune reactivity towards microfilariae or for 
administration of microfilaricidal drugs. So, the sensitivity of the test for 
microfilariae is not considered sufficient to rule out infection in the event of a 
negative result. Furthermore, in certain cases the identification based on 
morphology may be made more difficult by the presence of artifacts and/or 
intermediate morphologies, especially if the operator is not very experienced or 
if they are not put in place perfectly reproducible procedures of sampling and 
analysis (Genchi C. et al., 2007). 
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Blood test for antigen research of adult females of D. immitis 
Different ELISA kits for detection of circulating antigens of Dirofilaria immitis 
adult female in serum, plasma or whole blood of a dog are commercially 
available. Most are very specific, sensitive, rapid and easy to perform. The 
sensitivity is actually very high, but false negatives may occur during the 
prepatent period, very light infestations or when there are only males in the host 
(male filariae are not detectable by this test). Most kits are intended for the 
clinical diagnosis of a single sample, but multi-test ELISA plates are also available. 
Manufacturers claim that for a positive result parasite is sufficient 1 female 
adult, although many factors may influence the sensitivity of the test as the age 
of the parasite, the ratio between parasite females and males, and the size of the 
dog. Reliable and reproducible results can be obtained when there are 2-3 or 
more adult female worms. A detectable antigenemia develops after 5 to 6.5 
months from the infestation. After the death of adult parasites, circulating 
antigens disappear rather quickly; for this reason, this technique can be used to 
evaluate the efficacy of a therapy adulticide. To confirm the success of adulticide 
therapy in dogs, the antigenemia must be reassessed at 5 and 9 months after 
treatment. If the test is negative at 5 months, the test at 9 months can be 
avoided (Genchi C. et al., 2007). 
Chest radiographs 
Chest radiographs may show, in an advanced stage, the enlargement of the 
pulmonary arteries, abnormal lung pattern and, in the worst cases, right 
cardiomegaly. In the event of congestive heart failure right payments and 
peritoneal effusions are found. Radiographs are useful for assessing the severity 
of lung injury, but not for assessing the parasite. The radiographic signs of 
pulmonary vascular disease in advanced stages may persist long after the 
infestation has run its course and some of the most severely ill dogs may have a 
low number of parasites. In contrast, some dogs can host large parasites but 
remaining clinically asymptomatic with light or absent radiographic lesions 
(Genchi C. et al., 2007). 
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Electrocardiography 
Only at the last stage of the disease, when the heart chambers are seriously 
damaged, the ECG may show a deviation to the right of the axis cardiac and / or 
atrial fibrillation (Genchi C. et al., 2007). 
Echocardiography 
Echocardiography allows direct visualization of the cardiac chambers and of 
communicating vessels. It can also allow the visualization of parasites in the 
cardiac chambers, the caudal vena cava, the main pulmonary artery and in the 
proximal portion of both pulmonary  caudal arteries. The heartworms are 
highlighted as floating objects in the right cardiac chambers or in the lumen of 
the vessels. It is performed mainly in cases where the clinical and radiographic 
results suggest a severe form of the disease. The cardiac ultrasound can increase 
the accuracy in the staging of the disease and in the estimation of filarial 
influencing the treatment plan and prognosis (Genchi C. et al., 2007). 
Polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) is a sensitive and specific technique that 
allows to detect the presence of DNA belonging to a given organism, and as such 
can be used to identify the different species of heartworm. During the last years 
several researchers have developed different molecular protocols with 
diagnostic and epidemiological purposes. In particular, specie-specific PCR assays 
for single species identification, and multiplex PCR and PCR-RFLP assays, single 
and multistep, for simultaneous detection of the different Dirofilaria species 
either in the vector or in peripheral blood of infected dog have been designed 
(Favia G. et al., 1996; Mar P.H. et al., 2002; Casiraghi M. et al., 2006; Rishniw M. 
et al., 2006; Gioia G. et al., 2010). For diagnostic purposes, protocols applicable 
to the identification of microfilariae in the peripheral blood are particularly 
useful, especially in cases where the morphological recognition of microfilariae 
proves to be difficult, or even in the case of mixed infections (Genchi C. et al., 
2007). In addition, for clinical diagnostics use, it is critical to perform fast 
procedures getting simple and clear results, and including a precise assessment 
of the level of sensitivity and specificity in the peripheral blood. 
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2.3.2 Application of the HRMA  
 
The purpose of this work was to develop a HRM analysis, fast and relatively 
inexpensive, able to simultaneously detect and unambiguously identify D. 
immitis and D. repens in the peripheral dog blood samples, targeting nucleotide 
differences existing between the sequences of a target gene in the two different 
species.  
 
Materials and methods 
 
1. Sampling procedures and microfilarial phenotyping 
D. immitis and D. repens microfilariae were collected from anticoagulated canine 
peripheral blood samples referred to the Faculty of Veterinary Medicine of the 
University of Milan (Italy). Blood samples were tested by a modified Knott’s test, 
and circulating microfilariae were identified based on morphology and 
morphometry (Knott, 1939; Euzeby, 1981; Soulsby, 1982; Genchi 2007), and 
counted in 20  microliters of blood. In total, 3 D. immitis blood samples, 8 D. 
repens positive blood samples and 3 blood samples with natural mixed infection 
were selected for the HRM analysis. Furthermore, a Knott’s test-negative blood 
sample was included as negative controls and single adults of D. immitis and D. 
repens were used as positive controls. Also, positive blood samples from dogs 
with different filarial loads (i.e., 4 mf/ml and 32250 mf/ml for D. immitis; 4 mf/ml 
and 100000 mf/ml for D. repens) were examined to test the range of sensivity of 
the method.  
 
2. DNA extraction 
Genomic DNA was isolated from 300 µl of each mf-positive peripheral blood 
sample and from isolated D. immitis and D. repens worms by adding  900 µl of 
TNNT lysis buffer (0.5% Tween 20, 0.5% Nonidet P-40, 10mM NaOH, 10mM Tris 
[pH 7.2]) and 50 µl of 20mg/ml proteinase K (Lachaud L. et al., 2002). Samples 
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were then incubated at 56 °C for 18 h. Proteinase K was inactivated by 
incubation at 95 °C for 10 min. DNA was isolated by standard basic phenol 
chloroform extraction followed by ethanol precipitation. The extracted DNA was 
resuspended in 30 µl of PCR-grade water and then stored at −20 ◦C until tested 
by real-time PCR. For each sample, 2 µl of resuspended DNA was used as 
template in the multiplex PCR assay. 
 
3. Design of primer set 
Dirofilaria mitochondrial gene for cytochrome oxidase, subunit I, was chosen as 
gene target. The gene sequences of D. immitis (AM749226.1, AM749228.1, 
HQ540424.1, EU169124.1) and D. repens (AM749234.1, AM749231.1) were 
obtained from GenBank and aligned automatically using the CLUSTALW program. 
The primer pair was designed by us in a region where there is no variability intra-
species (the sequence is conserved), while the interspecies variability is 
maximized. In addition, the primer set for the Q-PCR mixture containing the 
fluorescent binding dye was designed to have no misprimings and no dimers. 
Also, the primer sequence was proved to be unique for Dirofilaria species 
through a homology search using Basic Local Alignment Search Tool (BLAST; 
NCBI, NIH. The forward primer (COXdirHRMF): 5’ –AGTATGTTTGTTTGAACTTC- 3’ 
and reverse primer (COXdirHRMR): 5’ –AACGATCCTTATCAGTCAA- 3’ have an 
annealing temperature of 52 ° C to give an amplicon of 256 bp. 
 
4. Real-time PCR amplification and HRM analysis 
Each amplification reaction was carried out in a mixture containing the following 
reagents: 7,5 µl Supermix SsoFast EvaGreen mix Biorad, 0.3 µM of each primer, 2 
µl of resuspended DNA and H2O to reach a total volume of 15 µl. The real time 
PCR-HRM amplification reactions were performed on a EcoTM Real-Time PCR 
System (Illumina, Inc., San Diego, CA, USA). The thermal protocol started with a 
denaturation-activation step at 95°C for 8 min, followed by a 40 cycle program 
(denaturation at 95 °C for 30 s, annealing at 52 °C for 1 min). The melting 
program comprised 3 steps: denaturation at 95 °C for 15 s, renaturation at 55 °C 
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for 15 s, and finally melting with continuous fluorescence measurement (ramping 
0.1 °C/s) to 95 °C, kept for 15 s. The HRM curve was analyzed using the Eco_v4.0 
software. Raw melting-curve data was normalized by setting the pre-melt (initial 
fluorescence) and post-melt (final fluorescence) signals of all samples to uniform 
values. Pre-melt signals were uniformly set to a relative value of 100%, while 
post-melt signals were set to a relative value of 0%. Genotypes were defined by 
selecting a sample from each standard species as a reference control to identify 
unknown samples. As a blank control double distilled water was the used in 
parallel with each experiment. 
 
5. Sequencing 
To confirm the results of HRM analysis, after the HRM analysis the samples were 
run on 2 ethidium-bromide agarose gel followed by UV-visualization and gel-
purification by QiaquickTM Gel Extraction kit (Qiagen GmbH, Hilden, Germany). 
The concentration of purified amplicons was spectrofotometrically measured 
using a ND-100 Spectrophotometer. The purified amplification products were 
then sequenced using standard Applied Biosystems  technology on ABI Prism 310 
DNA sequencer (Applied Biosystems). The obtained sequences were aligned to 
expected target sequences using ClustalW (http://www.ebi.ac.uk/clustalw). 
 
Results and discussion 
 
All samples showed a robust and reproducible amplification signal, this allowing 
an optimal HRM analysis. The amplicons were of the expected size (256 bp), nor 
any nonspecific amplicons or primer dimers were detected (Figure 55). No 
amplification was obtained from Knott’s-negative samples, confirming the 
specificity of the procedure. Sensivity range was confirmed for the two species 
by successful amplification of the highest (naturally infected blood samples of 
32250 mf/ml for D. immitis and 100000 mf/ml for D. repens) and the lowest 
(reconstructed blood samples of 4 mf/ml for each single Dirofilaria species) mf 
load.  
183 
 
 
 
Figure 55. Results of the gel electrophoresis performed after real time PCR-
HRMA. The amplicons are of the expected size (256 bp) and the amplification is 
robust, reproducible and don’t show nonspecific or dimers of primers. 
 
HRM analysis allowed to discriminate clearly the two species according to the 
different melting temperature of the two sequences. Figure 56 shows the 
normalized graph of D. immitis samples (bunch of curves to the right), the D. 
repens samples (bunch of curves to the left) and the three mixed samples in the 
centre (asterisk). Figure 57 shows the difference plot curve, that allows further 
analysis of the differences in melting-curve shapes by subtracting the curves 
from a reference curve (in this case repens 4 mf/ml), which helps to cluster 
samples into groups that have similar melting curves.  
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Figure 56. Normalized graph of the melting curves obtained with the HRMA. Are 
clearly distinguishable the D. immitis samples (in blue on the right), from the D. 
repens samples (in red on the left) from samples with mixed infestation (in green 
in the center, indicated by an asterisk). 
 
 
 
Figure 57. Differential graph of the melting curves obtained with the HRMA. The 
three different types of sample are easily distinguishable: in blue D. immitis 
samples, in red D. repens samples and green (indicated by an asterisk) samples 
with mixed infestation. 
D. immitis 
D. repens 
* 
* 
D. immitis 
D. repens 
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Conclusions 
 
In this work we report a new molecular method based on real-time PCR and 
HRM analysis to detect and differentiate simultaneously and unequivocally D. 
immitis and D. repens on DNA extracted from canine peripheral blood. The 
availability of a HRM assay reduces the reagent cost, the labor time, and the 
contamination risk. This quick, sensitive and specific single step assay able to 
discriminate the two most common filarial parasite in dogs represents an 
additional tool for epidemiological studies and routine disease assessment in co-
endemic areas for the two species. 
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